var title_f14_30_14816="Scapholunate dissociation";
var content_f14_30_14816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scapholunate dissociation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph of the wrist shows a &gt;3 mm separation (black arrow) between the scaphoid and lunate (Terry Thomas sign) that indicates a scapholunate dissociation (tear). This patient also had a distal radius fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14816=[""].join("\n");
var outline_f14_30_14816=null;
var title_f14_30_14817="Bedbugs";
var content_f14_30_14817=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bedbugs (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/30/14817/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14817/contributors\" id=\"au7016\">",
"       Dirk M Elston, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14817/contributors\" id=\"au2132\">",
"       Stephen Kells, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/30/14817/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14817/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/30/14817/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14817/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/30/14817?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BEDBUG OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Bedbugs are small insects that can infest homes and other structures. There are several species of bedbugs, one of which (Cimex lectularius) is responsible for the majority of infestations in temperate (moderate) climates; another species can be found in more tropical areas. There are also related species known as \"bat bugs\" and \"bird bugs\", which infest the habitats of those animals. A microscopic examination may be necessary to distinguish bedbugs from other species.",
"    </p>",
"    <p>",
"     This topic will review how to determine if bedbugs are present, how to treat bedbug bites, and how to eliminate a bedbug infestation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHERE ARE BEDBUGS FOUND?",
"     </span>",
"    </p>",
"    <p>",
"     Human bedbugs are found around the world and can infest any structure or site where people may rest. Bedbugs tend to be more common in apartment buildings, other multi-family facilities (eg, homeless shelters), and hotels. Historically, they have also been found in public transportation systems and entertainment venues.",
"    </p>",
"    <p>",
"     Bedbugs from tropical areas can be transported to non-tropical locations by international travelers, who unknowingly carry the insects on their clothing or luggage. If bedbugs are seen during travel, clothing and luggage should be inspected and cleaned before re-entering one's own home. Washing clothing and then drying it in an electric clothes dryer on the hot setting is adequate to kill bedbugs.",
"    </p>",
"    <p>",
"     Bedbugs feed on the blood of warm-blooded animals, including humans; they are attracted by warmth and carbon dioxide, and tend to bite when a person is asleep or still for a period of time. They favor cracks and crevices in mattresses, cushions, bed frames, in the folds of curtains, behind loose wallpaper or baseboards, and in clothing or other items on the floor. During a heavy infestation, bedbugs may spread to other items in the room, as well as to adjacent rooms.",
"    </p>",
"    <p>",
"     The females also lay eggs in these locations, which hatch after four to 10 days. Because bedbugs typically hide during the day, they are often not seen or suspected until bites to the skin are observed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BEDBUG APPEARANCE",
"     </span>",
"    </p>",
"    <p>",
"     Bedbugs are small and wingless (non-flying), with flat oval-shaped bodies and six legs (",
"     <a class=\"graphic graphic_picture graphicRef66540 \" href=\"UTD.htm?20/1/20500\">",
"      picture 1",
"     </a>",
"     ). They are reddish-brown in color, and may appear redder after feeding on blood. Adult bedbugs reach about 0.25 inches (5 to 7 mm) in length, and the body elongates and widens after a meal.",
"    </p>",
"    <p>",
"     As bedbugs molt (shed their skin) several times throughout their lifetime, cast-off skins may occasionally be visible at the site of a previous or current infestation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      REACTION TO BEDBUG BITES",
"     </span>",
"    </p>",
"    <p>",
"     It takes five to 10 minutes for a bedbug to complete a \"blood meal\", or feeding. Bedbugs often inflict a series of bites in a row, and typically target exposed areas of skin (eg, face, neck, arms, hands). The bite itself is generally painless, and may not be noticed until the person awakens or even a day or two later.",
"    </p>",
"    <p>",
"     Reactions to bedbug bites vary; some people have few or no symptoms, while others experience a more severe reaction. Typically, bedbug bites appear as small, red and swollen areas on the skin, often with a point or dot visible in the center. The area is usually itchy, and may resemble urticaria (hives), a common skin reaction that is often triggered by contact with an allergen. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"      \"Patient information: Hives (urticaria) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Bedbug bites usually take three to six weeks to heal, although new bites are likely to accumulate even as the older ones disappear as long as the infestation is still present. Bites may become infected, particularly if the person scratches at and further irritates the skin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Psychosocial aspects",
"     </span>",
"     &nbsp;&mdash;&nbsp;People affected by bedbugs may experience significant levels of stress and anxiety as a result of concerns about spreading the infestation. However, with the proper measures, bedbugs can be eliminated safely and successfully. Feelings of panic, depression, or extreme anxiety or despair should be discussed with a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      DO I HAVE BEDBUGS?",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Bedbug bites",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bedbug bites can be difficult to distinguish from other insect bites; however, several clues can suggest the presence of bedbugs. The discovery of red, itchy bites upon awakening (see",
"     <a class=\"local\" href=\"#H4\">",
"      'Reaction to bedbug bites'",
"     </a>",
"     above), particularly if they form a line or row on the skin, should arouse suspicion.",
"    </p>",
"    <p>",
"     Other conditions that may produce symptoms similar to bedbug bites include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Scabies &mdash; A mite infestation which causes intense itching, scabies also causes red lesions; however, unlike bedbug bites, they are usually not limited to exposed skin, and are sometimes accompanied by signs of a burrow (small line in the skin).",
"      </li>",
"      <li>",
"       Insect bites &mdash; Bites from fleas, mites, and other small bugs or insects can cause redness, swelling, and itching of the skin.",
"      </li>",
"      <li>",
"       Other skin disorders &mdash; Conditions such as dermatitis herpetiformis, a skin eruption caused by an allergy to gluten (a protein found in wheat), can also resemble the reactions caused by bed bug bites. Other allergies, aggressive washing, and use of some cleaning products can also cause skin irritation.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Signs of infestation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Minor bedbug infestations are often difficult to detect, as the bugs themselves are rarely seen due to their small size and tendency to hide in cracks and crevices during the day. Small reddish-brown specks of dung found on linens, mattresses, or walls surrounding the bed may suggest the presence of bed bugs.",
"    </p>",
"    <p>",
"     Severe or widespread infestations can cause a coriander-like odor that may be recognizable to those familiar with it; however, this is not usually helpful when trying to diagnose bedbug bites. The only way to definitively identify a bedbug infestation is to collect a specimen (bedbug) and send it to an expert for evaluation and identification. In the United States, most states have an extension office or entomology department at a local university that can perform this service; other options include contacting the local health department or a pest control service. A bedbug specimen may be stored in a plastic pill bottle, zipper top plastic bag, or taped to a piece of white paper.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CAN BEDBUGS CARRY DISEASE?",
"     </span>",
"    </p>",
"    <p>",
"     In general, bedbugs are not known to spread pathogens (germs) that can cause disease in humans. Further research is needed to fully understand the possible connections between bedbugs and other diseases.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      BEDBUGS MANAGEMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bedbug bites can be treated with non-prescription lotions or creams that contain pramoxine (eg, Sarna&reg;, Aveeno Anti-Itch&reg;, Neutrogena Skin Aid&reg;). Intense itching can be managed with a corticosteroid (steroid) cream or ointment, which can be purchased at most pharmacies.",
"    </p>",
"    <p>",
"     If symptoms improve with treatment, do not assume that the bedbugs have been eliminated. If an infestation is present, it is important to identify and manage the situation in addition to treating the bites themselves. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Infestation'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Keeping the skin clean and dry and avoiding scratching will help bedbug bites to heal faster and avoid becoming infected. If the area develops signs of skin infection (eg, redness, swelling, pus-like discharge), a healthcare provider should be consulted.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Infestation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before bedbugs are treated, it is important to be sure that bedbugs, rather than another insect, are present. If bat bugs or bird bugs are suspected, bat roosts",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     bird nests in the area should be inspected and eliminated if they appear to be infested. Fleas, mites, and even springtails may be mistaken for bedbugs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Pest control treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;If human bedbugs are definitively identified, a licensed pest control operator or service should be contacted to inspect the area, design a treatment plan, and apply chemical insecticides as appropriate. Victims of infestation should",
"     <strong>",
"      NOT",
"     </strong>",
"     attempt to apply pesticides or other chemical control measures themselves. Elimination of bedbugs requires trained and knowledgeable professionals.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Rented or leased units",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who rent or lease their home should contact their landlord for assistance; depending upon the rental contract, the owner of the property may be required to pay for treatment by a licensed pest control service. Inspection and treatment, if necessary, of adjacent apartment units is absolutely essential regardless of whether bedbugs have been seen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Cleaning suggestions",
"     </span>",
"     &nbsp;&mdash;&nbsp;To aid in control of the infestation, clean the affected area thoroughly by vacuuming, laundering, and removing clutter. Washing clothing and then drying them in an electric clothes dryer is adequate to kill bedbugs; the dryer should be placed on the hottest setting the fabric can withstand. Remove drawers from furniture and vacuum cracks and crevices. Encasing the mattress and box springs in a zippered fabric case will make it easier to detect remaining and future infestations.",
"    </p>",
"    <p>",
"     Bedbugs may enter the house through cracks in walls and doorways. These can be sealed or treated with an appropriate insecticide. However, attempts to seal all openings in a room or house (such as caulking between the walls and baseboards) are unlikely to be successful and may actually prevent insecticide treatments from penetrating into areas where bedbugs hide. Peeling paint and cracked plaster must be eliminated.",
"    </p>",
"    <p>",
"     It is usually not necessary to dispose of furniture or bedclothes entirely. If a person chooses to discard an item, it should not be left on the street or given away because this can allow further spread of bedbugs in the community.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804536888\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23444899\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/13/36049?source=see_link\">",
"      Patient information: Bedbugs (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23444916\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"      Patient information: Hives (urticaria) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39286?source=see_link\">",
"      Bedbugs",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Nemours Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://kidshealth.org/kid/ill_injure/bugs/bedbug.html\">",
"        file://kidshealth.org/kid/ill_injure/bugs/bedbug.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       University of Minnesota Department of Entomology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.extension.umn.edu/distribution/housingandclothing/DK1022.html\">",
"        www.extension.umn.edu/distribution/housingandclothing/DK1022.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       University of Kentucky Department of Entomology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.ca.uky.edu/entomology/entfacts/ef636.asp\">",
"        www.ca.uky.edu/entomology/entfacts/ef636.asp",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     UpToDate wishes to acknowledge Kelly Crowley for her contributions to this topic.",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/30/14817/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/30/14817?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14817/abstract/1\">",
"      Kells SA. Bed bugs: a systemic pest within society. Am Entomol 2006; 52:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14817/abstract/2\">",
"      Thomas I, Kihiczak GG, Schwartz RA. Bedbug bites: a review. Int J Dermatol 2004; 43:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14817/abstract/3\">",
"      Cleary CJ, Buchanan D. Diagnosis and management of bedbugs: an emerging U.S. Infestation. Nurse Pract 2004; 29:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14817/abstract/4\">",
"      Elston DM, Stockwell S. What's eating you? Bedbugs. Cutis 2000; 65:262.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_30_14817=[""].join("\n");
var outline_f14_30_14817=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BEDBUG OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHERE ARE BEDBUGS FOUND?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BEDBUG APPEARANCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           REACTION TO BEDBUG BITES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           DO I HAVE BEDBUGS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CAN BEDBUGS CARRY DISEASE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           BEDBUGS MANAGEMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/1/20500\" title=\"picture 1\">",
"           Bedbugs PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_30_14818="Degenerated uterine leiomyoma";
var content_f14_30_14818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterine leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross intraoperative photograph of a degenerated uterine leiomyoma. This benign neoplasm can mimic an ovarian tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mitchel Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14818=[""].join("\n");
var outline_f14_30_14818=null;
var title_f14_30_14819="Anatomy of the anus";
var content_f14_30_14819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Anatomy of the anus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anus consists of a mucosa-lined anal canal and an epidermis-lined anal margin. The proximal end of the anal canal begins anatomically at the junction of the puborectalis portion of the levator ani muscle and the external anal sphincter, and extends distally to the anal verge, a distance of approximately 4 cm. The anal canal is divided by the dentate line, which overlies the transition from glandular (columnar) to squamous mucosa that is often referred to as the transitional zone. The anal margin begins approximately at the anal verge, which corresponds to the introitus of the anal orifice. It represents the transition from the squamous mucosa to the epidermis-lined perianal skin, and extends to the perianal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14819=[""].join("\n");
var outline_f14_30_14819=null;
var title_f14_30_14820="Lichen planus nails";
var content_f14_30_14820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5aO7efmPX1qSPIIySfxob/WNx3pRycChBc+hfgBahPCAmIbfPdO5PrjC/0r2iLKQ45+bk89q8r+BcGPBGm5BI/ePx7uf8K9QB+4T0PBH0r5/Fa1Jep7VJWhFeQonIORkqDgLjOKtBJWXd5se7YW2oc7R7+9cwl2fOICsBnnJ7VtaeyyJJGDKGcLtWI8nnvWMFc2cLK5oK5AO2QgkcAR5JqJlzEXAQxAKWdDgpzgnFaXmIsrQ4W3hZcqxy2W9Cayrp/ImLlDGyFY5FY5GD7jtznmt3GxEHdio68krjICkrwCDyDV62kLxOGI3LkZI6elY4Jj8tZCHdZNjKCPmC9s1atpW83A/djjBf0/ycfhTiypxubtqUkgcK3zjB3E4x9KY8fm/dGGU8NjkVHDKolcE/KQGJ/T+lWPKLKSAXOcjBrSymcr0ZKJC8G5uG+63PGfauE8fMBp0zKPuHf0rsJCU37iM459j64rj/ABt+80mdFGSUP8q5MUrw1NsNH3znbK/+16Im5y7R5TLdT3H6V5V41vJrWK+VXKNsz8h/Sun8KXu+yZGYfN8pGehBxmuY8YWT6lr+m6bGSHvriO24/wBpgM/lTpQu43O63I5I9x+Gmm/2T4D0CwcEPHarLIDnO+QmQ59/m/SuvLb8rkscdT3qhFGGn2w4Cl/lX+6uMD8OK1oEES7SGJBwcDFac3O36nFKyGWKfLE6AlsHk9utWFtwwZu4HTuRTd8irtiiVQCc72zkH2FVJ4p5CDJOyqO0YxkY966ItRVkiEnJ3uX5BbxRjf14A5xzVG4u7eNz84DBhhOOPWqE+mpJncZZcHnLk81AdMs1b54RuJ5D5pub6I2jTj1Zfa4tVl2kKu9jlQ3QexqZBAVJwQw5PcAVlrpdgDkwKN2cPk8+1SSaXGsAe3luIYzxxJx75zUc0uyG1Do2a+yPKYw2cEe4pjW6DJKqWB4xWYlrqMGBFPHKmcgOMfqKkivXiBFxE0RzjLcj86iUo/aVieV9HctFSuNjMD/dbkGqc5VlYNgEdeMZq4riVcgblPIIqtexsEwOWI+U+9cla1rjXmYl/NnAOd68ggdRXkXxNuDBpWoRq/Eu1F/4ERXp1/MTbSMgImiyR9e/6V458T5Q8thCrcXFyrHHdR0/nXPRXNVidtJcqbPUfBWbfQbFfu/IoHcHiu+0u1IUSS4Lnk+3tXC+GQm21X51QKOvTIA/pXpdspKsInAHqFzXXFc0nfoc1eVvmTsTHlThXHVTnJ+lZl3dfIQpOFPXuamu7SSSMsszZ7ELzWNPY6kAdt1FtBzgxkt+WcVpKo1pYxpxi9Wy8tyihnLhmHC5/oKglukEmBgnvjoKovo91M2ZtRbpx5SAZ/nUb+H7QuGnmu5fYykCok5PZWNlGC6jb7Xbe3DfvVzzgZ6jHTFQwa/ZyJG0su3PzOSMVaSxs7OQ/ZraFOMblXJP4mp1YfNuRGUcdKzUX3KfLbRFVL+3ulYxyKcenYVUlQCUPbPtbjeM/K3PQ1FqmnW0+90VoZem+M7Tx7VjyXd7p77bqNJbdTzMvB9siolpuaRinsdFDJ5iMpOApPBHT6/0rmfG1t5ln9piBEsbKWx3XPIrTtLyOSN54nEm8YJBBH/66ZfRNcWjxSjLOh3AY4rKsuaNxWszyvxHKHubOMtgoWkUH+IdMZr0PwTaJLbqJgpweM15rds0viGKDaWMSbT7ZNe2+GLSKOxiDRHPc45qIRso+hdZqMTah09dvyyOh9jUwtpF6XRz7ipYol2cZ9ODTZYyqnEjA+4zW7fc4lcqzxzKoKzA468YqlK0xBzECP8AZOTVl5XJIWRT26VGfMAOHXn2rCSXQ1iZsjKSwKsD9MYqhetG0ZUkn3IrVuTME+UIx75NYWpTy7HEkYAxjK81hI0ijk/GV4lnoV/KrbXSIhT7mvmzzGbkscnJJzXr/wAWZpk0UqspEbONy+orx4+g7V9DklPlpSn3Z5WZy99R7EyysRjJx9akjYl1yx6jvVdSOKljJ3rx3r2jzRr/AH2+ppmcA/Q058726daa33W+lIR9U/CGH7P4P0ePBJa2DjnuST/WvRJjtgLAgFUyDj864/wHa+RoWmAjlLWIY9PlrtpAv2Y4wAykc9uK+crO8mz3bWSOQwyXpdh+7OBkHv1Fb+n84EbYcDO5T8yjuaypLWHfmZd2T8wQ9eOn4+taMN2zhGt4bSNEPlIuPnC45ye9Klax0N3WhvyKPLV4iwI4OCT5jf3sfSsu/l+0TTygbFkTryQCMDp/jVi3d12rl42AyrIc4PfHpmnbI1O1gWPJJ2Ekj0NbSszGPuspRRPJudl27xtORgMfT61oRwhDIHO8LtG1+qsP4R6/WpEtLhlDMgUNhtp5/L3q3FHDGzMwRiSff/8AVQrvYJzuJBbgQhpcggY259TU8cZUgxTsoI4yM49qTcDg8YA6A09CMZxgt6Gq5TB+YyWOY/fVGb1Brl/FuV02cnA+U5/KulupNicEAYzwa8u+J+ueRo9wiNgspUEHnJ4rlru2hth4tyR5p4WuNonwNyZYj/vrrWv4ZhOofFLw+GzttxNcN7FIzg/mRWJ4WiZYlPI44967D4c2xfxbqdynLRWYt1Ydmdwf/Za0g+XU7au/yPZNFR5d8pHDn5T7CtYqWHOeKbaQrBbqAoVEGBk0y4ulT7g3+wBranFQj7x5jk5S0LAVRknAJ/iNVbtgIXCZZiAFOfWqj3jkKqwTFum0Diq32u6jdnewlY5AQnGFrT2sehrCmy8lqdhLFRGTksTzn2pktrkDbJIAQMHdn8KrJdX4IdLJygO4DcOT9KlN/fYbfZOCSGyCOuKXPGxfLJP/AIIhgkVdqlj3B6gUnzIMjOPQ9CfcU7+1cHNxazLgbS23io/t9vKxUOB6AnGKxnKPRglLqiRZmdMKSQn8GeV9qtRMkihXGAwwcjv9KqpFFI+WOQR16Y460+OzOFEcpXPK55z9KUZNrXUUkh5tVjb92xiI4+TofwqO5P7siUjceVYVcgZthEy43HO8H0puowOLcsgzxnB5B+lY1oe7dEKWtmcBqbCO+cPwkqMvB7gV4j4tja78W+HbNSNxByOw+bH9K9c8S3Q89mQ8IQQR3B615hFF/aXxSto8ZFvDnJ9ck1y4L+I32TPSjH3PuPXbBY4oI1U/KnH0bsfpXY6XejY4bhyBla5a1tJSisu1sYVh6+1aUUdxGyloZAw+XI6EV1KVtTGcVJWZ2cbh8ckn16Ae1MaFS2RkEdKyLW9ZECPHJnqPlq4l1vOCHI/3TWvPFo4/ZtMe1qYmOJGVPUDO2qNxFKv/AC1QnB6rV9ZFY4yuB2PWmNlwcEZ74FZtdik2tzCktZXQZA644fH8xTWs90fMk6ehDDg9/wAD61rSRD0OetV2iYKeOv61nZo1UrmFc286KQk6uCMhSvT1OapLHK8pF1GI1IB2Nzu/pW5coAMKSCO/rUEaB8hhkDgZGc1m3qbKWhitocL3Ekqb4MruCxHaByPwq59gaBCUm3gjIDjBNa0MAUEk4wSMHnpWH4p1IabZSvvHyqSvPTAzisa00lYjmc3ZHkcZJ8famV27UuSi88cV7voTM1tGSOeOM180+F5ZZNRadwWaWQyE+pJzX0b4VnZ9OjDK2e1bOPLU5fJF1leCZ0gGFGAQPpUTuwBAYY9xT0bIxlhTHXHQg+xq5I5ooo3RQABoxk85FUGET5w5Q+ueRWnNGwUBVBz6Gs2dIiTvGD64xXNLQ2SKs8UqLmOYOO4fqa53VZyiOs0bIPUc10MygJkA7fUHNc1q0/7tkzkDpmsJtdDSJ5F8VmjbSX2MT+8HWvKMcnivTfixIFsYUGP3kmTXmYPU8V9PlCthl5s8XMn+++Q5B04qVAQ6n3pFUY6805Ad6/WvTueeMdfnbjvQqeZIqd3YL+tOkB8w/WrWkR+brGnR/wB+6jX82FD0RUVqfY3h6DbbRov8CKvT0UD+ldAwDQeWw27l25A71h6A+I2yDy5+tdJFyCOD/Ovm/iPcnoYF1E8fyzAlTwWX9DU1pHEyBR5cgjyu4DB2nkgj1Fac8TIrgLvQ9FHY0yFIy7YJVsZ+YDI5qYrlZXPoWLezQ+WUYYJyxHcdv/1VeSOK3UKNoPQ4GP5VBDbxqxAUkA/QGnyOoG0gYHbNbpGLfMxJLjMgCkMfVRwKgOP4iT3xjrUpX5iAVGM5I7VE+QBgFgRxjrWiVikl0L0EhEZPyHnAB/lTZJAucDGOQKoPJIMhUC8gYduv5fSs+6lnflZkCbc5QHj2qKsn0QKndjtY1Bbe2dmzwOK8E8bX7avqixQAuM8KBnOD0r0fXNO1HUrlbaO74Y5bauAq9yazdP8ADdvp6tMCPN7s3zGuOEZSlzM7qShSjfc5rT9PltLJXkxntt5x9a7P4RWy5u5znM12cZ7hFwP1JrndenWGKUZAxnnpxXZfDa2e08J6NLIhDSsZ2Of75OP0xWzkuhNRtxbfU9SSMbVL4JAwB2qMuR8owB0yMcVPbZeFccjnHtUU0bbtyqOCDzXdHRHkx31IyxIIBPTlhz+FV5Cvmx7tyJghvlzipSwVlzhBjOAec5qZSu0EI5OeOwx6U0zZaFKOaMZAZmKjAIXt/jU32iAxgl1HP3TmkaYqPugAA5APNRicrvO1RnJIIzj0xRcvluTFllTcjA59On5VnXlnFOxEsYyM4OKmkWBgWWLYD/EG25/zzSFdmNs7AZOFfBrnqa6NFQTWzM5oZYAyQTkqMgK/pU9o9ygDOi49Bz06k1O6lgGLo2eDk4IqxZEJdKAAAcjDDI54rnUfe0NJS93UsxDCFAVkJO47TxjFNeVVhyvyoRwDSiFVdo5IyFByTjkH1+lVr9dsbDdkdscit5/Ccys2eS+MVEGpXsQ5WXEi+3r/ACrhPA7m4+JOsSKA20KnPbAArs/HMgbWGVT0QDGe3+TXEfCJWu/EOr3IOVlnYYPcbq4MGrc8vl+J7O0Yr+tj3jT0JQAYIz0rdgiBAViR+NY+kZUjcBwOcjiuhg2OBg/MfSuuGxwVWSxxOM8Bh1yeCKCrAtuDoO2KlXchAyp780MWVQWjOCOo5rVxOVsrTIxT5ZMr/u1V8uZicMhHuMVdllTHIbPrjFVnuIw4xIRzjDVDiuppFsgYzf3Ub6HmoGkIz5kUgA9OasGQEZyPrmqrMOqE88fL61nJWNEQuyMQFYEdfQg/jVSRRFvOBuAwwH86tT+ZsJD5OMkFeaxtSM6L8pjZcfQ1zTNFqM1C/WGGQq21gTtzXlHjDWpNRt7ssCscSMCCe/Suj106hMzZiTb6765DWbORNGvxIRvK5OB71yRadRX7nTCKSM3wZbFpI9o5yOor6J0CEw2ceRXi/wAOrPzbiI7PlyDzXvFoNsKqP4eOe1dcffqykRX0SiW4lAHJH50vAByCcenNMBXoSKGZNp4yK1kcyIZ9gBwSvpWVds6g4KuvfNW9SI8orHnzCMAZ6e9Y93JMhCeX16EVzTN4IqXeF2lCYy3T0rntYcFSzrngj0rbumkMZSXPyNkDFcxrU29ZGUFQDjmuKorGiWp4r8VLgPqdvAvRBnFcOgGSK3PGl0LvxHcHPCHb+VYsX3iT2r7TA0/Z4eET5zFz560mSgU9OXXp1pvXA6U5Pvrjnmuk5gf/AFjfWrmhEr4g0kgdLuI/+PCqjDLtz3qxpkgi1fT3PRLmNj/30KJbMqL1R9h6A2Y2H+2ehrpLfAUYGB71yXh+UeTsyB8/X39K6iAMFBXaeOvTNfPQ2PdnuXlKkEE/N2BFK9pDKM4AIH3h1FV/tPluQ29e5BqwtxBu4ljGTxk4P61tyqS1Is1sRNa3UQ/cThxno1QyG+RhugLjGPkIrRW4j8pcTRFt2OeRnHbmp4RFJc/PcQqu0HPTdzR7Dsw52t0YRnuFbEtlcIewC5yPwqJrtskCC59DmI/lW60i+WQxj54A3A0srpgHzFAxnIbdx/Sk6b7l+08jmla6kYqNPnUdRkBRTo7K+mfdIIbdc8bm3sOOuK6F7qLao3rge9Ubu4i2EBzn0Xv7VEqaW7GqjelirFZwQQlQWLdWYAAt9TXPa1fQWodIl5zgKo5OfWtm5k3qQyzDIxjOMVy+sPGkZKhf97OT+dZSbasjSEddTzTxc81wJYypG47UXPUscDP4mverCyS00+C2QYigjEQ29AFGP6V4W+dQ8Z6LaqwdZb2NnT1VTuI/IV7/AAMWjO3qf1pxiuWxWIeiRrWBj8oADIA7VNtR25HHpVGEBOxUZ/h5qyrFQPnP1xXXT2szzWtbjSqpgRp+VKDkc4P1OKdk5ySSAey1GHVchi4B6fLzWhogeJiCwwcnselVDCFmRsNuHUbuT/8AWq+JIyuCyg9t3BphXdJlCCuOo7/UiixcZNFB4iQBzt4Hvn05oRS2dyHHpnv2q35b7QRGpxnnNMMbKBtKj6DLGpa0K5yqIG+9uUBSc4qdf3aKnfvz3p5CggFXOOxHWop22jP3e+D1rnlGzuPmuX7eYM3VmDLwc9DVDWbuO3tGMhG1Rniq8t+II1JyQVx75rzjxr4klvd9nbq6Iw2tIx5P0rkr4hRXKtyqOHc536HJ63efari6ueoyxH0GT/Ssj4Dxl4Z5QfmeTOfxqzrQ+z6FevgjZA5z/wABP/16n+AMH/Ej8xjgseD+NGEVqMn3a/JnoV2lKKXZ/oe32CnaMjjOa3IUVvm7+o4xWXp6Hao4IxnNbCEhACnbtXXBaHm1ZakgAU4LEZ9TTiUH8YJxg54pgUFuCw5GMdqeA5JOFZB/erc52R4GGw+SByBVWdA5O4KTjPTNWJWjWIMUA3dWB6VXZdrEJKxJ4w3NZyKjcqvaQjO5AD2HTFV5LEhhsndcA++R6VeeV13FhGR0Paq5mIBKwg++azkkzRORlzwTquQ4fjOSvP8A+qsjUPPDNmMMvGSpGK3rqTIIKPz0JA4H4Vk3U6gsMNg99lcc7G8Wzj79mzzG+Oq4Fc7ris+nXJEe1ShwSeT612l3sLfdckDIIHT2rmPEjbdOuVIIBU9Rz2rzHpUR1QZs/DSwVbJZjwcdTXpEJ29XPPAx6Vwvw/bbpSAkbe+RXWR3SR4JAYk8D2r1aTXJcyqpuTNQMu3AXBHcnFRTOAPlcA/Wq7XQZiPLcZ9KFmjwR5bE/wC7SlLoQo2IZd275ZA1VLkkD50wOzDtVuR4yxCLxjgHrWVezbZSoYq3909DXNJloy9RWU4CuHB7jvXKeILgIlwjHCgFvoQK6W724Mke4HPI/wAK4nxnP5el30nGfJJBFYNc00jW9keAamzNqFw7nJdywb1FNTqM/dqIMzIAfXg1NGcYHavuoqysfKSd3cc3SiMnevHelbpjHWkUEMn1oJJG++31NAby5Inx911P60053Nn1NJJu8onsOaYLc+t/Db+Zgodyttb25ANdjCZCCI27fdP9K4XwZKJrGzmUDDwI2B3G0V3VsgCkMRgdMGvnkrNo96T2ZJ5si5JRj64PWlG/ew+zAkDPUHipfLO1RsBUdBu5pWeRM5iO0nseT+NbpW3BSJTu2gCzVj8rDGOfXrU29VcP9gIGQdpC9u1NW4I2GQMhRsDK5GDSmaNlYOYDjPJY4/CrtHuQ79itdS9B9hkjy+7hAePTrUxkXARbQqAu3kDk/jVhmiKrsuIeOuASSPUmo2wSwW5+VgMkJ156UuW3UfMmtiuZGC/Lbxhl5wcc1UuZJSrFxCozwR1H6VanySDJM/zKc/Jgmqc0IH3Xk5OSGGaykjSPcytQlOHIuAjkc4FcfrNxFEjfMXkUk/MCR7V2OoLiEspBw3JIGfpXCeI7hUSXa4Un0XB/KsGbwZi/D3dqXxJjnKfu7S0mnzjGScIOP+BV7pAFC/LwcYrxr4QoZfEWu3TEkwwRQKf95tx/9Br2a0TcwwSR6joa1ir2RGI3LoOOHG3uMU4AcDjkfWkHQrkkHjHQ1KkSHACMPX1roSOJuwoRi/y8HP0qQF0Yso3LtxwaFXBIDnP+0oNLsw4HnR+oytaJE8w5XVgQ6rnOMGq0ixEncmMcfJmpSkj8GZOTjBXg1E1tMSQssRx1GCKH6FJoieKMD5Q65HGGzmms77ANm8DuetOkScAnEZI4yGxVeQT45RR/wOspPyNFqNe4dVJMUn1xWbqGpPtb93O/I6Ia1UZ1T+A49CSaoahJJggbixOMjgVyVb9zSLV9jkNXvdQuGEdtauFPRpCFH865y30maW4MtzKvmk8KOcfU12V9DNK+CqLjs5z+lU2tAQTJIQvYRjaMe9ee4K92dsJ2VkeeeP08nw5qjkjaLd1H1xitf4H2rR+ErByCNy7vwNYfxgmjh8I6hFCxC4QYHTlx/wDXru/hVbCDwbpKMMMbeMnPuoNd2HVqF+7/AEMqsvfS8v1/4B6JYJ8q7uorWjXCnnj0zWVanaFxggnpWpGTtHHHoa6qS0OKqTqMLjOQAKbIiKueQAMnbxmmK7A9e9O4bneAM8Bjx9TW9jFXIJQxjZUYdCcuM4FVmYiMBkzjAyDn9al2vMjzAny/uqFOOOvXvUT5EhARhjqTispR6m0StMRnAyq1A7ALjzFJ29COtTSSoDhkdsjrjpVSSWMMEePDAdx3rlmaoVyegVHA4I3YrD1NnVyfmA7jOc+1aU/llMY2Pn5gcgj3rH1AlVUg/Nn0rmqFwWpkSeZISw5z2PGK5HxPIxhZXZfmYDj0zXTX0mzzMk7n5wK4rXZBLfWsI5LPkjHUD/8AXXnct6h20kd14Q3R6eo4A69etdfbyblwRgAcY6Vz2hReXYoEO0helbsLseQVyR3FehT0jYierbLsOXUgcnNB3K2w888g9qbEZAow4B/nSFZt2N5YAcg9qJGRFc3AXhkzjowHFYWqOJlzuAIOQR1FbTxtvwxIUDOAa57UU/0h2Tr3GcVzTRcdyg02Y2V/vevrXnfxNmFv4budp5cba9Alz5fT5h+v+FeU/F+fbo0cZIy8vFGDjz4iEfMnEPlpSZ5HGOQBjA61YK7ahjXk45NT4z169q+2Plw5HfOaE4kXPqKFBGcmljJ3DPPNIBG+831pxXcpAPGKRh87fWnxdcVQPRH0n8Lrnz/CukSFhv8As6jPpglSP0r0u2lHk5AHpivFvgvdl/CdpGRlYpnT04znB/M17FYMGAJ+8RnA7CvAmuWpJHuwV4JmtDMpVTuxx0zzVlSNyrvQA9STWdC21iSgbI4IxmtG2Ysd+GPHAAraLYpKwbwgPykg91Oefzq0JIvmMcUysSeSucDbz+OaahlAXMYx1wTil3ERneHHJI2rkDPNa2ZDdyASygjbBAp9+SeKUvdNIrbY1bgDJ/wqWMqxB3Db33dc02Qq2O4znp3qGn3KVuxVuPPZiH2dNvANUpo2Kvlz/e+7/U1qOF5+Y+3GKpz7AxDByD655rGSLizntU3i2cRuflOT8vWvOfEEpDSs4dnOeeoBr0vVmVlwVcY4GOK8p8UOqxSkb1+vrnvWDOmDNX4MurtrzknP2mFTxn+BjXs1kGKDGNxPc14n8DZd1tr/AMwIN5Cf/IbV7fpbgjLAA9hW8VaZjiH1LQG3IIOR0JHWpCVJBO3k4yDUrDCk9sYNQPGpJ4X14roSONO+5LGu5gUZ+mexocNzllYr1B4NR/Z1ByFYZHGCaZJGDyJZVb65wfTmrtoFkJLNMMfu8gdApzUZeYYIgfPue9OMRTnznyfYUGI7sfaG5/2BmodzRWIWmfb/AKmUjGPu55qCWf5wSjqe2Uq26OFUeaCfQrULeaAApX5TgcHmod7FKxWebK5WVlPYbcVnXdwjeZucsc8HrWjN5m7BKnAIqtIHZCPkXHtXLUTNYmRcuSvyRyE8DLHH61QuLdpnJnkXZ/cQ4I49a1btyANu5s8YHFZt+SqEjaqHPHeuKaVzpieL/HC5SLQ4oI9q+dOoIU/3QT/hXsvgKIxeGtKRiBttYv8A0EV8+fHK43X+nwL0Akkx9SAP5Gvo7wimNOs++2JF/wDHRXfCHLhoebbOeo71pLskv1Out0ztJye4wKvFipX0Oeaq25I4XPP4YqyRlNuc8df5V0wWhzTd2NdiHUYHzcdaJGBjciRkcDaUccEHjj3pI2bcokA3dNxHyn/D6U6UkoAVyOvXdjn07VqldEkUyEIiyCPcBk44IByetVmd/KCyLIzBeoOeas3iRdFZIwAAVQ9c4H8s/lVC4kWJXZJdyhiAV4496zmuUuGpSmkLZEwBwMDPFV5HEj7l5bGAA2f8irUlykoPHI6Arms54oxOWbJViASCFIrinY6o7EM+4yKULPvP3WrOuZXeIrhSwIyxfJX29x71YuJGS6WNdx3N8vPzH3BrMmkyP3gIbbgDpxmuKozRIzdTdgrnAwFxkVxNsftfi3aDkRAL9D3rtNVc+UUxhdv6VyngCH7Vq0904zudmH5//qrnoxvKTOqm7RueqWkIRFC88DJPpWvbIG2ggKB3xniqdtH5gAUYIrUtYOCCOmOQ2DmvQtY5nLQbyE2AEN64xUckrxITj5u+eatXCbRtcMR/eYc1TdVk/wBXNsb1PQVnJiWpTeZpC2SytjgCsV4yZdzfMOrDNatwJLdg5ZWGc5Axn8azbmTEhwACwxXPNXNUjKuGDSO3OG4+hrxn40PhdPQEHLMa9iuDtkH91uMntXi3xnY/a9PTthjmry2P+1x+ZhjdKEn/AFueexYzjmpSvHUVHDyMqafj3/Ovrz5sU5NCj5l9c00AnkHjvSqD5ikHuKBCn77fWnDqeKYT87Z6ZqROp78UwPYfglLu0m6jJwqXZOB/tKP8K9v0z7oIOeMV4T8DseXqynGBNGR+KmvetOXKLwBhQODXi4lWryPcw7vRj6GjbpkEA4Y9AKvQEKqgbiCcDJqkm7JC8DOciri5AXADehzzRGXQqRYXeCRv3DHVfzqWJN2CwJGeAxyPqRSxZTaAUVxyMLn6U5skN5haXjk5ABHvitroxbGnHz4Kbs9AR0okVHUDeCBjaM9KcVQHdsiU9ADzS8bdpKA9DkA/rS33C4xoyF+U4Df3apXKsVbJzVyVgOCgJPdao3UwEREecHrWUyo3Oa15ttu2Rzng+leReK5W8qYOSWOWPNepeIrhvLkUAZJxj0NeSeMWZQ4Zh9zAxXN1O2Csjb/Z/ctB4kXjAurc8/7kle56cAOeAfT2rwv9nU7rfxQTj/j7tuv+7JXu9uOF+XB6/wD6q6ZK1R/I5pO8TWQqxAPX9KVos/dyGJ7HFV48rlgc54we1TB8KCT064reJytdgKkFm87aRwQcHjvTJI2ZgTMGJ54ZamRx93O8Bc44onKBcmIldvTgZPr1rWwk2mUTGCFLTuAT0Yj9KRoy0mwXD5B9RT2lhaPPlhQRjlePwpriHfIV8k4A+tS0apshkt12o32iTpg/MKjaHcuBM2B/tCrLzBowEXIPB2KOKjwwJ2gLhcE4/rWMkik2VJYoxu2s546ZIqq8XykEuKvOu4j94WwOACBmqxRGyG4XHrmuaojSLM6ZURNx+Uqp+Ynk/Wud1KWJlLDLMeACeOtdDeqkkbKgDcEfNXM66dtrsLABTgKF68cV59TuddNXZ83fFu48/wAXmMdIYUTA9Tkn+dfWHhhfLtbfapVvKXI/AV8g+NWN74+vVXLFrlYgOvTC/wBK+xtBA8tV6EDHP5V69SPLSpR8v8jgjLmq1ZeZ01tynzcnNT7ePfHaoLXkccj0q2MH7/QDFaRWhnLcaijgkA44xiq83lwxPIrIDxkYDce+OatM2EfcFwT64qlM+/cAAwPbp/Pir5khRTbJL4zNcqCmXjO4vG2RjHGAe/NZ1yR8pcli38Rxn6EVPtULt3Sryfvj26Cq13AcMd2QpBAC847ms6ktGaxVtDPcmKViPuYDAjPBBwePpVGRlyWC8k4DEe1atzAqPFtchQpG7IPBx2rPmhKSBk3EgYKkcEf41581Y6YsybuZJYJC3yqBkOBxn1HvWUUZ0JYMHX5Wz61v3UeIThWKn7wxWZdjYBKG6jGO5965KuprFnLeJLkw6dPIflaOJmx68UvwutWW1RsZ464rN8dT+Vp0gUjc7LHg9Dk8/pW54JZbbTU2ZGTnHp7VOEhpfzNmvcsd/aMFYbhg4rVtmVyeAD1rmI7r5STz3zWnbTNKhGTzzkV2VNDH2bNO4fchIcEetZMvlsDlgeeNvGafcXPkhQRlR6VRe8jCEue/HFYXuXGLQ8yBkZWOV7A81namFONp4A4NOvLpAFWNuCM4FZ0k5wAeg9azmWo9TP1RwqHbwfSvEPi9KX1GwXOcRMx/Ova9SJSNiQSDXhHxTk83X4lySVhzj6k1vlcebFL0Zy5g7Ydr0OUhBHA6Yp5XsRz3psRwMdqeRmvqT5sSTGRg4oQfOpU8ZoIyeooixvA7g0ANz87Z9alGevGKZgb2+tSRjJ+n60wPXPgUny6q7AY+0RDOemFP+Ne76Zyobg8cn1rw34GYNpqgGR/pSAnH+zXt2nMUHGBxnnqPyrxcX/Hke3hV+5ibEO05DKPm7nOfwqwkgLbVDN1BC8Z6cVTV9rABh0znnv3qyMMWJQ43fMenbt+lRE1aLq5XcxY+XjpSiZSPlyT15Xg/hUMaO7ElguR8p3cn8PSpI/JD7pGOMdR1zWpm0iSOVHDHAIJ52rz7/hT02bjjJyP4lpkYDhSA5yPmGzhfbNTRsQo3RyqB2Cj8KZm2V7yQrGxC8gZz2+lZ07t5bOWUEDk/0rXuwzkHy3yecHgYrKuwfKZWRkPUHH6VnOVjWm0cf4lcorHaORnnrXkHi+YHczBeRivY9cth5bYChWOdwGSPavF/HSiIMq5xuwPwrnjrI7Y2cTpf2cmKxeJ0xkC4tmJH+7JXvllggZycV88/s4Pu1XxRAMZMdvKPfDMP/Zq+h7IH5QRtyO9dc1aq16HA2uVFxCOuCPwqTcoAZh14GT1qOIHHBG4cnPSgbdgRt23sc8VtGxnYWWSZGHlDcQuCCOKtszjHnRSEjH8WSePr69qgVYtu7ecqPuo2f0pYL23gg6MCw4DAHnPqK0irO7ZMl2RFDfCVofNWaKIAhTtJ3AZyePyqubsvuZIWkIfZhiMDI49/Wrk00UbhoZJxExJKrG3yE5JxkdDVSN1dGZdxbfndt/PNKT6XKjbewpZUjDEIWI/ifIP4VErh1zhlA/hTvU02dhAkUAZxkZH0FQqrKpwSee45NYy3LRQumcOu6MgDPDNgUxzk/IgPHarF5vUDJVvTOKospUFjhmHr/TFcVTc2jsVJ3Vkc55AyexFcnrkyxxEBc5I69etdPccoVbJJxxXBeMrzybW7m+UJFG7kemF/+tXFU1djrpLW588Wji9+IUD4yJtTU8+hlFfaOnRlFboPmOPavjL4cQfbfiBoMb5O69jY/gc5/SvtizGRkdD05r3MWvejHsjycM7xlLuzXtgoQY5OO/WrCybVA75yee1VoMANnsBzTySy8fKAeSOaV7FtXYXGTkYHJ5welQtuG0cPkcCpiHLKMnBOORimFZE+QvECRnbjkfjSY1oNYyRRsvlrjg/eqnOzFG/dZGccPxzU8jNzgLkgcq3NVJC2AXB+8M88Gs6j0KSK9zISg3IxGMZZfp3FRMsbAlc5HJwTTp5QnCnIOeh/So2kwnJOCO/auORqloUb1Sg3K7KMdCeKw7xskq5zzwc9q2L1lc/MTg4GT1Irmrp2EEmT8wY7T/KuGs9DeCucD47l86aygBHzz7vwA/8Ar11WjQslpAq8cDPHeuO1sNeeKrWJM4RMn2JOa9G0+32Rx4UZBH411YdJQR1yajFI1tMtWnDEDgHkgV1EFoiwqWO1u2KoaFAywyY/dgH5uM1rW0wZSvIYMRyf1ptOTOKpVbehXu7OOSBxvPIzjFc/e6XcYjjtl35GSc9K66QRFCwkPTdtqpKjM0OEBAOTjjj+tZSTi7WJhXkjzfUILm2O2dcAEhW9aqxXWQAehPeuv1+2Ey4OAucjFcRcI0EkgzkDHHpWDlc76dRVI6kmpyExhVIwcGvnvx1cfaPE12QciMBPyFe63twFgLHsMV86anN5+oXUp53ytz+NejksL1ZT7I8vNJWpqPdiRBuSelSYxTUU7RtBx3ob15yK+iPBEHXjtSqBvH1HSl6elC43r05NUMQHLH3NTLjGR144qvkB2z2PFTRMRzik9gPYPgiSNP1E5x/pi4/BK9s08kIHRSoPXFeJfBP/AJB1/uHW66/8AFey2R2hFOARkD9OK8TFO9eR72FX7mPob1uuWKMwwVC7j0yfXNX034Z/kwW3eZ/D6frVCBVWMHJ/2h2rQjkIcJITvXOCOhGO304pRQ5DvMO4jaCR6d6nRXYgAY/h+bFEQYlSCjbudwPB54xU58qOMOzFWGcE9c+wNa2sYykJbtdbGVQjJ1JPTr6UwySAkngn72fWhZZjEjRQFVA27s43VBJNNvJlhc567SDU+0VupKV2PedvujH1Of0qrcXDBfm3kdx96nC5i3k5GQcYPUfhTnmQ8LGeepxispSTLWnQ4/WriDcyrui5yQRXk3jm3WWGZ0BOw8cda9l8RLtQuIlY8d+celeceIIfNgnjZSqlTgHqPSueL1OuEla5zX7PLOnj7Voe0mmFjj1WWPH6Zr6Xt+Y8ckDu3evmH4On7P8AFlI1ztmsriIgey5/oK+mrQ/u129cZ5rvqS5pJrqkcjjZWLgVcEjgY656UoUEDHzew4ohQgHeDkjOD3pWBXnKFj03DOKuJCHRlbdHZWdX6jj+dXjEwnYm1LsAGDKQN319fxrPjDSow3kDBzgdauQQ4JIxI6jAY7iR+tdEGRPQS6jklZhIfKhx/fJ/kKy2jihQbXIjY5Kqu3nOOtaFxNdLscKrLj5/3eMfrUU6SSA+azqAMZwuPXNTNJlQbRRuFhQsVByD/E24jtTHlCJtVDj1PH1OKivw24BJpcE4BwAKjm+0fKCW3Y6Ej9K5ZOx0KN0LOerfKB2OOtUZchiSP1qfYwtwZWJPTBqm7YIHABrkqPU0iivcnLc5AHcV5H8VboQ6DqrK33oinHucf1r1a+kYByXVFAPA5Jrwv4y3OzRZkyf3syrg+nX+lc9Jc1eK8zVvlpTl5M5H4HWrXPxK0xhgLAsszZ9BGw/mRX2Dp0iJCqgEMcZBHTNfMH7OWnibX9WvDnfBbLCox3ds5/DZX09aKfJByMdAW7162KletZdEedhYWpJvqaKlirbCu3PNKHYMcuQc4yKiBCBlyAD3PFBkijP7xxkjgLyfyqbm6RP8gY7m3Duc5pVYYCxqqF+Tz1GKoma4lfMMeVII+Y7ce9R7rogjfboD1G0k9OtLmBwL0m+TAdlBPQYqnPHJ5bqrjjjkdKb/AKWXAMsMjdgV2549aieaZARJB3+8j1nOatqCjYpX6ksCWCMR03cH8KhEkixg+WrqRyBxj/61T3N5G48sls5zhhVKQ4ZSrBSBnBP6ZrilJXNoor3LmSBscFlAC/hkmucvziJlB6Z61vXgaNSVxsZgevKk8flWBrHypnqoGSQe1clZ3VjeCOO0hPtfia8nYjbGQm7HoK9Q0O0EkxLjMcYG0MOp+tcF8P4QYJ52ILTOzY9q9J0OYiKSIlGjVw3Bzj2NdtKyVmPEyeyOhhUAthcLjjjFNSJQGOOo55p5cMhboNoNSopEZ9SOKq6OBGNqcTC2kZSQAMDH8VNiuLi1WTy8NG4EbZ/h4yCPyp+ryqLG4ZmIRI1QkDkMW7VHcRFgis3Rdx9zXNOXvXR0LbUyY74uzQzquDxux0rjtXkJu2GArj5SP610t7EwlcD7xI6Vy+oxs14JscOmTz1wcVyyeuhvSSTucx4vuTaaNcSnkrGfz6CvB+WbJzzzmvV/ipeCHSjb5+eaQAewHWvK1yWwvHYV9HlFPlouXdnj5nPmqKPYsR8DjODQT3XkUrDA5PTr9KAflweteseYNY/MOKchHmAEdxSKf84pUyJFGMjNAFZ2w5+tTxSbWyegqB8BnHOQTTlbjpnApAeyfA7EtvqCDbk3A6nHVa9psMuu75lJ+ZSOfb+leJ/Acg2OtjGWWaJif7ow3P58V7lpwCkll2YGcjqua8XFfx5Hu4R/uYmzZkheVLt2xyB61ejNtHMzSFRCVPAJ3BunAH+fWqlu+wHc3A6EDPfr9ParH2ldpIXOc4bHb2/xpJ22Lkm2ToWZswxLbLkEsTlm98VbjEakyHEr93kGfyx0qla+aojchcdt5yW6dqsSuAQxbyvmwUYgk4747da1UXuzKa1sSPM7ltuee2ccHpmqbDL/ALxSxBxsPH/66mZnLMqbnYHduX09qhb5GBcgkDH3ualpBGNiSI8YQKCT0xSvtc/MqE5IqPzCVyw3YxnBwAB3p6XXmAFmT0CKCBjt1qXGLQOLMfVrWDGcFW3AlhzXm/iqVd0hZQZDlTkYxjpXo2sy7IQxc4ckfLyVwOOteUeLp3LMI2I45L1xzXK9Dro020ct8K8/8Le0vHXy7lcf9smr6Ys2wuTj1wa+ZvhUP+Lr6QRnKrcsSBjH7pua+lrTO1CcZI5wetde3L6GNVas0kU5+bjP96kVj5gAVeuMjvSI2VXcORwT60n3Fywwp645raJgkSF2jUZyOOq81Os1vuOJJCQQcc9Pwqqx3E4jk2k5yRj+ZqaLdjcLaRs4UDcAQB1rVCktCV75URzC7MCmNuDVeR5to+RynQF+2PX86bNLOZHMUe0McLlgMc8dKqvJPlWaVQVPzALniolMcYItSBn3HzADjHyrkVTmDqig8gcgY5NTBW8sq87buoG0Cqkg3YPnyZ9sY/KsZs0giElHXPzMD3I21SnAUlQCB71LdiSORmU7hwWBH68d6qXTq0bHzQc9NqmuKozdIydSACSfKwGPpXzz8ZLvebOAHIZ2fr2GFH9a9716cm0lII3AYyO+K+aPijceZrsMXaKEf+PEmnl8ObEp9kLFvlwsvPQ9Y/Zuski8LX944+ae829Oqogx+rGvc7NQIV5U59Cfyry74LWRtPAOjqAUaRWnY4672OP0xXpVueSXT5cEZJxiuqpK9aTM6MLU4ryNOEjJ/wAj8aVj824bQPXGAefWmL90cIVPKgZ/SllaMTnyVMny8qh4UcZ64Ga06DsRu37teGDdh6f/AK6Z5zCd4nkUYxkk9aVjM1wGRX4BGWwcD1OD2H5020VHxkl8k5kxxnsKXoNqy1JJmGwlGXAxnjOKpvOWj3YIXuQpqa9XzpMeXHlRnk4Ppn6VXlt4WgRPLCssS/NuI/8A11lO7uKNihdMk2FkQOCpGAOR71RlVsosTbowMKw6/r1qC6cxTKsbERrn5ScsB7E1JA25AYzleoA4/SuBuz1OlRsrleaQlyrgBhxgn73v9K5fxRceVp1wzEHZEwPGMH+tdFe7VLbupGB+dcT42mJ0iWIE5dwn5kVzSV5JGsFqbHg62+z6NbZzkJuzjjA55rofDLsbi6iKgANzkck+tZnh1P3MSYBXGMduPSulg0+SG9ju4AG2ZHlk4BBrpknoyajV2dDDv8tkmxkMqMcdParwH7kntzms3T2ifyEIb97ISRnlT7/jWkWVwUMbJkBcMcgDbk+1bxipLQ4paOxi3sfmRTopYb3UD8OadKh3kcZwAc1IW8xZptp8oTLGNx5VgMkfTGKqXd4EuAON5JA+mK5Zxa3NrX0MbUlYNLKpX5HHXgkn09q5G4I8uA5Bwjgnrzk10WpTjexOOpbOa4m4vBDYz3DgbULH8BzXFvM2Stqzxz4l3puNfMAJKwLj8TXNW6jd82f896NRuWvb+4uX+9K5b9adF8q9O+M/0r7fD0/ZU4w7HzVep7So5D+/zevbsaTo5A6etKTkZwMdDSDIPP4f1rYxDJBwPzpVIMi8YJIFAxjC444pEPzr9aAImjIkf1J21GuOR2/pU0jEM204wWb8c4pi56L67OfzpAerfAC7a1v9VVMHKxMVbkEfN1/MV77ZMWTeOc/Ptz09h+tfNXwVmKeK54jnE1sxwP8AZYH+hr6U00FoYmAO7bwa8XGq1Y9nBO9JGvZSkLk5KkEc+tWBwflmZVQgnaOn9KihjUAHoSd34/SpHADNk8jGOODUxWh1XTLccZK7ld5MENkuAMfXGanVLgxlmnjiiRtzJCMN19TVSCfy1dY1VVK9e/5+lX4xcTkqt46QHjy0A6jjqR19q6oxTMpXQ3Zi2AghQk5PmPK24jHr6VAyM6quHAyPlznn1GeamvdAZlWW4u5iwHGyTJYf0qmtpE4jLvM7AH/WOQAPc0ThboEOV6xZDdsySujcEcEoAPxqKa/eYPhkxJjBdgzAgY7ewqs4iO5vKZ1Xuhyufqe9MkkljjLKgAHTgD8K5W2dSgrFXUjE8Uh80mU8plGIc/0rzHxGjOkj5Xg9B6V6DqlxLPA2UYdgBxj6Vwms5KSKW5PDEc5xWUkmdNKNkYPwsRv+FqWLEjiC5J/74Ir6MtyAqkDDLweAK8E+GNsW+IkUmABDZTMffOF/rXvNrlowCQSQDzWnVHFXXvF1COAcDJ7VLIFBwdp+tVQo6g9eemBUxUA4VVwTyTzitUznsPkkJZAoGQc8HpxUqecIcyMWUZx9PSqxuIUbCEEk44Gab587IfLgRQD1c8n6CtFOwnEsNEUZhKzJIB0HYVFLDGFAaQkY6k8c9/eq7RXDOAZY0JGcqOag+yZG6SSRiPfAJqJy7Iaj3ZYtZQF3KMOOMt6/jUc8ochQ2T9KrSQRpkeZIo6k7u9Q7GUnZck4PG6ueU3azNYxW5HOdpOHcAHPByaxL1080qTNsfgHPANatw0qNl1yD/Ep4rJv4y6MAdzdeD1xXLJ3OiCsYfiBTHp5zncSeO5r5o8bubvxZcomScpEo98AV9Ja4w+xqMYOCcY5HtXzvpiG++KVjGoz5mqxJ/5EArqyz+LKXZHNmOtKMe7Pq7w/Zx2GnWtpEBiGJYlxkZwoFbUfJbuF449apWuduRkjn5c4z71eh2sQdpxjoOaIas1Rb83CAlJFwRyAD/ninvOHjKNuMPpjHPvVYJkc8BTy4PH0xVnBhAZ0G0/xhdxH1Fbai0IpUGxVG5GCggBSQefSrkN1GATJHOJ8gYjj3qMj9CKWMyiJTFcKXccEOOR0/Sp5lhjtJIUcLISpSTcThu5+tVFOOtzGpK+jMmS4tZJRs3lNpUq4xgHnnPfIqK4k2q8BZTsAKtuyCvapru4kSZ2lTfjADR46fSqGpThC6QIzRhsAqnDYxzWE526mkI6o53UTukllAOUH9abDceV5fykts3kMOCT6VJKS0zskbOScncRjFZ8okUh3AUA8kHJA9q4KjSO3lurFi+k/d4LhueMDmvNvHVyqpaKSNsl0oyeen/6q7mV9xwmcYryL4tXRtE0oITjzXfj2A5/Wow8fa14x7/5ETmqMHJ9P8z2DQ5sWo6ZY8nHII4/rXZ6fdCNxlQdsfzjIwQa8Z8IeJIp7W3ZZTvAznOckjrXomn6woIKHc23Lt6rXZZxk4sykuZXR1jgwSC4ssIUGN4G4BT/C1Ph1NWTZM8cLqSWUn5Wz/dPfj1rnU1ZxL8oAB7dMfjTzqEbDyz2GSrIME+9S3bVEcl9zo9SigTUI7Wzx5EzqUbOc4xz+AzWHqhWB7+YhQ9sm1VI+Y7u4H0rIfVrmzZltpdkTLt28Hb7g9qxdV1a8uQ6y3kx53Hbhd3GOSBz9K5qsnK5cKUl1I9WlkjsWYgg7ecjGK88+I+tRR+D4YLeHyp2Bikfd/rCTyfyro9c1W8uE/eT/ACY2kYHI+teOePdY/tHUxbxEGC2zyOhY9arLsM6tdN7LX7jLGVPZU3fd6I5lADIB1Wrq/LGDyU74/Q1Wt+ozgZ7+9W2MflKFXLqScf3h6fhX1p86RyHnK8c5/HvRkbTg5pFIKkjJJGPx7Uvy9VwD/nNMBoBySSR7Uq8Oox3o5yO/rTs/vEx0zQAk/wB1hjLdR/31UZzvJ4A3n+VWrgEhsnoD254bNQOn7zGDt8xhg+uKLAb3w8vVsfGekO33XPlMR/tZA/U19U6KylMBQMDAAPX/ACa+NraRra4t51zmLbIMHnhq+uPCVwLizSaFhtdFfIHUHkfpivKzCPvRmengJe649jsQxRQFOcd8c04kM+5yRlv6UluAfujrwM0jFgeOMHvXPE7kyzGw2MHKrk9WHDY6Cta1kcxrJHkK3O9SQmff37ZrAeQAZPJAycVsR30KIyDzgoBCMDgjjHI9Peu6k0RVi2tEaobECyS2/wDpEeQVQ5znuD/jXO6mJBcs06CKINgRE8nPbjrWra6+qW5HyGIDASZiN578856VjanfO++6KtE5x1468flWtWUWtyKEJxnqjOnJVxvUEqMgdlHpjvVG6mYghV2nH3getPkm3TbUUuSTk7TtFZ91KyAK6gsTjC9BXnT7o9SEe5VupBsZWOW6561x2sviNioxk9B3ror5iGYFguOPauU1dy7scAYGMVkzqjAvfCyIHxRqUuQTHaKmf96Qf4V7JBnGH2begxXknwoj/wBL1abYTkxRg/mf616xbMADjGR1J70l8R52IVpMvhmMeWyQvHBxTtgaMuTux/eP8qYSFYg4OBx7fSnwq7yKCGC8jp0+tbJNnKShkjyX2AH5cd8Gkm1G1iAZZNzL8pUjB+n1p893aQRb5GIds5ypJPTAHrWTc3F3eGRI4/IgJBLkDec/yrVyUVZbijHn1exFPrsBmK4diDgLGPmI+vanC/uHQL9ldUHTLAt+NRJbNEXMKt8vyliPvnPvU0s0Efy7gHDYZRzjtz+tYT57as2cYbRRTlvZizLJbOqeq80wTQzkkSYPcAcj8KW5uERiMkgHr9aVwNzK4VmVc8j71cruapWRFdRSqo8mYPjqjrisiVz5qieMoV5HofxrcyWiVQwMW4BATytZ03Jbg8dc+lZy0HF9DlNfXyLdmLBlZjj6V4R8M4vtHxWsXPIjuZZyfTaGP8wK968WyKLb5ANzc+w49K8X+DcPmfEi7ZiAI4pmJ+rBf6114B2VR+X+ZzYtczpp9z6b07BjRRySBya1raAqAQBkVlaWuQiAZ3DJbGK34xtRcH8cU6cRzlbQYkLshDdB3rV0+1ab5d/lfNtDbck/l0qrApxyep79K6LSmKIuDvQHIC9Qa76FNN6nJWqtR0IrmwtYbeS5gmuYJiDulQkhmz3BGM/hXMXCSO7sXBPqkYTP1HTNdlexyOjMku0ZLBQuP++h1zmuSu2woVkUEfMGJxu+tViYpIjCyb3dzPbzA23fuIHIZOAfrVW6xIhzsTP/ADz5H41YuJgNqlFO4dznFZ4ZBJtkUDnjk8j6ivLkkj0op7mXcW+CSmeex6VkXYK5AwGHHBxXSvGhDKq4PJOGzXPXwAbcRjPWuSqtDphK5nPiJWlyDITwwrxT4zSlr3TYyc7UkP8A48B/SvYrxgQADtA7V4j8W5N+u2y8fLBnj3Y1eWRvio+SZy5hpQl8vzOb0LWbjSpgUJaHOWTP8q9O0PxdFPGnlzfKOqnqB6GvIIAS428P1U+9SMWVxPCxjYnB28bTX0NfCwra9Tx8PjJ0dN0fQEPiTzWJJXd1yDWiuuFyS0i/gcYr58h17ULZtrSFsf3utaCeMLoJgpz67q82pl1T7LPTjmNGS97Q9tutXRsneMj04rMm1lMNtIIxyc15DL4quXBwnPrurMvNWvLsFZJiE/urwKhZXOfxOwTzKlFe7qdl4t8VoFaCxcNO3DMvRPX6mvP8/NluecmgDtj6U+KPcNx+76fzr1sPh4YePLA8eviJV5XkTwoApDHHI/D0NPOT069vrSnAIHVR39V9aUn5cA4Oecdc1sc4jspK8EKeOPSmg/NyuCDz/WnFwx3MccdPf0prEsSSfmNUMaBzgAA9qWPAkAOc5pDtBGck+tOXBkBz3oAt3CmXeqkdCOT/AJ9KgkG6XdtPzOGz6gipVbLNjsc47k0xh+6xtI2jjB7qcj9CaBFZQAFDf3GH09K+ifhDqoufDlkC5LJH5Z+q8f4V8/lf32Cqn94wAb3Ga9M+DGoQJvtI2kDxgSkt0JJwcD8K4sbDmp+h24CX7y3dH0baSZUEADuMVO3Ktu6461ladIXWMgYGent61tW8GXVTwoHOPevNg7nqN8pVijYOu3HzcYxlfxrXs9GknVTK4jXGFwM7l+nWmWsXlzBEBeZgV2gZI9/rXQWEkMSqCC5A5C+vvXVSab1Ma1eSXumanhm2jkUrNI3mMfl2nAP86vvoFurjHm+U3QE9/U1rlzPJvBkjQHKgAfqfSm3E7bVwEDBuQgwSDxW7hFI4niKsnqzn/wCzIQSdpJB45wD+VY91ocLuX2ZbPOe9dRKGieRfm2A49DWdcnC8lh24/nXPKF0dNOtNPc4vVNEi+f5WAHOQM4PvXn+v6e0ccjRDcQv9a9gvCArEMCAO4rzrxLhvNWM7mzuwh6fhXJNOB6FDESuZnwvQqmokMwUzqvTP8NemwyFkAJIYnbsYZ6kc15z8NAWt9RBUbhcncP8AgI6V6JGrHopTOGGOO59aUXdlVnzSZqZUSNsIyT1/+tU8YVwT5QJPy53kc+tUEIJJL4PcdDU8SsqFczMp67Ou31roizlkizPDHCDK4LsOSxYbiCccD8Kq3E5jhlcRJEHdPLhZyTwf4vzpt01pDkw73YHPJ5C/4+1VHRrjeNg+YAlpB8wx2Hr9avmSHCHVktx5sMa27HbvkG6bPG3dxgZ46VYdoZIFiCRkgfMW7sD94/Xr+NPt4JhuLyFFK84AI/H0pZA4SSMSKwlJZ1lUZ575HsOlDd9BN3ZgzQRmYgxpkdRnr71EsKM2ElZMnkZyKsNExhlm/eeY7M33MKFGACPTNUZJAhz0OCSTxgGuKcEdkddhrrKAd53rnqgwR74pJI12KcbY3G3rk1At6fM2hMfIcjPKn1qSW9jRNxbbyCRxksK5tmOSaOO8SurYwxyOMEdcdK88+BVmW8R6/cFclGWEH6uSf/QRXomvKVQFzk7cg49fX1rlvgjAFtNVue8mpuvHoqj9PmrowbtCovQxrrmlT8r/AJHtdqPLkjbHy461sxyjbz0xmsaBldVx2FWpJAQqqCRjv7V0R0IceY2IZQwbIAPGPTHet7S5/KXbgbBxg8c/WuVscuwzlgDnk9K3IImliMbZVfvA5xn2rvoPqcleC2Zp3t1vLBgAAo4z82Ox965K/kaR96nA6An0rYvnuI/lUqFQYC45x7c9PWud1K6J3EDBJAwD7UsRK+48NTtsVrr5kA4b05qgZCgwp254GegqGS9ABEgbg9cjimXN1HuVc8nliDwa82aPTjBrQUTZfOBnkHFZl5EWUHgjqeaJJdjNtI2k8GqtzMywkAlmzgCuOoXytbGHqRAdlwfY5rwr4mTeb4mIB+VIVA5+p/rXt+rt+6dlbrzXgHjJ/M8S3vzZCsEB+gFdGURvXb7L/I4Mzl+5t5/5mXAAVw5+VuAf7rdqkJOWYjn7sq9f+BU63RREZGyYj8ko6bfQ1LIjhyzIpMQxt/vp619KfPkDAkH+J0/J1qPyVbdtDZPKe/qKsKhQIqMMgeZEw7juD70mRtwpIV/mXH8LelAyv5ALJtY4YcEjv6UogBC/N94EdP4vSpiQ5J4QSHnn7rChQznDAZZtp7YbsaAGpApwAQNwxk/wsO1SnnBjUAn5sejdx9KTaOjnBJ2vz0YdDRuKgE8SE4I9GHQ/jQAZAVdvzdcZ9D1FI20EHd7fhTgvO4HDElgp9e4pvGDwfX8KAFzuycYPX8aQAH7oORx/hQ2WZdud5+U47EdKQckYOABwPagBDkrn1pEDF1yDnNSyFFQY9c1EjZdcZ60ATZKSMQO/BzUyBWJ3nao5Pv8A5B/SoJFy7fWnr8zqGHyMfXk0CHMzeSdwXKgMDjn5Tg/pXQ/D+6/s7xhCAR5cjvDwexGRWCWAZfMfIJwQB0BGDj9Kkgma1urafgPEVZs8Hcjf4VFSPNBoulLkmmfXXh+XzLeMnduAGQOnrXV2Z8tAZGwV+bP0rgfBN750CspX5jvU5z16fzr0WURWlpBczgyQSDbhRln5xn25Brw4beh7VZ6+oyNmEUrsESSUiRmIyVXHai2nYyDZuVVGAN3b60OuF8s87SwP58Z/CnWUf78DGRjHWtoaNIysrM3YZ5IoonSTduTIQ+makvLw9JBtI5GKYLeQ2sDKnBjY8f7PJFN1aFi8DDlnj4x3GK7rOxypRch9w6PIQWGXCtn8Ky75o0DEsMjrg0oO9rXJyTDyPoTWTcknzQv945zXPUlZHTSp6mfrN4BbsI8rnjNec6lvVj8zDP5/jXfX0W6HJ9a5PVLUlm3DNcUnc9GkklYj+HmRHqAkU7Tcn/0EV6E0aKQAejD7xzwRmuB8Cjy7q/ibr5itux0yvb8q7lGySfuHg7fT3rOBNT4i8gAUKAq+pxVu3jnELuMiI5BZjzgdhVINuAGQBjBOafhmICzbecYc8YrpiYtXLRtnZS8KKykgAg/N71LZ6fI2xxkyMxCqe+apSCSQA4D+UpONvB9K000q4iiRI0CXBUMUjJyh98dK6KaXYib5Va5V1aKGyjkiLlrn+N1bHI44FZEktyycOwHGGY4//XWnP9ihBPJnDEs05yV9cfrVSW5gdSWO9QRt759/pWNZ3fY1pKy2uZ8kEzQNJJIAN2CuM4H+FZdzG+8srqxHGAta8lyJAxeRwenyAVSuYkMe4cjjNck4nVDTcw5/KjGcOrHqD1NR2QhR2IiLSF/vN16e9XrhFiIO1cDPJ5IqgZm+fa42FcMcZzXNOJrJXRR1sGRZJpV+bG0AnpzXNfBGIHwxIT957yZv1A/pXR6tcb7SXaMFkK5PPOOtZfwagKeD7QnaC8sr/nIf8K6ML8Ml5ownF3T8n+h6NH8kajPXmrtsjTN8vX3qiQSFI+7jmtfSSEk2vgdBzW703M5Oyujc0ayDK24ZK9PeuibyhahSQG/hQjBHH/66yLRHbJAKL9MVpW8SrnfuYnnKnJzXXTqtKyR5FaXM7tla6t0mBLsX3DGAuMDt/Kudl0tPMbeCCDnPYmuwuQFQlQfTJasa6lj2AIMA8jP+NZ1pSerLo1JLY4jUNFZI/dmJyawb6xeELjketek6kEFtGSpJ9Bz2rEvbcfZ44ypGI8nIrgnOzsz0qWJlpc88ErNMFkX1xj0plzIchB0AzmrWrQ/ZrkleOwJqoHWTKj05Nc03odrkmrmDrEm2LggY7GvnjUZvtep3MxIxLKxz+PFe5+Orj7NY3E3XZEx/HGK8DQKxGSeTg16mT0/jn8jxs0n8MfmaEWFj80oGC4SZT2/2qcyFGeNGUvF80TA8Mvp701Qyx+YwPmR/K6Hoy+uKds8vZECpIxLC453D+7XsnjgRHkLCcI/zxMeqMP4T7VGxDZG4qr/eH91/WnfI+SMCKXjHTY9OkCKA0gTkbJUHG09m+tAEZI5DDGfkl/2T/eozgnzBk/ck54I7MKXO1cnLNjZKv94djRuVAu7LMgxyOGQ9/wAKaATOzl9ufuPkdR2amkYLKSN2drH27Gnj5Qd5L+WMH3Q9DTWP97JwNp46r2IoYCcl/wDbJ6HsR1oOA5APyn9falVS7EO2D0J9D2P40w5LEkYYdPr3FAx2MOezAfn6Gm5z1ABHJ/ligYXqOO5J7GlxuKnjPU/X0/KmA3C5CkZ9DTlbDDI4BxSHpyMUq53rxxnnNAEjZ81sHk560i/JuKr06HPQ05wTIemR1FI/ICqMUCJI9oUFxuUckZ60shIXEijO7LAnPPQ/pzUCEq2APl6kY64q0cOIw20DO0nHXIx/hQI92+DOrmbRLeMMTdW7m3cHGAV5U/8AfNe0Xd7FJ4dJjdnkj3RsB0AxkfXOTXyt8JtXey8RraPN5Md7GAWbtInH64/WvpTwwBqUF3BtjIeNim9iE3EZH04rxK8HTquMep7NKSqU1J9DoLZ/MQMWyW/wq/p6gXKnrzjHrmsiwMixhJwyuApwe2QCP51pW0m1s9wc0U5pu4NHW2JR7VEkU7Ucrkdsgjn86o6sMwWzKT8o256cCo7bUVjV14IfBI+lVr6+EqLtwuGOBivRlUTiccaclO5WssNJbsWPDsuPUEVUvUCzS/Jt54qQTsmOPunNU7qU78sTzXJNrlsdsYvmuUrhAVHGM9q57VbcYJ29/wAq6KRsp0/HNYWpHIwDyTXKzqg2c/oDCLW7xcnDxqePbiu0tfvbW54AHOa4Oxk8vXowDgmJhnHXvXe6eQyKSACeeO5rGOhVTQ0okDgAYwB0p5UEkZAPAp8WOFIwxqZ0K42nax7dcj3rtpq5z81i1a2gnMf7zaxO5mRvmAHXjpWjf6dBFCPtGt30fyghDIN5HbgDJFUrNC8YRcx5JDOh+7x39q2rawCKJRJGjBAnmeTmTH1Jr0KcE1oclao073ONu/siyBFZrqT1KHLD3NVyu1WEiRqoHEa8MfqewrqtXSNVcxIw9gOSfc/4VzVyX2/KkcZPG1+a4q1PlZ3UKnOisYJRjoFA6KM1Qu0VcLhizfMWJ4FWXdnXE8zAHgKvyiq16saKoPAHGd2a4ZLU7Ib6mVchZC+SGOKypWzK2Rx6e1akqBskL8g4JHes+4XyweOFrGR0IxdYJFpMqdlOPpVn4VwhvCtkeQEU9P8AeJqnrB/0KbOSCuc1tfC+PZodmAQq+UxO0Ekdz+maeGfvNGVbSFzsTBKsilVDl1DJ2Bz7noBVjSIHgklklRjcFtpyeF45GO9WLmKILbJcsB5kRVSDn5U5bPscquf9o1YtdzxbmA3F2c454xxXbKn7yPNdRtGhaX0mFDgEKMD6VqWd1GQqkhRk4x2rBhTCZJ6D0q1HHjys5BwCuff0rpWxzTppmzM+6Fyoxx1PJrGlYsYRz7jtUmpTyRwNtPtWetyS4zwFXj39ayqySdgpU9Ll26AKZKAf19qxr9thmUk7FQAZHc0+fUJDIiBe/wCdY2rXbl7vGMGQJj8K4a8lJHTTpNHN68qmdlbBO3eBnmsaFS3zKSBitq/WW70u6uPNj/0G5jO0jG1GJDc9f7v51QWFVjIzyQQTXElZHdGVo2PK/ircGPSJwGXL4XA7ZI/+vXkMGN/z5C/dc+g9a9J+MEwXyoAfvOOPoD/jXndpld0hCsoG2RT6etfQ5XDloX7tniZjK9W3ZFs7gNu0meAcEH/WJ/8AqpfLLhY424f95CyjHPpRt2Ikas32hDuhYdGXGcfWmD5oxncIpCWRjjCN/SvQPPFJymWA8uX5ZQTyj+tNZgrZljBdRsk9x2anYO2SV1zj5JkA5H+1SFmQqThzGvbnzEP9aQDW+QDvJF+O9DQWHAHQfNHnuvcU8KwYLDhtn7yLJ4Ze4zTBgouzhWJePJ6Y6rQAMduEVeIxuQ4+8p6imtngAkqozH/udx9aUMDtVG3Dloj791pACoUxnhuV9m7rQArAKASdwAAJHdex/CkILSBWbDA7ef73Y0hKIGCgsoAxj0PUUmAeCecBDnt6NTGG3sSCoJxz19f1pCp+6uAfX+VLjgE9Qenv3poH8PPXCt/KmAEjgDkqaEJLLg5GeaDgYJ4IH505DlgVxhiM+woAkzl2z3NB+9wOaCcuwHYkUu7OCPpQSHCycDIAzmkRjtbgrlcKDSL0Hbjr603cy44yTQMuRXE1pcwXduCrwOJ1w2cH+L+VfTvw61yPUtNtbiCYqJhhxnBBHYj9K+Wo2UgD7oOQ30PB/pXofwj8UQ6JrDWOoxNNY3kZj+VtrRyjqVPY8A+9ceNpOpHmjujrwlXlfI9mfTrxSRu81srEKoLR5JYKfTPXFXbedZFJQ7h3HQiua03VBPbnyr398iB4bhBg47kg/qK1YtRWdv8AiYQLC5O03NoCytxwWQcivGg7vmgejytI2Y5vm6jjtTZZMDJPQ5qilwDFuiIkjU8yRYIP4dR+NNEwdW2uGUjOc9a6FVT3GkaG7gj1qG4xtU+9QGY4O3v3NQTSOYxn603NDS1CZxlhWBqTMwwvFaU1wqnBfcB0UYzmsvWhDZWhudbuVsrU8xwnmaY9gqjn+lYuVzROxy8aSSavBdx/LbQyeXlvl3s3YV6FpjbYNoxjPPNeNeKPEdxfatpkk0R0/TbS5R7eyByxPA3yEdT+gr1jS5CEYcFQevqc1NrFzTa1OkgG/ByeOp9a0UU9/vH1rJtmCgADnH51owsZF+vFd1G1jkmi9pzqkoUEgA5wDWxZ3cCNhgVz0LGsG0Qhcg4wc1PJMizptkDLjncOhrug2kc9Smps0dUlMkbP5myMdAQMk47d/wAa4q+nHmEgH6EZP1NW7vUoUM7QwZbaVXcSxA9a569vHlUYbC5OWz94/SsK80ztwtBxJZpvmTIDNn16VTnkSTkqWLN0qpFO25XB5BJwabKx+UKOgNefNJnpKFixInyMRjk5+lZt0SYmzzV2ObYp3YAK96oXEm5WArBxHG99Tn9YJNpOAMnB/lXU/Cm1kuNH02AKPLjTzC2MhmOAuT+NclrOfJnz0wen0r0D4OQTJ4WijUsYZyI5Ap+6VAIwe1GH+Myxj5aTaOhm3o+yYRK25toTsgOPyJHFXrGPbbkNnce/pzVKdlbU5EjY+XvEaE55Axkj8a3DFtkZRkgtgfhXZCXNJnlSdkiuUPkkKvI4BHPU1adQt0VXftQDG454ApTCWVIuhck8+wPNPXEl3MyqFQsFVQeBwB/Sugy5ivq2BZBgBudzj8BWZEhLOx5OOuK1fEhK/ZYeAEj3YA7k/wD1qq2sI2uT6dawqq9SxpTlancyUQG5UnoME1i6lzCZAceZcE9OoFb0WRNLkHI4FYl4hdIol6ljn2zXm1mdcXqcxayyNr9vbIcR3VyquM8FSCMEd+35Uj/utOztUAggtzk46nmrF8FsfEWhzxxuzGVZGHqd2Qo/AfrUnihVMly6LiJiWGOAB/dH48VlTd4Nml7yXmfNvxXuBJrcER6KhZsepOP6VydopCmRBl4vvKP4lrU8d3Qu/FN4w+4hEY47CqFuNmDj95GNwBH30r6fCR5KEV5HhYuXNWk/Mn2I5MQcAnEkD56eqmogVZWkdNtvMdsgHOxvX2pQInAiUqkch3REn7h9DSK38UoDITtmQdj2NdBzC7nDGRtpeL5ZVXOXU98Uz5o2xG2SmWi44ZT1FPbeGC8tLFk5zy8fcGmryNkQA5MkLfzFIBAoyFhyQx3wk9j3FIOWBT5VJz0+647fjTlwfm6B+UPQJJ6UwjIZjnYxwwBxtftQAgORjBG87lP91+4pykSDaDjeeAf4XH+NDnIIcAZO3/rm47/jSZzuyCu47Gz2bsaAFG4bSqdckLnof4hUZA4GeAOD6qf8Kexbdk5Vs5x/tjr+dMJUn5VAX7689j1FMYYYMckeZ1PpkcfrTd2QqsfYY/SlG8H07H+YoGGXOML2P+femAhGGA5yKemQVPGSe31powD/ALR5/GiE7nDds0AWDxuPuajwRyD15pejlQOCcUhIPTtQIe7AqDjI9Pemkq0RzkY6EHpRkKOOaCCBkgBTQA0NmRPMYgH+IdqlJZ+IyG/jBHyn5RyfxH8qhaMKgJPLduuKIziRW6YzyKAPX/h743aSOPTbyY+bGcqxHMqjgEH6dR616voutgr87ZHZh/Cc55r5QG3zEXf5TZChh27qc+x4z6V1Og+OrzT0WPUcyRhtvmqctuH94dxXk4rAyUnUpfcenh8ZFrkqfefUKX9lf+S7mS1ulYnz7d9pB7E4q693fTSHE+kX4K/KJMxucdi6nr9RXiuk+Lba+jMwkSXcASYm2kH6dc1rW+vrx8wJPQsBmuF1JR0mj0FTjL4WespcW6q323Tbi2Ix81rOtwo/Dg1WudU0JFkDzapIy9Y1tHVj7elebL4jYeYI32EAZ5xmsm+8TO0mSWYY/vHn65pe0vokJUH1Z6bqXiKQxY0fT4dOiUZFzehZZseqxjgH3Yn6V554j1a2glubiSd7vUJxhppz5jt9T0A9AMAe9cpqniZ2iIeYhM8bTgD8K4jWPE6OHWL55G7jjH41tTo1Kr0WgpSp0FeT1LfijWWeOR3ky+4bc9yPT8q+j9BulubS2myMzRpKMd9yg/1r46llmvJSzlnfqAO30FfUnwyuvtXhPRJAQT9ljjP/AAAbf6V1YmiqdOJz4fEOtOXY9KhfKjOQB+YrRgnK/L07A+nvWPA4wcHn1q7FISwXOecdKwhLlN3G5tRyE4YEjIwDUc7PI/Hz4HHbHvVjTIPOQrIwUgZViOh9K3oLC2KiTynmkGMseBn0xXbFua0OOdWNNnFW+i3F25SKNiOpZjj/ACKgu9DmDsFiDBGCn0Br03IVsOy9yF9BWRKiyXUvll1UkEgduv8AWsa1LkS1FTx02ziJtCeBSyxoTuAb2zUU+i4kXgYYEYFdpcwGSJy2SAQCAMdaoqiv5ZB2kc/OcVxyi09DojipNHF3+llU+X7y8Ad65vU4JInYMQMYyRXpF/GZCQilicHAFcpq1qsgkjYZZcEAcVxzqOLszso177nn+sAmOYf7B/lXYfDG7lg8P22258uHAdlxnYwGCffPH0rkr/MkkiYIySv6Vv8Aw+kJsYmViImXpge4q6UveudGISlCzPSbExCUSAKzSxqynb8qDqT+OK115k2k5cDk+p61jaLdWxc2Epf7S+UhcrwyHk/iMniteIm1uZfOGFB2qxHBHrXpUVdHiz0dmTrKscrNK+0LCx3Dnn0qzo8YmcHAAOGII/lWPeSbYpxE6hWZI8HrjknFael3KW8XmyA4ji3nPauiDXPZ9DOpB8mnUqeIyZNTYn7qkKPwA/rRbriyLgAs7bQPbvWVPceb9nkdsyOplx2Ge1akbeXaq2CTs359K5XPnlKZfK4QUTMZmtoZ3dgHlxApPq3JP5CsJ1BAZcZZGIz29a0NclcS6IiMph+0CJcEHecct+GcVnarcwaYl1NLnZbgQ4ZcF5AchV9cnFeZWidcE9O7OW8QTxtcWN1aTK0kF6kEpDfdwRkHPTg0eNpVhsrlUd9gdiuWDfLkfLjtznP1rL8H2Uup67GlzGzpeXBlMCylmkf5ssT/AAhTyPpVf4r3y2+iXEysFEcT9gcnoCSO+RUUk1Fx7s3doSUex8yanOLnU7y44IeZmwPQmp0QquxRmdBvjYdGTGSKz7cEyA7d2OSPatBU+RY0cDndE7dCe4/pX1yVlZHzcnd3Y4iPawC/uJgM8f6uSmljG58xPmUbJVPdfWlcoxMhUiF8LMndW9fzpxLwOQ6K0ka4K9pE9T/jTJGY2PsV8lBuhOPvr3BpCvCkNhJPmjP9xh2oC/IkKv28yFge/cU5mUoCMrDN94f3JB3pAR/LJ1wqy8MCfuP60rNxufnjbMo9uhpB8+S3IY7ZsjGD2NLh4WDFAxQbWyfvqehoAYQAMSd8LIT/AOOtTwoyfMI4+SXHf0aozkEiQkr0b3Q9D+FLwhIZicEJJ7qehpgJtznd3O3/AIEOhpGOcMEx/EAB+YpzIdxU88hCc/8AfJpGYMdwYlySSPfuKYxChGFZsYO0kc/7tISTj06kDt2/nSgFQpIO0jAB9D0P4GkAIAYg85J9j0NACNuySxAJGB9KVM7kzwAeaaoxk+/8qVPvrn15oAmY/vDnPWkAwADg8cYpXbEh55zSLgYJHB6kUCALsY7yQD6Upzt449AfbmjaAoPc9z2pdxKlV5GQQPx5oEMfazBsnGKiYKp5D5PQjoandSGDZPIxgCo2ThQR0/TigaFVgQORhl+Ynp+dWmUXT7IyvmyruAAwPNHYfUfrWeMK/C9OufSrKSbo2BBJJB3Hs47n8OMUJgBhMcjyW7yoxUyRleuM8gkdMVcTXtXgwhuDKgXeu9c/L6+tRjaFUpG5eP8AexgHjyz94Y/pTZI1jEjJwYGDKAfvRN7+3FTOEZ/Ei4VJQ+F2J38TaoQAWT5hkYB6fnVSXW7+Qcybc88L/jSSxrbyYxvaJt3H8SEf55phjVASFZxHhvrG3/66hUKa2ii3iKr3kytNLcTgmZ3cAZ+Y9qb5LDcWHC4J57H0qyyFGO8gmMjgcjYe9IDsA6FY/XjcrVpaxk23uSQlYMmMDfC29W7spr6K+DJSTwVYKjbgm9VPp87HB/OvndSEZMkERNtbceCh6e9e7/AWcr4ae1c58i8dBxxggHg1yY5fu/mduAf7xryPXrUcYA568+laEREYEjn5RzgcnNRWsIJj6beFA9QamZMXTwhl2qQrAeoFeVJNRuelKRraddBbiHzpMGQMQnc4wM/qK7GykeWElQsSKdpVRk571yejpGdThlaIGRFZQSOxA6fkK29Nu3RrtYzujEu75+TyK7cG9NWebiVzPQ1diQyRE/MWJ+Zjz61VmIeVwuGHUEdaqanO6wiUt0mXP0wajSZxe8OMFCcegreq0/dRjCm7XZJHKVW4Xja2CfwNZ07mKEHdgLwD1qKKdzDc5YFgpx+FUWmD7RK+Ig3zH0Fcc3sdcKbuM1W5VXBV3DEdQ3JrFvWC6PLd3UQ2yHcrEdQMj+nX3q7qqFJ41YgkZBPqO1VdWO/Q7WJFYsbeZQCeDtIPT8TXDWSk22dcFZKx5neRtBrUsb7WTG9CDkMMdj3qz4EuvItpon+7DO8TDpjnI/nUbRqz2sy/6yO4ERjXsnBJP4kfrWLYXg0zxF5UhBivwSvP/LQA/qRisqa00PQburM9btpC6qFbbJH8yOp5B7EV1mn6wPsLDWHhyGG11HzN+HrXn+l3Y8hBk5OAfXHr7VpQXflOwQJMuc4b+ea7KVS25xVaSnodTc2rXJ+12Mi3Nvv3EpyRjj/Hiqmr3jrZ3MEZkZnAGSCoUE9Ofesm21KWIn+z5fKlb5iIjyP94HjFTyeIdTiV47+xttTUuGWSNfLYEdM9uK1ctHZ7mapzTWl7D7iQrNGsShikaxgDue/H41U8ZX5Mi6dA7CSJlSQrkAkjoD7Ulp4ktLV/MFhe294zfM7qJAvPUY5P5CsiTWp7uWV7WzlWZ2LGZmChm7E55FYN2ibQjLnu1sacSJBaaKRbzTPAZpIxggnHYgjp3/CsjxTqA1a1iuZ/3EcLNshjcMZpCQc5HoPyqkdQ1OC8W4ivYXlCkRySRmRoweoXPSqMr728y9mknnP3pJGySPYdFH0rmqyuaqn73MyZtZd9VtlEEVhYrmcRWxPzSkY3F+p9uw5ry341a2TpQs1Kj7RIIgB/CiHd/PFdVq2oQQksqqAM8E4AH+A6/hXgni3WG1nWpbgEmFP3cfuB3/HrWuXUZVqyk9o6nLjZxpU2lu9DNtCyuSihnQZwRnK96vLtIWFCFil+aIschG/u/jVWzR+i8TIN6j++vcflVghdm0bhbSnIIH+rf+lfSngi7j89w3Qjyp0Hb0/lmmldgKs+6WM7o89JE/wpS77nmmQEr+6nX1B6NSbGyI1+ZkG6Fz3HpQA0APhI8CKQ7om/usO1KxGxXYkI/wAky4+43Y/1oXDbVZysEpzxxscClLO4mlkYs4wky9eOm6gBY8ZZpshVIScL94js1I8hjbchy0I2jI6ofUfjUbgKAcbvL+Vzn7yHoaVGYAbcM8AyDj7yf1xQA1QMHALKnPI6of8AA0rIUP7wjEY2tjnch705pEXGN3lqCwU90Pb8KYy7Oc7hGOfdDQAMnl70dskYTOeoP3W/CmkDClR827oOzD/GhhtBDchV2j3VuhpMHHYN936MOn5igYFl68lTyR6A9RSEnaQR16/Uf/WpSc/PwATux6eopCTzjnnGPX0/SmAg5IwDj/CnKW3qenODxTUY4AyNv+cUq8yL06jNICR/vN65NLx0z3ppOHbnPNOK5YBTncOSKYhSuDnDMf8AZ7UkgYgANggkc+4zQxZQ4yOehpJMErgdVB/UigBzE/cI/eDgn16GkxtVgWyy9l+vf8DSk8hQecDr26ihVzgsoAOBx15GM/mKAIpFG0g4BI656UkUwiSRQFdHwMt1B9RT8K0RABBPqfbP881CwVSC3JAzweaQFyFyshOAxjJbkcN/e/Mc1KuI2iyGaNPlLgH5om4H07is+J2Rl2gZ6/N29KtRuEQNJjIzuVSM7M8g/TqM0AW9piXdIhZrVvKkUPgNGRwSe/8A+qqhQRA55KOYpOvKHofpU8XlgbpNoJAimZ852How/DH5U5yoQLLhG2m3uOeCwPDk/l+VAFUosU2w5KxHDkDloz7VEVWNxvG4RnaQf4lPQ1bCnC+aWiAJhnVV4z/Dgd89KhWNUKLISjLmGUn5goPRgPpxTQxm4HAlzhB5bnuUPQ17N8BpANG1KIn5orwZbPUFf/rV40qsvFwH2Rny5QDjjHy/59q9N+BFx5eoazbSYD7Y5Ae+QSP61y4zWi2dWClaqj6Z0+VUsmOAWK9AeAP8a04YoZImdP3S4Bcvzl/Wub0S4knaS0iOGYF0I9ewrctIZLW2ZJiWkZ1abd/e29cV5UZc2h6FVWZq6aqsVIxvUg5z1Fa1pH++k24+ZBkdwQcZrP0xgUi3cNvwSfr/AIVsTbYdhAJBBX9a66SscNV62KuqRLLbIiNyZVyDUUaBdXEa/wAPykH6U+8kDyQuuOGHWq9xIftsZRQpkYOXzVSetxwTtb1KsCFZ7hM/3xkis/yy9vPlFPy4I9ea15Bi/d+gbOB74qgiF1CKMswYkZ9K557I6YS6la5tpLqWzC43NEp56YxTbeEtc6bCNrhnngOei5XOR+X61cmH2RMluYoFGc+prLvN8OmpcQsUaC4jIxz7VyVXZlxbZ5q1utv4pMOPkE0sQDZz9xscdzxXE/Fy1a18O2N3ZSD9zDFIkyDawfqSR2Oc13viKRZPEUMunkxySXMUpMg6SZGcfrXP/HmAwaZfRSx+RIAzGJWyuOx44z14HTvipwrs0vM6qsnb5GX4D8dJrGnxiVwl6gCzx5+8f7w+tdxBqiPH94Z+tfJunXE9pcC5tZmilj53L1/+v9K7zRvHk8ZRNR+RiOGA+Vv8K9DEYGSblT2ObDY6E1y1XZ9+57zFq4jkUPHFMpHSQbuPQdxVhtZtkViluI3b5gFkYAfrXltt4rjuFVkkUAD7wxVk+IEc8zjHQZrifMt0ekoKWp6IdShd0kAcMgxnzDnPrVGfUlXcQeSM4J71xLa6gJzIvOeQeKpza5Gv8ecjrms5cxXIkdjLqTEMd5GR0XvWRqOqrFE+XVOOrH+dcRqnjGG2j2lwW7IOTXB634gutTZ1J8uEn7vcj3Na0sBUrb6I5a+Mp0U117Gx4x8Tm9L2dlJuiJw8wJG4f3R7VyUS5boSB94D0701VLsFUfeOB9a0LOIJh2Yb42CSIeMqff065Ne9RoQoR5ILQ8CvWlWlzSHRpgLGpIlUeZA/94H+H/P0pX/1ZkGGt5ceaucFXH9B2pwhIPkxNluXtpFbG4dx/nuMU3evExX9xL8sg2cKf739a0MRzSSozTMAzw4WQdVdOxP8vypsg+Uxx7imfMgJbOPb64o3G2b7oMsPyuD0kQ9Dj6EU1VQfICQjZkhfBJz/AHf/AK9ACL5bqRwEl+8WP3HFIeB5sgwy/u5UHdcfeoZlkO5xtWXh8fwt/Qd6P3mGdxuaMbJge69jSATIjI53NHwRj76GkwQCqfM0Y3Ic/eQ9qeN0e0oQWiG5SON6HqKjyqrhCAV/eRHuR3WmgAkKBs5VfmT3U8EfhSN8uFGWKcr6FDSs+MeXkqP3kY9B/EtJyCQvzBBuX/aQ9RTGOZSqqSSQg4z3Q/4UzYd20kbvu5+nQ0/cUfBIMaA45+8h6j8KYRjI57D14P3TQAjOpII/i+bHp2IppODhOAOOf0p7nI3YXJJJHo3cf1pBnOBjHTg59xQAgXJ4xg9PanRgB1bOOcVHnHHTPpTgf3i9VOcYpAObiRzx1p+QF9D70yUEEn3NNB5PHB4+tMCVW+mFOR7044G4DhQxHJ7cEUkRUSqCSBkLxSAGSRQcHPGPzFADlJWJiCMgN+hBFDLsD9d+DgehBByPwNMVCxXHU8EfUY/pUikEb9wI+Qv/AOgn+lACAoCxZQVG7aO/HIz+ZqJ0B+U/p9M/lipBkkZIAAGefQ7T+lNwE5BO5R9c4OP5GgCCXJyOuMAE05HYHk4OMHjOPf8Ap+NPkTAO5wCT2PHFRjcqugPBbBB6mkBaRlC/OW+VNpTdjKH19wccVPFtknVJCE3gRkkZwwHyNg9O3NZykxuMAEjrmrcZUssbMcOPL3ZxnP3W/A0wLKKJQFkBTMZhucn7rjJUk/gPypiI5ih8xWVJc20ueBuHKnHr06+lIhMjiN2yzLsb5ePMU5B465Ax+NOANySzgg3SEHjGJl/l/wDZUhECKN0fmYJU+TKOD6gECul+G182m+M7NZNytLutZvQ7vufrisEfvyHmKhJ/3UpJ4SQdCfwx+tQruikikDPFIrhZCp6OOh/SlUjzRcS6c+SSkfX3gW7VNejV1G5vlRifukc16AYPtQuJSXHnAShJONjAkcexrw3wjr/263sNWgA3SKHk2L91xww/AivUodXkvWE/lqN7Bjt9un0rwKat7kt0ezXi5NTibC3ZWAwsSJFlDggYKkDGPxq6l+7yAs5JLHg9BzVG2vY5nkjugqI/AlwAc9s+1RPHLGyiVSAGPK/drdTcdzJRi90a0soa5ijJXk8kGobqYS3Ay2EGRkDB4qohH2yFxktuGTVcSs7LvLMC79eTjPGafNqVGmjbhkiuYT++RJIzzvPSqokWOWB43BVnKkjkAdf6VjW8onvoYi6RhmAOf7tV7+UQXN0LdiIImD7s9sY4qJz0uWqFpWuW3vnuLLMpzK/Dt3OOgpqXStZsg/1ryoq84UHnDH6ViWtzm1nkPC+YSMn2qnczmWxMO/BaVDjHP4VxTfc3dJLQ5jxMxnkKr80m8gFTyxDdRWD8bPEsms+Fo4pyyC1t1RV6qWYAMfrmuwkgt9NEeo6mxW3RWMK/89JFbG0DvzXiXxGunXw2ElfMkk+zB692b9cUYS7qqK6sK7Xs3Ltc80tWMbGReSvUex4NX5IEYtDIoiDoHtzyQW44/H9DVWxDYlkjUOYhudT0Zcgf4VcaMEm3Rz9nl/fQHvuHG3P6V9T5HzjKCCaJDLA7qAcNtJBH1qYarfrgfaH49QDUnmgD7Sq4OPLnTBzjpn8f50eWJALVFySd0DHjIPYfX+dJwjLdFxqSj8LsRnV789bhvyH+FQzX93N/rLiVh6bqsxJCSsrRlkIKSKB91ux9h3zTRbId0C4acNlHB4kHYCkoRWyG6s3o238yhjIzz71NDbvLIU6OF3AHuMZ/lVseUoSdVDwv8sygcqx9Pb0qRUDKLfjz1O+CQA/OOyj/AOvTIILZIsKpYbJhtJPHluOhz6e/oTVoswbdIPMntwVYE481P6jqD7YpoZHUyFT9nuPkkGOUcc5B9O/0JpGDhifkFzBwfSRP/rf1oEAjRgYUOfNxJAxP3T3BoMg3O7IQHytxH0Cseje3P5YpGEbExpIRHJ+8hZjyp6YP5EU0uNhkcZflJ0xzg/xfXP5GgBwYxiNflE0A3DB/1kZ5xnucH8uKMLjykwIpSXhkbjaR2/x/CjYwCplWeAb4x3Zeu3+ZphCN+7Y/uZhujJPCP/SgAZ9xaWSP5WGyUE9H7NSEtHkuMyxHY6n+JD/nrSu4J3ODubKTrjAU8gGmFjHguMvEcEH+JKAFMYjbCAMUPmISchk7rTV2A/u/4fnj9x3WnJuRAEPKjzYye47ikYBgViCgN+8j74x1FMYmRwQOD+8THr3WjoBs4A/eR8/wnqKQjJDLj5/3i+zDqKOv3BtUkyR/1FABu28BtwUb091PUUhO3quVHB56qf8AClBG0BQCPvofb+JaVQv3eNoH3s8lD/hQAFs4wRuPDcdGH+IqPggD+A8A/wAv1pyhsZP3jx/wIdDTSBxz8nX8D/8AXpAGfujByeSPeljb94M88008ZGeev09f1py8yLx1OeKBDpOZDycZPNIRkZwODTpc5baRwTikUBgwA5zyTTGLEQzNxnI4Pp70BwmGVTuB3cntnNMRSdwLYAGQMelPOzzODiMk8460APYtvYIQvU5HfB/woIYIwUcEtyfzFNVt5UgMpPHA6g8E08kbgJFAU7SxPXH3SfzoAVlDfKoGCTznruXI/WmsgHTbtJDcehBBpMbI+ACF+bIPJ2tjj8DT1iACgbsHdHlRnnO4fWgBiqMndyB8x4/A/wCNRsh3YCqWHcdM9+fpip2IaRiAdzPgpnIAYcn86aWfYFcExg7yvQEjg/pQBXKkEKDnJ6joaVGABbAGeNueoNOYKwbJPPzbSPToM/Q011x0Oe+ccj/PX8aQE8LuQxZ+VKqpzyrfwkflUxLSRsqlx5uZOSRiUcnNVY1+Q49Dls84/wAipYXLZw6KzHcCRwrryMfUUxFsGOZgyswS4XKNt4jmXkgD3/k1MKloVfIUXK7So6rInc+nTP41GG3p3CSnf1yyuo5A9M1ICZlIQKy3H7wDoEkUZIz3OKYHX/DfxD/Zl4ttdyhbKeXqD/qZPbPXIH517to2pLDApAw2fnIPv3FfLCkyBXVSPtQCEk42yA9h9QD+Jr0L4e+M5FZbHU5Nswygkkf72Ox9+teXjcK3+8h8z08HiFb2c/kfRUN9HMiggMc4VvStyy1AywguRNFjG3OG+teV6XqCupeJ8L1KhskH2rUj1R1fcH+cnG7GK86FW2jO6VBM9LS502fMdtPIj/xCQYGfxpzabJCiy2yiVRj/AFZBNcdDrLToqzBJFQdSMGkNzDvWSDzonX5laOQitXViZKjJbM3zZyx3ZxbuzHgAr3qC/tLqCxvv3Rid0CbWHLAnoo71heawvZrlru5keQYJknPH0FZN3aWxcyG6uHk4YP5r7l78HPFZN6WN4xd9WdBpemXUu9TBJAqjP7wYycdxVB5LKxgFxqF1AyB8oiNuLH04rnWnhjvJZpJ724kkJDyvcNuIxjHX0rIv7yxsoyLWPy3Xpg9q5ZqxpyNvcl8RXrXrG5uAUZT+4hdvuBj2HY14f8QtQS51OO1hkLxQLliR/E3J/pXW+MvEywQEswaV8hYh3Pqa8pd2llLO2Wdskn1r1Mtwzv7WXyODH10o+yiXLLCRtIm7fFnzFHSRCOn09fY1aKjb5P8AyzmHmQN0ww/hB7eh/CooCYkWaKMedCGWZM53rnByOwxxTgqlfs8bFo5DugY8c9x9Ox9cA17R447z2Y/a0jXa7eXcwr354498dfWlaB2YW0bKTgSW7huSME7AfX+o96j3gL9oVVDY8qePoScdcdvr65qSOISlbZSAZGD2zlsBW7pn9M+oHrRcBjSAr9oZSUceVcqvr2P4+vrmk+zs6NAH/eoN0Df31znA/H9cipWm27p5BvJ/c3UfTd7j06dfWmNG58u2Du20GS3Ycb8kHAPYf1oAAwUPdBVe3k/dXEa8c9ePT1B9eKXymdhCspNxw1vIDgOvXHtj/EU0yl2N20IZGPlXCL0J9cdvXPrS+URi1EiOy4lt5egYY6D0HX8RQA1jGx89wRE5KToOdrf3gPTv+lKoZZNihWuIMspXpIgGfyx+dJ5hkEl0MFW+S5Qcdf4h7cZ+tJKrIFTfmSAB4WI++mc/j7D60gF3iVYI2lPkOx8rn/UuTz+tNLlQJpEZ5IyUmQ9x3P8AnvQ6RlTtdhDIcDI4RsZ6/Xih2dcyuhE8fyzqw5IPQ/j398UAGGDCOMHcv7yBgeSvUrQqo2EdsW1x8yY6I/pTdoClEJLL+8hfOOO60gIcYZtsM+Tz0VxQAwEbszFtxykq9x7k96U5ULgAyRLz6OvalkZlYPKuHUeXKD39DSANGQR8zw8Ef3kpjDkELFk4HmRE+ncUmARhSFDjzI8dm/u0YIwqNgj95Ef6U3mQhU6v86c9G7igBRkqCP4/mX2cdaN24qU43fvEA7N3FNOWOQBh+QOwYdaTPUpxu+dQP4WHUUAPBO0FOQf3iDHcdRSNgDGfkGSoI/hPX8qMnIKDhvnX2I6im5GB1Kjkf7p60ALglQejE7SPcdDTeMHI+XOf8ad94nd1+6T7joaaAcHcPVv8RSAQgj7x4xg+/rT0b5xgEnIx6f5xTNuwn8wfftTl4YAZ2g/pmgB82d7ErjHoaMjjGRnvmnOPnJx0OMVH0YnPNMByZXJOTx2pEYBwMggHqODihMsRzz2GOnsKAd2A3AzyCOtAD25jXJK4JHTOcj/61KV+6D8wIJA44yOB+dNGcAjcGA4/DmjaTyAQzDn+eaAHnlxnC7xyR0wwx/MUkbMZC+QdgDHJxjBwcVGpJJGRyCvXG0dRTy4YgFRtbOPxGD+tADnVC7BcbSCqA9VI5FKG5BfayNtYsewIwf1ppPy9ArAZIxwGXr+lKq4+UN8q/J7gMMj9aAEf5i2eCowMHrt6/pUb8kKhG7qM9x2PPtU2VUCVCPMAD7emGHDVGI8soOBg7QSencHNAEZyY12D+LAI7jtmnsBk7mYr0zjk+h/A8U1xlWIAUH5uvbP+NCgDn5uQR8p/P8KQEyszZLEFXbBAP3XHQ07mRdwzvY5CgDCyDrx7gGoT0/eMNoAUhR/D2PvzT9zFcZG5yPqHHQg+/emIsxtG7eUj4S4UsOP9XIOfw9PxppVWVAcKsvyP83EcgwN5Pv1/GoR8yHIO1iSe2yT6+hp6hZGXe21ZTtYt0Rx7d+v60Ab2h+K73S28u7laW2WTYzr94H+o/wAK9D0bxfb3aKVuBIfQ9j715FI5MzO6cyL5M4IBIYfxe3r+BqvJGYk82JjFLEwV9h6A9GB71yVsFTqarRnbRxs6ektUfRcGtIQuJFIz0B61YTWVLn59or56j1vU7OXy2k84DkZ7j14q4PGd0Wy8Q+isQK86WW1Ftqd0cdSe+h7rcaoFXLScD9TVGfWULHbIFG3JzXjEvjG4deUfOc/fxVOfxNeSZ2BEz6kmpWXVXuW8fRXU9V1DxBEob58Zz3rhde8XFg6WzmRyMZ7CuPnu7m7YCSR3ycBe2fpUawthmcMFVgH45FdlDLoQfNLVnJWzGUlaGn5i3FxLdTGSZmdz61LDCoKeayhZFBD5+4anghMMqqq/vV/eRsP+Wgx09qkGwwOVCm3l5bIOY2z0A/zxXopWWh5rbbuxuJwWYE/aovmcEcOvrnv/AFzTvLheTyvMxBKC8ZAwUfH3T6D/AOtRtnBAx+/g+5gZ3r/7NTgsLsvzLHBNw4zkQydic/560XEKHdl89QPNA2XEWeXX+8fQetMKIYlj35glO6FyMlG/un0HT9DTi8zB32k3UPMw7Mo/vev/ANeljiEn7rzAlrOxaNn6K+M5Pp6UAG5iJJ+TMg2XEZAy68ZOP8880gjUyLb+admPMtpM8ZPPPp6H0NLK7Ss05UtPCAJ1PWRfU/56U1lyv2TzFMUpEsMh4wx469hxj6igBwnJ/wBKdAX3eXcxEEBwe+OwHT60ySNUX7OjEkDzYpD/ABEHt7Y/UUCY83GzMirsuUfneDxnH5fjihVbatrkvk+bbP0z/gPb1oADOJSLtkVyfkuE29f9rjt/WmlTgIpJkg+eJz/Ev/6+n1pWl8xftRXrhLhc4z7+3+NNfIHlCQs8WWgcD7ynr/U4osA0nfvLYEE+SR0Eb/T9PoadJNI7iWX55IwI5lJyWXgZ/p+ApvysAxIEU+QwP8D+v+e1OYlMOVBmh/dzKP4lHGf8fwpgNfpGkeW43xN+H3f8aAFkx8iiGc4yeAj+1GBv8uFslfngYH81z+f4im7lkLscCGU8gcCNvXFAw3EEvIpJA2TA88dAabzEwwAzJyMdHQ0jE/ekGXT5JF9R6/WlZXTsCYhkf7SGgBrDb8qf78ZB+77UYDYCE5f5056MOooIONqfdPzx/wCFNwGJKtjcNy9sN3FAEjHfkIvEvIH91x1ppOeV6v8AMvsw6im53EhPlD8j2YUbjzg43neuB0YdqQC/7SkhW+dP97uKBzuwMqo3YB/hPUUm7LHy+/zr7HuKUHHMbDIGQB3z1FACY+Ugn5BhGPt2NKGbIGMsOfxHX9KacLnkkYweP4expzlt3zEg9yPXsfxoAQj3OD6+h6GhQdyn73zfkaQsSoO35emP5iiMHzRgnHB/CgCdlPmuPmzn0prKSWO0bfpRRQA0o28ZUkY6dKcFxxgnGPeiigQDcCCUYA9SPy/lT/mXaVQ4Awc89OP5UUUDGtE+zAT5hnJHcj/61O2GRTncE3MNoHAyMiiimAbiRnYQww+f0NI0TmMAhgVJTOOM9Rz+dFFADiGOXdG5IkBAzweG/WjypCNoXp+7ORwT1H40UUCIwrZ+4WGN+MZ4PUGhkbeyYOV4HGRjtRRQMVAVcs0bfL/CenuKRQ4HKuVxhvl6rng0UUgHFTsZH3AHhxjADdmHrmntvZpBKP8AWcScdCOhFFFMQAHALqxH3JMcDPZqn8uSAncreZEDFMOo2Hpgf57UUUDARPEGiimYyRfvIWQnlT1B/DB/Co/KWQfLERDcZ2Dsknp79R+BooouCQ0QRt5cjwlUB8qYdNrY4b+v4VK1k8EjW5jBuoyHjYLlZFIyMDvkcg0UUXCwixGQblQpBM2P+ubjuT29aeqyrun8oebH8kqMn3lPGQtFFIQogP8Ax7fMG4e3bg5b+6x9T0+tIAMi4lSUwv8ALPGq42NjGfb1H5UUUAPWGQxCKNiLqP5oHUYDoRnAzz/kimkrLG9w0f7uRtkqY+4xHDD3J5/OiigByJcZkY5+22pDnP8Ay0Xrz/ePT8DUZQIn3f8AQ7vgnHMbjsfTB/SiimAuJVTzDGBdW3yyJjG9MYyfbGBj0pixIf8ARnXEUo3wv/dJ/vfyoopAGWZhOY2MifJcJj74zyT/AJ64NCxFo/snUMwkt5Dx19T/AJ5FFFMBkpD/AOkbWKyfLcIeSG/vfjTCkiDau/zYvmjbnlf8/wA6KKBkvlKSpcKLe5z90H9049fft9DTAJFHmshMkJ2TJ/eXp/8AWP4UUUCDyTgxRHdtPmwHbyemR/n0qMIDhsHypvlY7T8rdaKKBiAsArshLr+7kXHUetDb025BZouh5+ZD0FFFADBGw+RNxP348DrRhmUhYzlzvU9wR1FFFACEMcgKwDncvHRqewLfdTaThl4wQw6iiigBAGIwqnL/ADL/ALLDr+dRqGzlUO7OV479xRRSAcFYJwpx97jup6ikKEA7lJA4z6jsaKKADEg4KnJOMY79qFDbgQhBJzjH5iiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus of the nail may present with nail plate thinning, longitudinal ridging (trachyonychia), fissuring, and rarely, pterygium. Nail plate thinning and longitudinal ridging are visible on this patient's nails.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14820=[""].join("\n");
var outline_f14_30_14820=null;
var title_f14_30_14821="Conjugated equine estrogens (topical): Pediatric drug information";
var content_f14_30_14821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Conjugated equine estrogens (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=see_link\">",
"    see \"Conjugated equine estrogens (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17158?source=see_link\">",
"    see \"Conjugated equine estrogens (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8090825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8090835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10478194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Estrogen Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Estrogen Derivative, Vaginal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10478301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=see_link\">",
"      see \"Conjugated equine estrogens (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Female:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate to severe dyspareunia: Intravaginal: 0.5 g twice weekly (eg, Monday and Thursday)",
"     <b>",
"      or",
"     </b>",
"     once daily cyclically*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vulvar and vaginal atrophy: Intravaginal: 0.5-2 g/day given cyclically*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      *Cyclic administration:",
"     </b>",
"     Either 3 weeks on, 1 week off",
"     <b>",
"      or",
"     </b>",
"     25 days on, 5 days off",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8090970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premarin&reg;: 0.625 mg/g (30 g, 42.5 g [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8090838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10478303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravaginal: Use marked stopping points on applicator to measure prescribed dose; to administer, lay down on back and draw knees up; gently insert applicator into vagina and press plunger downward to deliver medication; wash plunger and barrel with mild soap and water after use; do not boil or use hot water",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10478243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of vulvar and vaginal atrophy; moderate to severe dyspareunia (pain during intercourse) due to vaginal/vulvar atrophy of menopause",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8090828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Premarin&reg; may be confused with Primaxin&reg;, Provera&reg;, Remeron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate [topical]; Strength of recommendation - weak [topical]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8090875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Due to systemic absorption, other adverse effects associated with systemic therapy may also occur. Reported with daily use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic reactions, breast cancer, deep vein thrombosis (DVT), dementia, depression, endometrial cancer, gallbladder disease, gynecomastia (males), hypertension, leukorrhea, MI, pulmonary emboli (PE), retinal vascular thrombosis, stroke, uterine leiomyomata (increase in size)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10478284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estrogens or any component; history of or current DVT or PE; recent (eg, within past year) or current arterial thromboembolic disease (eg, MI, stroke); undiagnosed vaginal bleeding; pregnancy; known, suspected, or history of breast cancer (except in select patients being treated for metastatic disease); estrogen-dependent neoplasia; liver disease or dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10478297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with asthma, epilepsy, migraines, diabetes, hypothyroidism, hypocalcemia, hypercalcemia, endometriosis, porphyria, SLE, hepatic hemangioma, history of cholestatic jaundice due to past estrogen use or pregnancy, cardiac, liver, or renal dysfunction. Estrogens may cause premature closure of the epiphyses in young individuals; may cause premature breast development in prepubertal girls or gynecomastia in boys; may induce vaginal bleeding or vaginal cornification in girls; may increase risk of ovarian cancer. May increase blood pressure; may cause fluid retention; may greatly increase triglycerides and lead to pancreatitis and other problems in patients with familial defects of lipoprotein metabolism. Estrogen vaginal creams may contribute to the failure of barrier contraceptives by weakening condoms, diaphragms, or cervical caps made of latex or rubber.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10478294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens have been reported to increase the risk of endometrial carcinoma",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding; the addition of a progestin has been shown to decrease the risk of estrogen-induced endometrial hyperplasia, a condition thought to be a precursor to endometrial cancer. Do not use estrogens (with or without progestins) for the prevention of cardiovascular disease",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; a significantly increased risk of MI, stroke, PE, DVT, and invasive breast cancer was reported in postmenopausal women receiving conjugated equine estrogens combined with medroxyprogesterone acetate (Rossouw, 2002); use of conjugated estrogens alone significantly increased the risk of stroke in postmenopausal women, but did not affect the risk of coronary heart disease (Women's Health Initiative Steering Committee, 2004); due to these risks, use estrogens (with or without progestins) at the lowest effective doses and for the shortest duration possible that is consistent with an individual's treatment goals and risks; periodic risk:benefit assessments should be conducted; discontinue estrogens immediately if MI, stroke, PE, or DVT occur; in order to minimize the risk of thromboembolism in patients receiving estrogens, other risk factors for venous thromboembolism (eg, obesity, SLE, personal or family history of venous thromboembolism) and arterial vascular disease (eg, diabetes mellitus, hypertension, tobacco use, obesity, and hypercholesterolemia) should be appropriately managed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Since estrogens may increase the risk of venous thromboembolism, discontinue therapy, if possible, at least 4-6 weeks before surgery that is associated with an increased risk of thromboembolism, or during times of prolonged immobilization. Estrogens may increase the risk of breast cancer, gallbladder disease, hypercalcemia, and retinal vascular thrombosis (discontinue estrogen therapy in patients with sudden partial or complete loss of vision, sudden onset of diplopia, proptosis, or migraine, or if eye exam reveals retinal vascular lesions or papilledema). The combined use of conjugated equine estrogens and medroxyprogesterone acetate was reported to significantly increase the risk of probable dementia in postmenopausal women; it is currently not known if these findings apply to younger women or to patients receiving estrogen alone.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Systemic absorption may occur with intravaginal or topical use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8090889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8090890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8090861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are not indicated for use during pregnancy or immediately postpartum. In general, the use of estrogen and progestin as in combination hormonal contraceptives have not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy. Use of the vaginal cream may weaken latex found in condoms, diaphragms, or cervical caps.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10478484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, weight, serum calcium, glucose, liver enzymes; dysfunctional uterine bleeding; hematocrit, hemoglobin, PT; bone maturation and epiphyseal effects in young patients in whom bone growth is not complete; breast exam, mammogram, Papanicolaou smear, signs for endometrial cancer in female patients with a uterus",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10478299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synthesis of DNA, RNA, and various proteins in target tissues; reduces the release of gonadotropin-releasing hormone from the hypothalamus; reduces FSH and LH release from the pituitary",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10478300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Absorption: Transmucosal, transdermal: Well absorbed",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10478486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17158?source=see_link\">",
"      see \"Conjugated equine estrogens (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit caffeine; notify physician if sudden severe headache, vomiting, disturbance of vision or speech, numbness or weakness of extremity, sharp or crushing chest pain, calf pain, shortness of breath, severe abdominal pain or mass, mental depression, or unusual bleeding occurs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15981 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14821=[""].join("\n");
var outline_f14_30_14821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090825\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090835\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090836\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478194\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478301\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090838\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478303\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478243\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090875\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478284\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478297\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478294\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090889\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090890\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090861\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478484\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478299\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478300\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478486\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15981\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15981|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=related_link\">",
"      Conjugated equine estrogens (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=related_link\">",
"      Conjugated equine estrogens (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/29/22998?source=related_link\">",
"      Conjugated equine estrogens (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=related_link\">",
"      Conjugated equine estrogens (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17158?source=related_link\">",
"      Conjugated equine estrogens (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_30_14822="Measles-mumps-rubella vaccination in high risk adults";
var content_f14_30_14822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Measles-mumps-rubella vaccination in high risk adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14822/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14822/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14822/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14822/contributors\">",
"     Michael Boeckh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14822/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14822/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/30/14822/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult immunization programs, in sharp contrast to pediatric programs, are not highly successful, although there have been improvements in immunization rates. The national goals of Healthy People 2010 include reduction of vaccine preventable disease in adults as well as children. Specific goals directed at adults include: elimination of diphtheria, measles, mumps, rubella, and tetanus, at least a 75 percent reduction in the number of cases of hepatitis A and B, and 90 percent compliance with routine administration of pneumococcal and influenza vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination MMR vaccine includes the measles, mumps, and rubella live virus vaccines. Single antigen preparations of these vaccines are no longer available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale and risk-benefit considerations for administration of MMR and varicella vaccines will be reviewed here. The principles behind adult immunization and the recommended schedule for healthy adults as well as the rationale and risk-benefits for influenza and pneumococcal vaccine and tetanus-diphtheria toxoid are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Immunizations for select groups such as immunocompromised individuals, healthy women who are pregnant or breastfeeding, healthcare workers, and international travelers are also discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEASLES, MUMPS, AND RUBELLA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Which adults are at risk and is protection important to healthy adults?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The live attenuated measles vaccine was introduced in 1967 and by 1985 had prevented about 52 million cases of measles, 5200 deaths, and 17,400 cases of mental retardation attributable to measles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/3\">",
"     3",
"    </a>",
"    ]. During the years 1989 to 1991, measles cases started to increase again, and the United States Public Health Service responded by recommending a two-dose immunization schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/4\">",
"     4",
"    </a>",
"    ]. The rationale for the second dose of the measles vaccine was not to serve as a booster but rather to immunize the 5 to 20 percent of people who had not responded to the first dose of the vaccine.",
"   </p>",
"   <p>",
"    This two-dose approach appears effective. In 1990, a peak of 27,000 measles cases were reported in the United States; in 2006, only 45 cases were reported. Of the vaccine eligible subjects (ie, born after 1957 and older than 12 months) who developed measles, 69 percent either did not know whether they had been vaccinated or had not received two doses of the vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While indigenous measles is rare, continued protection of adults and children remains important, particularly since imported cases still have the potential to serve as a major source of future exposures. Adults with measles are at increased risk of mortality compared with older children, and measles in pregnancy is associated with premature labor and spontaneous abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like measles, the incidence of mumps in the United States fell dramatically after the introduction of the live virus vaccine in 1967. There was a resurgence of mumps in 1987 to 13,000 cases, probably because mumps immunization was not recommended by the American College of Pediatrics until 1982, leaving a cohort of young adults, born after 1956 but before 1982, at risk. In 2006, 6339 cases of mumps were reported in the US. Eighty-four percent of these cases occurred in six states - Iowa, Kansas, Wisconsin, Illinois, Nebraska and South Dakota [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/7\">",
"     7",
"    </a>",
"    ]. The median age of cases with mumps was 22 and almost all cases occurred despite receipt of 2 doses of MMR vaccine. Factors such as close contact in college dormitories have been suggested as a reason for the 2006 outbreak of mumps.",
"   </p>",
"   <p>",
"    As a result of the outbreak, ACIP recommendations for prevention and control of mumps have been updated (",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5522a4.htm\">",
"     www.cdc.gov/mmwr/preview/mmwrhtml/mm5522a4.htm",
"    </a>",
"    ). Evidence of immunity through documentation of vaccination is now defined as one dose of MMR for preschool-aged children and adults not at a high risk for exposure and infection, and two doses of live mumps vaccine for school-aged children (ie, grades kindergarten through 12) and adults at high risk for exposure and infection (ie, healthcare workers, international travelers, and students at post-high school education institutions). Additional recommendations for outbreak control include administering a second dose of MMR for preschool children and adults not at high risk for exposure and infection if these persons are part of a group that is experiencing an outbreak.",
"   </p>",
"   <p>",
"    Continued protection of adults remains important because the most serious complications of mumps arise more frequently in adults than in children, including neurologic complications, orchitis leading to sterility, and fetal death.",
"   </p>",
"   <p>",
"    While adults born before 1957 are generally considered immune to measles and mumps, rubella immunity is not assured for adults. Rubella immunity is established by a positive serologic test or documented evidence of rubella or MMR immunization on or after one year of age. A clinical diagnosis of rubella is not reliable. The rubella vaccine was effective in reducing cases from 57,600 in 1969 to 213 cases in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ]. There was a brief resurgence in rubella in 1990 to 1991, with 40 to 45 percent of cases occurring in adults and teenagers aged 15 and older. Disturbingly in 1991, there was also an increased incidence of congenital rubella syndrome, representing a failure of the immunization campaign. In 1992 to 1994, eight percent of young adults were estimated to be susceptible to rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ]. Data from NHANES III indicated that persons born from 1970 to 1974 had the lowest rate of protection against rubella (78 percent), further highlighting the need for continued vigilance in immunization of children and adults against this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/8\">",
"     8",
"    </a>",
"    ]. Even though rubella is rare (only 8 cases were reported in 2006), continued protection of adults (particularly women of childbearing age who could become pregnant) and children is essential if the most important consequences of rubella (congenital rubella syndrome, miscarriages, and fetal deaths) are to be eliminated.",
"   </p>",
"   <p>",
"    The epidemiology of measles, mumps, and rubella is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=see_link\">",
"     \"Epidemiology and transmission of measles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, diagnosis and management of mumps\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link&amp;anchor=H3#H3\">",
"     \"Rubella\", section on 'Epidemiology and vaccine development'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Which adults should receive the MMR vaccine and how should it be administered?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following groups of adults are at increased risk of exposure to or morbidity from measles, mumps, and rubella:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Women who could become pregnant",
"     </li>",
"     <li>",
"      College students",
"     </li>",
"     <li>",
"      Healthcare workers",
"     </li>",
"     <li>",
"      International travelers",
"     </li>",
"     <li>",
"      Individuals involved in outbreaks",
"     </li>",
"     <li>",
"      Persons previously vaccinated with killed measles vaccine or vaccine of unknown type between 1963 and 1967",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These high risk adults need full immunity to all three diseases which is provided by any of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Documentation of the administration of two doses of the MMR vaccine administered at least 28 days apart to protect against measles and mumps",
"     </li>",
"     <li>",
"      Documentation of one dose of MMR or live rubella vaccine to protect against rubella",
"     </li>",
"     <li>",
"      Laboratory evidence of immunity to all three diseases",
"     </li>",
"     <li>",
"      Laboratory confirmation of disease",
"     </li>",
"     <li>",
"      Being born before 1957, except for women who could become pregnant and certain healthcare workers, as discussed below",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If none of these criteria is completely fulfilled, high-risk adults should receive two doses of the MMR vaccine (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64771 \" href=\"UTD.htm?12/11/12476\">",
"     table 1",
"    </a>",
"    ). Most people born before 1957 were infected naturally and can generally be presumed immune to measles and mumps [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/9\">",
"     9",
"    </a>",
"    ]. However, for unvaccinated healthcare workers born before 1957 who lack laboratory evidence of measles or mumps immunity or laboratory confirmation of disease, vaccination with two doses of MMR given at least 28 days apart should be considered. During outbreaks of measles or mumps, such individuals should receive two doses of MMR.",
"   </p>",
"   <p>",
"    In the past, documentation of provider-diagnosed measles or mumps disease was considered sufficient evidence of past infection, but starting in 2011, this was no longer considered adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults who are not at increased risk of exposure to measles, mumps, and rubella still need full immunity to all three diseases as defined above. If there is any doubt as to adequacy of immunity, adults who are not at increased risk of exposure to these three diseases should receive one dose of the MMR vaccine (",
"    <a class=\"graphic graphic_table graphicRef64771 \" href=\"UTD.htm?12/11/12476\">",
"     table 1",
"    </a>",
"    ). In addition, young adults who received measles vaccine between 1963 and 1967 were immunized with inactivated measles vaccine; these individuals should have one more dose of MMR, regardless of serologic evidence of immunity to prevent development of atypical measles. Since it may be difficult to obtain childhood immunization records, a practical strategy endorsed by the American College of Physicians is to immunize all adults born after 1956 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/10\">",
"     10",
"    </a>",
"    ]. There is no increase in vaccine-associated adverse reactions in people who are already immune to measles, mumps",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is rare for any immunocompetent person not to be fully immune after two doses of MMR. If an individual is found not to have serologic evidence of immunity to any or all of the three diseases, they are at risk of acquiring the disease(s) for which they are seronegative. A third dose of MMR should be administered when such individuals are detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     How should an unimmunized person exposed to measles, mumps or rubella be treated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-exposure management will occasionally be needed for susceptible healthy adults exposed to measles; vaccine should be administered unless there is a contraindication (",
"    <a class=\"graphic graphic_table graphicRef64771 \" href=\"UTD.htm?12/11/12476\">",
"     table 1",
"    </a>",
"    ). Adults vaccinated within 72 hours of exposure are considered protected against measles, but MMR does",
"    <strong>",
"     not",
"    </strong>",
"    prevent or alter the clinical severity of mumps or rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ]. If more than 72 hours but less than six days have elapsed since exposure, intramuscular immune serum globulin may prevent or modify measles infection. The standard dose of immune globulin for immunocompetent individuals is 0.25",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    intramuscularly, maximum dose 15 mL; the dose for immunocompromised patients, including those with cancer, is 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    intramuscularly, maximum dose 15 mL. Live measles vaccine should",
"    <strong>",
"     not",
"    </strong>",
"    be given for at least five months after immune globulin is administered in immunocompetent hosts and for at least six months in immunocompromised hosts in order to avoid reduced vaccine efficacy in the presence of passive measles antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for immunocompromised individuals are different and discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     How safe and effective is MMR and what are the contraindications to immunization?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the serious adverse effects to MMR are rare, particularly after revaccination (",
"    <a class=\"graphic graphic_table graphicRef64771 \" href=\"UTD.htm?12/11/12476\">",
"     table 1",
"    </a>",
"    ). Possible anaphylaxis occurs in less than one case per million doses and thrombocytopenia in one case per 30,000 to 40,000 vaccinees [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ]. MMR is contraindicated in individuals with a history of anaphylaxis to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , gelatin, or gelatin-containing products [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/9\">",
"     9",
"    </a>",
"    ]. MMR does not appear to cause aseptic meningitis, subacute sclerosing panencephalitis, encephalitis, or Guillain-Barr&eacute; syndrome.",
"   </p>",
"   <p>",
"    Joint symptoms are associated with the rubella component of the vaccine. Arthralgia occurs in 25 percent of adults susceptible to rubella and 10 percent develop arthritis-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"     6",
"    </a>",
"    ]. MMR should be administered to all adults who are susceptible to rubella (or measles or mumps); there is no evidence that adverse reactions are increased in individuals who are already immune to any vaccine component. Single antigen vaccines are no longer available in the US. MMR should",
"    <strong>",
"     not",
"    </strong>",
"    be administered to pregnant women or women considering pregnancy within the next 28 days; this 28 day interval represents a change from the previous recommendation to avoid pregnancy for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/11\">",
"     11",
"    </a>",
"    ]. MMR is contraindicated in solid organ transplant recipients. Hematopoietic cell transplant (HCT) recipients may receive MMR 24 months after HCT providing that he or she is no longer receiving immunosuppression and does not have active graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14822/abstract/12\">",
"     12",
"    </a>",
"    ]. In other types of immunocompromised hosts (eg, cancer patients, HIV-infected individuals), MMR is contraindicated when severe immunosuppression is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunizations in solid organ transplant candidates and recipients\", section on 'Measles, mumps, and rubella'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link&amp;anchor=H19#H19\">",
"     \"Immunizations after hematopoietic cell transplantation\", section on 'Measles, mumps, and rubella'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H22#H22\">",
"     \"Immunizations in HIV-infected patients\", section on 'Measles, mumps, and rubella vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link&amp;anchor=H14#H14\">",
"     \"Immunizations in patients with cancer\", section on 'Measles, mumps, and rubella vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects associated with MMR are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=see_link&amp;anchor=H14#H14\">",
"     \"Mumps virus vaccine\", section on 'MMR vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMR should not be given to patients who recently received intravenous immunoglobulin, since this product can blunt or block the host response to MMR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H25#H25\">",
"     \"Standard immunizations for children and adolescents\", section on 'Immune globulin recipients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53647128\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination MMR vaccine includes the measles, mumps, and rubella live virus vaccines. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following groups of adults are at increased risk of exposure to or morbidity from measles, mumps, and rubella:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women who could become pregnant",
"     </li>",
"     <li>",
"      College students",
"     </li>",
"     <li>",
"      Healthcare workers",
"     </li>",
"     <li>",
"      International travelers",
"     </li>",
"     <li>",
"      Individuals involved in outbreaks",
"     </li>",
"     <li>",
"      Persons previously vaccinated with killed measles vaccine or vaccine of unknown type between 1963 and 1967 (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Which adults should receive the MMR vaccine and how should it be administered?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These high risk adults need full immunity to all three diseases which is provided by any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Documentation of the administration of two doses of the MMR vaccine administered at least 28 days apart to protect against measles and mumps",
"     </li>",
"     <li>",
"      Documentation of one dose of MMR or live rubella vaccine to protect against rubella",
"     </li>",
"     <li>",
"      Laboratory evidence of immunity to all three diseases",
"     </li>",
"     <li>",
"      Laboratory confirmation of disease",
"     </li>",
"     <li>",
"      Being born before 1957, except for women who could become pregnant and certain healthcare workers, as discussed above (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Which adults should receive the MMR vaccine and how should it be administered?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If none of these criteria is completely fulfilled, high risk adults should receive two doses of the MMR vaccine (",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64771 \" href=\"UTD.htm?12/11/12476\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Which adults should receive the MMR vaccine and how should it be administered?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-exposure management will occasionally be needed for susceptible healthy adults exposed to measles; vaccine should be administered unless there is a contraindication (",
"      <a class=\"graphic graphic_table graphicRef64771 \" href=\"UTD.htm?12/11/12476\">",
"       table 1",
"      </a>",
"      ). Adults vaccinated within 72 hours of exposure are considered protected against measles, but MMR does",
"      <strong>",
"       not",
"      </strong>",
"      prevent or alter the clinical severity of mumps or rubella. If more than 72 hours but less than six days have elapsed since exposure, intramuscular immune serum globulin may prevent or modify measles infection. The standard dose of immune globulin for immunocompetent individuals is 0.25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      intramuscularly, maximum dose 15 mL; the dose for immunocompromised patients, including those with cancer, is 0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      intramuscularly, maximum dose 15 mL. Live measles vaccine should",
"      <strong>",
"       not",
"      </strong>",
"      be given for at least five months after immune globulin is administered in immunocompetent hosts and for at least six months in immunocompromised hosts in order to avoid reduced vaccine efficacy in the presence of passive measles antibodies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'How should an unimmunized person exposed to measles, mumps or rubella be treated?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the serious adverse effects to MMR are rare, particularly after revaccination (",
"      <a class=\"graphic graphic_table graphicRef64771 \" href=\"UTD.htm?12/11/12476\">",
"       table 1",
"      </a>",
"      ). Possible anaphylaxis occurs in less than one case per million doses and thrombocytopenia in one case per 30,000 to 40,000 vaccinees. MMR does not appear to cause aseptic meningitis, subacute sclerosing panencephalitis, encephalitis, or Guillain-Barr&eacute; syndrome. Joint symptoms are associated with the rubella component of the vaccine. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'How safe and effective is MMR and what are the contraindications to immunization?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MMR should",
"      <strong>",
"       not",
"      </strong>",
"      be administered to pregnant women or women considering pregnancy within the next 28 days. It is also contraindicated in solid organ transplant recipients. It may be administered to hematopoietic cell transplant recipients 24 months after HCT provided that he or she is not receiving immunosuppression and does not have active graft-versus-host disease. In other types of immunocompromised hosts (eg, cancer patients, HIV-infected individuals), MMR is contraindicated when severe immunosuppression is present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'How safe and effective is MMR and what are the contraindications to immunization?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Healthy People 2010: Volume 1, Objectives for Improving Health file://www.healthypeople.gov/Document/tableofcontents.htm#volume1 (Accessed on August 13, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/2\">",
"      Kimberlin DW, Bocchini JA. Monovalent vaccines no longer available for measles, mumps, rubella. AAP News 2009; 30:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/3\">",
"      Bloch AB, Orenstein WA, Stetler HC, et al. Health impact of measles vaccination in the United States. Pediatrics 1985; 76:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/4\">",
"      Centers for Disease Control (CDC). Measles prevention. MMWR Morb Mortal Wkly Rep 1989; 38 Suppl 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Epidemiology of measles--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2004; 53:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/6\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Brief report: update: mumps activity--United States, January 1-October 7, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/8\">",
"      Dykewicz CA, Kruszon-Moran D, McQuillan GM, et al. Rubella seropositivity in the United States, 1988-1994. Clin Infect Dis 2001; 33:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/9\">",
"      Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     American College Physicians Task Force on Adult Immunization and Infectious Diseases Society of America. Guide for adult immunization. Philadelphia. American College of Physicians, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14822/abstract/12\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3893 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14822=[""].join("\n");
var outline_f14_30_14822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H53647128\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEASLES, MUMPS, AND RUBELLA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Which adults are at risk and is protection important to healthy adults?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Which adults should receive the MMR vaccine and how should it be administered?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      How should an unimmunized person exposed to measles, mumps or rubella be treated?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      How safe and effective is MMR and what are the contraindications to immunization?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53647128\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3893|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 1\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3893|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/11/12476\" title=\"table 1\">",
"      MMR in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=related_link\">",
"      Epidemiology and transmission of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42567?source=related_link\">",
"      Mumps virus vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_30_14823="Anatomic sites with waveform";
var content_f14_30_14823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    The panels show the anatomic sites and typical waveform patterns for the umbilical vein, ductus venosus, hepatic veins and inferior vena cava (indicated by grey circles)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 522px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIKAhsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKK4H46eItS8K/DPVdW0SZYL6DZscoGxlgDweK+UdJ8W/EPVdJOoDxld2xIlkMU3ybgo3DYTw2fbpQB92UV+c//AAt7x7/0M+of99j/AAo/4W949/6GfUP++x/hQB+jFFfnP/wt7x7/ANDPqH/fY/wo/wCFvePf+hn1D/vsf4UAfoxRX5z/APC3vHv/AEM+of8AfY/wo/4W949/6GfUP++x/hQB+jFFfBngnx5411+6uVu/GOpwRQIrlY5E3sCcHG4gcdTVa9+IPjtfEV5p9j4u1Ga2gkKickcr2JxUqacuXqU4tLmPvyivgI+OfiQ0gSDxVdyEnA/e7f5iq8vj/wCKMZwda1Y9sqwYfpVEn6C0V+ec/wASviZAcT61rUff51I/pUS/FP4iM20eItTz6bh/hQB+iNFfn1b/ABE+I8zKP+Envlycf6wZ/lTdc+I/xE0e6ENx4ovzuXcrBxyKAP0Hor85/wDhb3j3/oZ9Q/77H+FH/C3vHv8A0M+of99j/CgD9GKK/Of/AIW949/6GfUP++x/hR/wt7x7/wBDPqH/AH2P8KAP0Yor85/+FvePf+hn1D/vsf4V9LfsjeK9c8U6Z4hk8QalcX7wzRCMzNnaCpzigD6Cooryr48fFO4+GFlpM9tpcWoG9kdCJJSm3aAeMA+tAHqtFfJH/DWmo/8AQq2n/gW3/wATW7oX7Q/izXbZp9J8EWtzGCQSt8QQR1420AfTVFfOcnxx8cx7t/gG2XaAzZv+gPQ9O9LH8cfHMjhY/AVqzHGANQ55/CgD6Lor5Pvv2qdYsLya1u/CNrHcQuUkQ3bZVh1H3ag/4a01H/oVbT/wLb/4mgD63or5I/4a01H/AKFW0/8AAtv/AImj/hrTUf8AoVbT/wAC2/8AiaAPreivkxf2rtWaPzF8I2xTONwunxn/AL5oj/at1eVtsfhC3duuFunP/stAH1nRXyX/AMNX6rsZv+ESttqnBP2p8A/980z/AIa01H/oVbT/AMC2/wDiaAPreivkj/hrTUf+hVtP/Atv/iaP+GtNR/6FW0/8C2/+JoA+t6K+SP8AhrTUf+hVtP8AwLb/AOJo/wCGtNR/6FW0/wDAtv8A4mgD63or5I/4a01H/oVbT/wLb/4mj/hrTUf+hVtP/Atv/iaAPreivkj/AIa01H/oVbT/AMC2/wDiat6X+1JrOqXqWtn4TsWmYEjffFQABkkkrgdKAPqyivle/wD2nPEGnxeZeeDrSJd/l83jfewDj7voRVD/AIa01H/oVbT/AMC2/wDiaAPreivkj/hrTUf+hVtP/Atv/iaP+GtNR/6FW0/8C2/+JoA+t6K+SP8AhrTUf+hVtP8AwLb/AOJr3j4KePpviN4QbWbmwjsXFw8PlRyFxgY5yQPWgDv6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8v/aTVX+EeqI4yjSwqw9jIua8tv8Awr4QTSbjZoNkGjtmKHByp2dRzXqP7Sp2/CHVj6SQn/yIteD3uulrG4Xf1hYdf9mvms/hWlOl7KTW97NrsetlmGVeM21t/wAE+dW6mkpW6mkr6U8kKKKKACiiigBy7iQFzk+ld14W05zIsKxSRyPjzQCcjiud8PWUcztcTFgIiNo25BbtzXdaZuhR52VUlnG0sp4CjqfqaALczWjb45rPYuMcEjbjpz61PZxwx+V5bTxRhfMO9gcgexqdY4zDuSbbvwMOM/j/APXpvlwHU5EBj8tAMAvyT/WgCK81K3ZxDeSXZBzyyAkjr61LP4Ng1DTze6Xcbi0e/wAtiA3HXgd6q6vbGeRNjpuAy2Ofx9zWro0kqWaLHdIjwlgG2539wDQBNofh+1t7KNyFkkcjhx0I6lu4rl/iE1tqdg1uluFurRiUlU/e55BHp6V2+kX8TJIL1GIYFin3c/59K57U007TJHuo1+0FmBVWXHB/hI/rQB4setJWv4nSD+1ZZrOMRQTfOIx0jJ6rWRQAUUUUAFfW/wCxB/yB/FH/AF3i/wDQTXyRX1v+xB/yB/FH/XeL/wBBNAH07XzF+2//AMgbwv8A9fEv/oIr6dr5j/beBOj+FwO9xL/6CKAPkevSPA+v6PoXhae31TStSnmvpd63Ns4AVV42rk8e9Zd54f0WDw59pXUA+oC3DyRiVcI+egHfPT2qeTVpdIsbKGG8YwtppKCPgby3oR1qZPlVyoR5pWvY7W7+J2j3M0jnS9WRGjWIRiOPCgHIwc5znvWdN4y8MMFZdE1qJzHtEgCZY5OXPqecV5t/wkGr/wDQQuf++q1b7xdqsukWFst5KDGDvYcE8nHNEpNNWW44x5k23axj65Ib7WLy6t7eZIZZWdFZeQCeM1SNtOACYZcHodh5rsB4vUWd0BJeG4IBhYtwDjBz7d6wz4m1lnVjqFxlTkDdx+VTCble8bF1aUYWtJP0MryJv+eUn/fJpTbThQxglCnoShwa6fxL4nvJ7uD7HeTRhYEEmw4BfHNVdJ8U6tbXsckl/O6Jk7XO5fyNEZuUOa2vYUqSjU9nfruS+GfEl/oFpNBb2SSrKxYmRCcZAH9BWpceOtWe3tVi0uC3WJ8hoYiu8c/KT6c81UuPE+oR3Qllu5f3sKOFUgAEjnis+88U6nIdlteXEcQzgF8nnrTUne1hckeTn5vkXvE3iu916xe2l02G3DSJJmFCv3VxyMc1zTWF0tuk5gk8p2Kg7e46/wA66O08VXo0G6t5ryX7QGDRSZ+Y54I+nGarHXtV/sNX/tC43faCM7+20URk5N3VrCnDlSad7mB5E3/PKT/vk0v2afbu8mXbnGdhxmum1LxdqlxHYD7XJGiRjdsABYjgmrU3jSZdKaCF7kzk4V2bgD1+tR7SVl7u5sqENbzSt+Jx3kTf88pP++TS/Zp9u7yZducZ2HFb2leKtUg1a2uJ72Z40cF1bkEemKk1/wAUX1zqkz2F5cxWxI2oHwM9zir53z8tum5l7Ncjnfra3X1OcMEw6xSf98ml+zT7d3ky7emdhxXS6D4w1WxkuC10ZQ8ZA80b8EdMZ6U6x8Y31vbIks80vLFxu656H8KmU5JtKNy4UoyScpWOX8ib/nlJ/wB8mr+i3F1pd6t3HZ+cFVkZJEYqwYEEHHsas3XifV55mIvpkUnhVOMVvS+K7z/hBYrf7XL9sNwfnH3to9T3onUceXTd29BQpKblZ7K/qc/rer6nrMNvHeoSsBdl2xkcsc8/TgD2FZsdjcvbyzLC5jjKhjjoTnH8jV5fEWrKQRqFxkc8tW3rnjLUb65tN1xJBEsQ3+SAm8nnJAqpSaaSRMIcybvbY5LyJv8AnlJ/3yaX7NPtLeTLtHU7TgV0D+L9S+yiNJ5BKBtEme3+NXvBfia/i8RQC91CVrZsiRZDuU8HtUzqOMJTa2/EuNFSnGEZbnIeRN/zyk/75Nfbf7HX/JKH/wCv6X+lfH2qeItRkv7kwX8/ks7bQGwNua+wf2Ojn4UyE9ft0v8AStE7q5jJcraPdKKKKYgooooAKKKbLIsUTyOcIgLE+woAdRXI+G/iJ4c8RXNrb2F1cJJdo0lr9ptZIFuFX7xjZ1AfHfBPQ+hrpo721k8ry7mBvNUvHtkB3qOpHqB60AWKKwL7xl4csVtWn1my23NyLOJo5BIDKQSFJXO3gHk4A7mtYX1oRkXUBHmiHPmD/WH+D/e56daALNFU4NU0+4vpbK3vrWW8h/1kCTK0ifVQcj8auUAFFFFABRRRQAUUUUAeV/tOHHwb1o+hiP8A4+K+LpPEiNG6725Ujp7V9pftODd8G9aHqYh/4+K+QJfDqrbu3ljhCentXdg8mWZKUnK3L+v/AAxcc4eW+6vtfp/w558etJSnqaSuEgKKKKACrOn2cl9ciCEoHIJG9sA47fWq1db4H0/fNPcs6JLEMKrj170AbdlaHT7KC1iUGd8Kccq2eTuHqKt6TcXdxrEdlbQNJGxEcUSLuL/Tv1rUtJYkjM5t9km/yweRvJHJH4V3ejTQeD/Ch1+KCL+2tSdrbTm2ZMKAfM/17ZoAangC6SV49a1XStOlkGYoJpgJAT2ZR0rB8SeCb/QNst/bpJbMdsMsbArJn+6w7+1Itnea3eieGGZ5kTdI8oLFWzn7x65rpfCOsCWQ+G/Eaq+mao+wKVI+zSH7jL6c1t7CXIppp+XX5owjiKcqjpJ6rc83lj8kJv8AnJHGz7wrZ0ZgArIVKBxgHqM8HIqlq2lzaXr95pc7bpraRkYlcDj0+oqXQmjXUZ/KSORTGGweNpB71ibljV0Q3RkV8+WpClDgPntj1Fclf6ksSujRFJAOSx6mu08QNHPe5iZWk2gFyehx7VwGvSrHeZMJn653e1AHO3eb6VbdMF5DlWYgDJ9T2rFkQxyMjYypIODmrd++6UlQQD+lU255oAbRRRQAV9b/ALEH/IH8Uf8AXeL/ANBNfJFfW/7EH/IH8Uf9d4v/AEE0AfTtfMX7b/8AyBvC/wD18S/+givp2vmL9t//AJA3hf8A6+Jf/QRQB8kVua//AMeWjf8AXoP/AEI1h1v+J1jS20YQyGRPsa/MVxzk5GKAMLtTmclEUnhc4ptW9LsJtSvY7W2XdI54qZNRV30KhGUnyx3ZUoHGK0dQ0a9seZYXMfPzgccVnURnGavF3HOnOm7TVmHJ5zQvXmgU+CPzpo496JvYDc5wB7k+lURctat9+2/69o//AEGqXaurm8LajfLbSxfZ/L8hVDGUY+UY/XtXM3VtNa3DwXMbRyocMjDBFSpxk7JleynGKlJWTIqvn/kAD/r5P/oIqh2q/wD8y+P+vk/+giqJKDMSFB6DgUdqt6dYXGoStHbIWKqWb2Aqa70XULSN5JraRI16kiodSCfK3qaqjUlHnUW0Zw6UZOc0UZqzIASKMmgfStpvDGrBokW0kZ5IvOAHOFxUTqQh8TsaQpTqX5FcxeuaXcdoXJx6UsiNG211Kn0IpvaqI1Qd6dISSNxzwAKaav6XpN5qjOLGFpSgycUpSUVzSdkVCMpvlirsoe1AO05FXdQ0y5sWHnxnaf4gMj86pA0RkpK61CcJU3yyVmJ3r7f/AGOf+SUP/wBf0v8ASviCvt/9jn/klD/9f0v9Kog90ooooAKKKKACobyJp7SeJSAzoyjPTJGKmrgfid48l8DTWkk1mk1jdW9wI5Mnd9qRN0cZ9n5HrmgDm/Cfw01+G08KWHiG40qKx8PCZ4msZJJZLiSTcBu3IoVRu6DOcdqoWvwq8T3Gm6dpmpajpMFrYaVd6ZFPaNKZGEuNrMrKB2wQD0zyc8aerfEzX7LxHJpUeh20kmnxWj38fmEMxlVWcxsSAqpkjLZyQelTL8SNcGtRmTTNPOinxFN4eJjlc3Jdd22QDG3GF5GTn2oGQ6p8O9Y1LStLV9I8IW95pl7azpHCH8u6jiR1ZJGMeQDuGF2tjHJPYl+HniUayyw3Gjf2M3iaDxCSWlWcbdu+MALt4C8c898UmhfFTU76GOeTTdOlW90y51Kzgt7rDxeU20Rzs3yjdkDdwAcjFRaR8Wr147UarBYQTvq1pp9zEySwNapNHI25t/B+4MEHB56cZANH4dfD7V/DPiua/nm0+HTDHKFtoXM5Lu+7Ks8atGPUb3zXqdeMat8W9UjtrmfTtOs5LS31G9tZLsFp1SGArtkMaHcQwYksPlGPevWtDvRqei6ffq8brdW8c4aLOw7lByu4A454yAaBF2iiigAooooAKKKKAPL/ANpUZ+EWqj1khH/kRa8UvdFA064OzpAx/wDHa9r/AGlHWP4R6q7/AHEkhZvoJFJrxqP4i6Tq+i3j6bpOpzxiCRWdVTCYTksM8CqWNr4bSir33PnM9wmIxM6ToK6V7/gfMLfeP1pKVuSTSVJ9GFFFLQBd0fT5dTv47aBSxPLED7qjqa7aDTo7PVI5rWYmIqAQzdR0wak8AoNP04zERC5uDkCQDa6D+EnrzVqS9iTUWlgtxFLjKQlwVYnjgnsKAE1zULyaZY7SdTHBiMYxww6n/wCvXpXxAHl6T4IUF22abvVh0LFuSa8is4Jre8l8+LHXaWBX/wDXXp9xHL4m+FukXsMzG50N3tLoJziFjlGI9O1AFfwz4lXSJpIr4SSWszq7GJjlXHTg9qyPFd/cafqgEtwzp56vBMpyzAsDn+lY1s0Mcv2IXKK5YFmJ3fj7Cuq8JaZd+JPE9lpFxNG1lalbh5cArHApyxyR7VVChQjKc2rN9e9v6/z2OarGt7WM4O62afTzX3Gl8Z1htfHNxfyPiSW2gkK9txQZJrykeI3TXN1vIG3xspK8DOOK2/jPqWpa74s1W+hjzpryf6O6jP7sfKo/Suc0nS7SfTrWa15vI5B5wbhgDx0oxEJ4a3tYtXO3CwWLUnSadlcS08WTsRJdykkEHaeQ1M1S+W6QyJKrbu3QVzRgb7W8I4Icrz7Gtr7A8EMb/Kqupw3XFSZmNcls4J4Paq4dgrKD8rdR61PcpsY5+8Kr0ANop7sCqgKAR1PrTKACvrf9iD/kD+KP+u8X/oJr5Ir63/Yg/wCQP4o/67xf+gmgD6dr5i/bf/5A3hf/AK+Jf/QRX07XzF+2/wD8gbwv/wBfEv8A6CKAPkiui1K1kvU0K3hAMj2oAycdzXO16j4SgtJ/EOjeVDJII9O3xrJjO8Hk+nrisMTV9jSlU7I2w9NVKsYPZs4XxHos2h36207Bi0YkUjuDXY/CrTYkiudUuBkhxBFkdz1NXvjFZieGwvFQibzXtyoHXvXS6box0vQrW1gkf7ObcmQkD77DmvDxOP8Aa4KHM7Slo/luexhsIoYuTWy2+ZPf3VqZHgkgSRh8s4HO0txuFeOeL9IGmatOttG4s+CjHnqM9a9Ni3WzKrFNjRJGwzzwfvZ/PNX9T06z1GFbC5jDySHKMOB9PyrlweJ+pTvunv8A5no4zCLEU+V6NHk9l4Yubnw9camQyLGN6gjhl9c1n+HdPbVNYtrVQCHcZycDHpn36V7VfhodDXTDEhhZfIjCdM7eAa4XwFoFwyz3It1dw2EcsR5ZB/8A1/lXp4fMnOlUqT0tt+h5VfLlGpThFb7/AC6noln5Futzb3CkRoqh1IyGPAH5cVzHxA8PDVNMiu7WFTqMZZTsH+sjHTPvWtNPBJdWEUnmOS5PmL0LY4GauxzyxXcxmxsbAdVX+Ejn8eK8eNWdCv7Vb7+vQ9X2EatHkfY8X8LaLJrWtR2ZVggOZT0Kj/HNXPFOmDR0uLNQ3lpdEoWzyCg9QM/WvYNN0ay0+5udQgCebcqC0x4Dc9h0Bx+tch8TbCTUk0QW6lru5laEr9MAE/hXs4fNI18Ryr4bfjueNWwHsqF95XD4T6YsGj3eo3BbZcny02jJAU8/nXbalZwai0lrcyobeSE5fABAJ4H4UzSbNdP0q0tpgsUdsm1V3YBbpuP4mo5pYxbw2qEM0bqpbB688579a+dxFaVevKqn1/4b9D2cPR9nTVPseKeLNEm0LVZLeRcRk5jPqKs3PheSHwpFq5lBZiC0fop6GvX/ABJ4btPEAgju5JFaErzt+Z+Ki8SadA3hi70qFFjTyy0QC9McjJ/CvWhnTlGnH7V/e9Dz/wCzoOU2lutF2Z414S03+1vENna7lRS+5mboFHJ/lX0BbtAJPNjKtGqgbh0x0Arzr4RaV9ntbzVriMMH/cxqw/M5P5V3WnGG2nZTIVjm6IV4Rsfyrlzmv7as4LaOn+Zrl1FwotvdnE/Erw3bzae2p2ETxvCNzhuMgnpivPfDWjS65qItYTg7S5PoBX0C1tutpY72KMrOhUgnO489axvBvhu10O0uJxCyTTbhy2Sq+gNVhc2dDDSg9ZLb+vIWIwUalVVOnXz/AK6nhF7bvaXcsEow8bFSK9f+FOmQ2/h/7WyMt1LIeWPAXHBH4VyvirQZL74gRWcY2i72sWA/h7t+leqWdhDZOLS1D+VGiqAfu4Hce5PaujNcaqmHhBPWSTfoZYLC+zrTb2Wi/r0H6xpdpqljNbeWjbkKfLgAMehr5/8AEOkTaNrM+nzcvGePcHpX0IixAMC0ssyMSwB29ev5Vma74YsdevbG/uFK7G3MQPmYAcA+3FeflmYfU5OM/hf5m+Nw3t4pdV1PHdf8L3Oj6Np9/OylbsZ2jqpxnBr69/Y5/wCSUP8A9f0v9K8Y+JOnJqPhSWSFCTarujTpt9f0r2f9jn/klD/9f0v9K+jyvGPF0XKe6b/4B4+OoKjNcqsmj3SiiivSOIKKKKACquo6dY6lHFHqNnbXaRSCaNZ4lkCOOjAEcMMnB61aooAzNS0DR9UuobnU9J0+8uYf9XLcWySOnOflLAkc+lPGiaUMY0yx4ujej/R04uDnM3T/AFnJ+brz1rQooAzIfD+jQPeNDpGnxtegi6KWyAzg9Q+B82ffNRR+FvD8emPp0ehaUmnu4ka1W0jETMP4imME++K2KKAMOXwh4amiSKXw9o7xpI0yo1lEQrtjcwG3qcDJ6nArbUBVAUAAcADtS0UAFFFFABRRRQAUUUUAeVftPf8AJGNc/wC2f/oYr4Wg8Q6pb2qW1tdyQwqpXbH8uQRg5x149a+6f2nv+SMa5/2z/wDQxXwBQAUUUUAFdHoVt/bv2ewWG3ga3DN5/dyTwG9RXPxIZZUjXqzBR+NdvPo174dsGinjCyMQWfbk8+hH8qAInWWJZYb11idG+XnKn6UzzJLeVBcEtbk9ByOe49KseePsx+0sJDJwu4c8VlOyl2EhdQwwB0A/CgDZt9SkgvWhSdXtOySDctdv4D8XNomoTXdppsRjlHlTwKxEcydwwP6V55pEIkbAAxHnhx0rUjkjSKR4ldtoAcluMegoA72XT/h7fXj6nDqWr6G07EtaeQswB7iNvStqTVNJsvDM+l+EY7i0t5QBd390D9onUfw8dF9hXlliDL5Sq4yrZQ9SCfauqtnvLYzBsZCAGNnD7gf7tAGTY6hb2z3trdXtvsBJiwC20ehGKwIzo1tqEt7d30/z8r5UT7c56duKt3WlLqRnCYjuIyTwMVw+qSXiMba5kcohwFJ4r0JZlVnSVGaTS7o5KeCp0qkqtNtN9maGqPZ3t5O1lCIxI5dG56e9UoNRaMmO5XcANvuK0NJ0K5uvJZ3RIpPl3Mfu1pax4dgit0RLqJ7hTtCopDH3OeteedZyTjfllHX1quRzita5027tgyOhwDWaykHA6j9KAGKAWAY4Hc01gAxAOR2NO/nSrGXR2BGFHOT/ACoAjr63/Yg/5A/ij/rvF/6Ca+SK+t/2IP8AkD+KP+u8X/oJoA+na+Yv23/+QN4X/wCviX/0EV9O18xftv8A/IG8L/8AXxL/AOgigD5Ir07wQ4XW9I3yBFOmsMk45ycc/WvMa9N8Mi2n1rSh5AW2bTCrJI27ByRnPHeuTH64ad+x1YL/AHiHqejfZYprVRe2+Qm11B+b5hxkfWquoGMCCOVgI3bdkA9Ow9uatWCBjC0W8NGmMsSQecYqrqoCwTy7DKjsqfL/AAMDwa+Ig/ftc+sj8VineRF4vOaJEgI2eXtyzDv9KgsoY9Pt4pftu4BSq72yWOf8OlWoNTkaGN7wQmOckR7OG64JIqr5CARpLD8jkmJmGQCMnj8K6Y81uWWxotRZZGlKbZSwQ5d15KMT09setbt/9ltJfIt42VZCMBU4YgZzWAZ3jf7W8aRoUwTj5evpW3rl4ltdRzbJt7uAi9F3YH8xROLcbL+tyZr3l8/0Ma/RvsswsXCzRsJUVuBsOP8AA1PDdO7wTFHlkmYRshHEfGPyqKS4NqgMsQPmjDrjOwD+EH8alvLsrLCYZAIypXBGdw6jnt3q6ibla3cmivcRs3lzFbxm3cII1GMk5BAHANIZkRoJJPnCNhCU5GcZ+n1qGFre4tYTKIi4Hmc8/wCTUgFsiyod7fJtYE7s7v61yU/dTWt7MynFJJNdRt9GkNo4mPJZioPQ/X6iqxZbeK3iL4AKlGUbtoAxnPvUl1j7EquGeFRwd3b0/Cs3Ijkjh3EwshRSw4xTpxutTeK01N8yzI0nlKGI6n19hVW1uUhtHF2nmkFjt65HU0qDdG0LjbGVIV1ODkgdPemFEeSGWbMQiwNzH73sfwrNRWzI5VqmaEVtCLHyYQEjILLHwOSOntWPLaziZrgtIQw2tGODj1/wrUZkRQcAL5oyV/ME1SdXSOYs4dJnwsm7nb6fgaVNtN67ip3RYtYY7u4dhIrwMBtUHnHf6c1JeOkdxCgUiEkrjPDAj/69Z1iZLeWaTPnOw/dMuO/Y1dt5knVDEgPyblJH3CD93P1olFqV90DTTv0JbKyiBhuJoo/tUaGND1OzPr71GlxMZGWVF8wt8yg8cnAI9wKsRBxIzXDO77eWUY289MVl3aD7Yk3mIPMysaZ5YZwDmlH35PmJgk27l+TJiAbHm8AkdWAOSRU1owD/ALpHMci53k8Z9hWTZs8sjreSD7Rv2LCpztB9DWlBcCFfJRQuw7SzHgdaVSDSsOcdLBdeU1vNFOu5mhY4bvx3r0f9j4Y+Fs3GP9Pl/pXmFxFJJdXcmHVRC0av1DDBP5e9en/sf/8AJLZv+v8Am/pX0fDyt7T5fqeJm32Pn+h7lRRRX0h44UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlX7T3/JGNc/7Z/8AoYr4Ar7/AP2nv+SMa5/2z/8AQxXwBQAUUVPZW0l5dRW8IzJIwVRQB2Xw20U/2pDqt6gW2g/eRbwCJGHt6CvWdY1PTtWs5SsKm4yMqR82T1we4qLwvothD4YjtbTy/tlsDujuMrvPcqfX2qr/AGa6W8kiuI4M7lQcNnvj1oAztW8IW80ED3FtLbTtkgoNyn0Irhtb0S80y4KzKsrfwlGzx7ivUbLURJatHDNnyhjbJlsjvj0rXt9Q0zUzHb6lYxtG6bUbywGJ9mFAHilikkcZdFKJ3c4/EVfO3OxArSEjHXaw969P1b4aRSyi60VzCrcpDK4+fP8ADWDfeGNR0pEjutOklVTuOz5se2R/WgDL02yVV8vZH5i/vDJuxgf3c9662W2s30vltjqVMgZhiQ+3vXNaKk51WL7SsqW6ZDYBB/I/yroLvy/LWOXc9mcyMdmCGoAxJI7eOKbyFcozhcEZz69DVM6lZ6G8jvawSTyHDSTQq4HuM9K2bOAQlvLaGIOSV6ZHpWd4h0qK+V/OZdo5aRBwfYUAYU17dTbliaNJG+YbNuPwPanWdlJfRK7xu04PM+ThB6e5q9Zx2+lBEkgEqqMAuB+YFbeleJILewbTYVYRyud7JHjJ9qAOI1OD93tRHklHVyDgD1Ncm0QMjiUjefXgAV6frBm1TVDGNOeC1AEYI+UH6+9ch4k0lLLUWhMIJ44D5A+poA5kW+Rl8JEO/U1TkChiEyR71tyRIin7QxyB8iLx+dZNySWBKhQR0FAEUkUkao7o6q4ypIIDD29a+s/2IP8AkD+KP+u8X/oJr5OlmllijSSR2SMYRSchR7V9Y/sQf8gfxR/13i/9BNAH07XzF+2//wAgbwv/ANfEv/oIr6drxf8AaM8J6x4lfw1Jo+ijWI7OaVp4C6qMMgAzkjvQB8KY4zjivTfA5jGu6MJlDodObII44JPNddqXwo8ZXNvfW8HgTyIpkzGFnjzHLkfMOemOMVe0X4e+OdMe3kTwCGkitfs+43i8984zXPi6bq0J047tG2GmqdWMnsizFcywM9zdRpDbYLMf4UA43GsLWblraxVbRnZJfmyOdw7Z9OoNdSPCvj4WrxnwDuZwQ4a9Uq2fbNJH4S8dxosY+HwMR+aQNeKct6jmvnaeT1oS5mke880ox13OHtNR3RyJdLGrxx4CA8HPVl7961beMvBaqZ5XhCZU45DDkDNdBceDfGs43t8OIvOOVZ/taA7fTINOsvCXj20VFi+H4CoNo/0xT8vXuevPWtZ5ZWkrxVmX/atKyOa1TD23kAktdqWEIGXT1/UVpz6nbPq32SU4aIBXVj8wO3hgP0q+3hH4gfaftUfgPbc7t24Xi4/nQ/g3x1PqUuoXXw+Bu2Hyul4oGR0yM9KP7JquHLL8+opZnQvc4q/laV2VpAsKnL4b7xxwM/lUymEwxQSb3e5ULmPk5zjj0+tdnb+DvGogEc/w83h/9aFu0Ab8M/lVK0+H/jGybNr8PZFPzL82oA4U9hzxW0svqyb022Jp5rTVO1tSO1khtYIWtY8LwdhH3R05P1FVrNJNPuZJZpVc3UpKs3O0ccVvXnhn4gXNmIW8BckYc/bF6Dpg5zUK+E/iAlrHGvgPcyZAD3ilRn05rlp5TXSle2ug3mVBpXOb1W8RdOH78tG5ZOBwDn5hmqTXltcyW8Vm4ktwpYqp+dcAZOfX2rsP+EN8bnETfD0G1AJCG7Qncfx6VD/wrzxMIE2fDeSOdQcPHfquCevetYZXUgrNBHN6T2TRVspTA4JbdE2359vAPTP1qC9lmMsyWyGaWICXaeQ/Yg/XmtrT/CPju0mVx4Ck+55bf6epyB04J6+9OtfCvj23uJJk8BN5jLjP21efTPNYPJ6yk2rMI5nSd3LQyrrVVNuTJ+7mUBScfePcAe2KxtMurdYpRLIMRjIIOQcknOO3Wuwj8MePmSRp/h+GnxiNheJgcd8mkj8GeLDbiOb4b5yQzlLtBubuetVHKasItW+5hHNqC0szn7CSKRs+YjRsxbYgJ385z9KvyPFBbKItix7x09M9D7VNF4F8ZQXbvbfD6VInXY3/ABMF3AdeDnjmrl14V8dXMQWXwFIxAxg3iYx+dTPJ6zkrbD/tSi5a7f10Ibu6FtAx80iR+FLrgD61jX08Ez2nypIy/O2OvuV/OuivPDnj65RY28AloeAyteLyB1xzQPC3jcXZb/hX7+Qq7Yl+2JuT171FLJq8FdrX1/4Bms0ow2V2cjBc28sjwk4kjlbEp4Kj/wDVit23KvbpHMALd+N7DntgfjzV298G+Lbm3KN8OXD4PK3qKMn6Gp7Xw546hhCf8IDKOOcXqEE/iaqplNeavFFTzSlJKxguY4bmXyndYhGy4U7lPy4I9iK9Y/Y//wCSXTf9f839K4EeGfHqx3Cx+AmHmliP9MTgkYJ616x+zX4X1jwl4Ak0/wAQ2Zs7xruSXyywb5TjB4r1crwdTDc3tOtv1PNzHEwruPJ0PWKKKK9c80KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyr9p7/kjGuf9s//AEMV8AV9/wD7T3/JGNc/7Z/+hivgCgArW8Pa1Lot0Zoo0kyMYcZxWTRQB6d4e8Srd3irvBR/vRO2MfSu0tbqKVPJE/k+X0y2/IP618/AkHIOCO4rY0rxFfafKHDCYAY2y84+hoA9rGlAlxG8U2Tw8H+sX/gPce1RWek/Y9Ug/wBLS5szyWKsGT6r2+orhNO8bwb4y4ltJQd3mKd2D7d8V6J4e8RwahbKh1GA722ibIVh7EelAGvcapJZoljG7ssYLMpbJCnv64rctdVMVnFLDNErnd8jNk9OpB5xXHao0cU4W7t5Jo0yrS26/Njt9aoypDcahai1MwK4YrLlGI+h70Aempb2upZ+026XR2iTzYTkr78dKyNR0Sy1EyQW8ssORlZHz+IA6VyEuuS6b9uQGSJm4Abpj29qnTXbaWwV9Sa43qgKkNtGf8KANNNAtbYeTp9+98WG3KISue44FMXQpQYFkxGx4liY8oPXFO0KC3ktzc2ur/YS6/6uAgn8cnrUCXetWU99KiRz7QF8zu6+ufWgCDVYDAs1nFbie33ZaXYC2fQHsKyBZazLNE8FpK+2PKKDk/gKzn8R6tp9+zCHzECkiOVCwXPqKyb3xpr8E4lW6kt/MOVSNNoQUAWDYa20sBvnl2yyHy45G24Oe/pVXxjZ2+lTrG91bzXnWUwksqH0J9azrnU9WvSLpJp2C/ec9zXP3uoBpC8iCSUk7y5zz7UAUrm7aSQkjv19aqSMXcmkd9zE+tMyaAHAhWBIBAOcHvX1r+xGwbSvFLBQoNxEcDoPlNfI9fW/7EH/ACB/FH/XeL/0E0AfTtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5l+0fY3eo/CLWbbT7ae6uX8vbFChdm+cdAOa+N1+DvxBZQw8K6jgjI+Vf8a/RWigD86/+FN/EL/oVNR/Jf8AGj/hTfxC/wChU1H8l/xr9FK8g/aK+IOueAdP0GTw6ts019cvC4nTcMBQRj86APkr/hTfxC/6FTUfyX/Gj/hTfxC/6FTUfyX/ABr0jXP2ifHmkXKQyNo0xZd26OA4/nWb/wANP+Of+eWl/wDfj/69AHE/8Kb+IX/Qqaj+S/40q/B34hqcr4V1EH1AX/Gu1/4af8c/88tL/wC/H/16P+Gn/HP/ADy0v/vx/wDXoAwLP4f/ABZs2Bg0TWAB2Ygj9TXSaZpHxYtJfMn8GS3T9N0kSgge2DUX/DT/AI5/55aX/wB+P/r0f8NP+Of+eWl/9+P/AK9AG1caT40v7P7PqPw41Bhjho3XI/A1l3PgjxXLbeTF4N16OMjG0iNto+u7mtLQ/wBoXxtqkF5K91olqtsm7EkGWfOeANw9O2etZo/aX8eFA3k6aM9AbY8j65pKSbaXQbTSuRaX4L8aWCbP+EM1iYA5y6pn6ferXj0DxnDbSLH4K14zHG05QKPwzVA/tJ+PQgJi0zJOAPsx5/WkP7Sfj7ZuEGnE88C2OMfXNMQ7VtC+JF6oEXgnUI2H3nJXLfXmuavfh/8AE+7YlvCt9jGOVU/1rc/4af8AHP8Azy0v/vx/9ek/4af8c/8APLS/+/H/ANegDmbn4a/FG4hEMnh3UxCOQihQP0NZ5+DnxDJyfCuok/Rf8a7b/hp/xz/zy0v/AL8f/Xqxp/7Svjm9vYbYf2NCZWC+ZLFtVfcnNAHA/wDCm/iF/wBCpqP5L/jR/wAKb+IX/Qqaj+S/416brH7QfjvTY1bz9CucnpBEWwPXOayP+Gn/ABz/AM8tL/78f/XoA4n/AIU38Qv+hU1H8l/xr6U/ZJ8I694T0zxBH4j0u40955o2iEwHzgKc4wa8i/4ae8c9fK0z/vx/9eve/wBm74jaz8RdF1i715bZZLW4WKPyE2jBXPNAHsVFFeIftJfE/Xfhz/Yp0BbRvtfmeZ58ZbpjGOR60Ae30V8Q/wDDT/jr/nlpP/gOf8a9Asfiv46u7WOUavoMUskPnrDJYyBmTGcg5xjtmgD6eor5hvfiv4+sndbi/wBIAVFcldPkOAQOvPH3hzXP+Kvj5430FbRor3Q75ZwSfLs3Qxkdjk0AfX1FfEP/AA0/46/55aT/AOA5/wAaP+Gn/HX/ADy0n/wHP+NAH29RXxD/AMNP+Ov+eWk/+A5/xrpI/jV8V5oYJrbTtLmimUOjpDwcgf7XvQB9dUV8jx/Gb4syFRHpulMxcIwEPMZPTd83Fc/d/tMePLW6lgki0jfExRsQHGQcetAH2xRXxD/w0/46/wCeWk/+A5/xo/4af8df88tJ/wDAc/40Afb1FfEP/DT/AI6/55aT/wCA5/xo/wCGn/HX/PLSf/Ac/wCNAH29RXxD/wANP+Ov+eWk/wDgOf8AGj/hp/x1/wA8tJ/8Bz/jQB9vUV8Q/wDDT/jr/nlpP/gOf8aP+Gn/AB1/zy0n/wABz/jQB9vUV8Q/8NP+Ov8AnlpP/gOf8aP+Gn/HX/PLSf8AwHP+NAH29RXxD/w0/wCOv+eWk/8AgOf8aP8Ahp/x1/zy0n/wHP8AjQB9vUVx/wAIvEV74s+Hmj61qgiF5dxl5PKXauckcCuwoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxX9oe5Wz13wDPIFKpe3GQwyP8AVV7VXzr+2LdNY6d4RuUBZo7yYgDr/qxWOJpOtRnSX2k196NaDiqsXPa6ueA/Hi/jv/EtlJEEAW1C/KAO59K8zrX8Sak+p3UcsiupVNvzCsis8Fh3hsPCjLeKLxbg60nTd10N/TfC97qCwmGS3USruG98Ad+TVfxDoVxoUlvHdSRO8ybx5bZAGcVliRwuA7AemaHkdwN7s2OmTnFdRzjKXqeKACTgDJrR0203OskgYYORQBc0DRHvNsrnbz8oPeutt9ClkUQoQGHQlec/Q9qzkkMcS4kBX0AxirNpessyv5zs3qTQBefTbm0IS4g88Iucxw8r9agXQ727kJ8hxHgY3DYB+HU1qnxJIIRGu5sD+Jqin1qe6UbjhSAAB60AcR4m0JdOkzDJ5jfxKo/X/wCtXO9K76/tpZVLlSMEkgdq5XULAgNLGCST09fcUAZVafhzA1m2YuE2kkEx+YOn93vWaRg4PWr+gm+GqwnSsi8GSmMdgc9fbNAHZ3Pii+s9VlttNNpc2z4HnrZbQ/HQrjjniuN1W/mutXe7khit5wwJjjTaqke34V08GteLZL8W7TSmSNxI6hVyAGA/nWDcaTqt/cS3ht3kEzyP5nADkE7sUAXh4zvDBFFLZadKsYAXfbqf8n3r6e/YvuTd6F4puGSOMyXyMVjXao+TsO1fIWoWVxp9ybe7j8uUAEqTngjIr62/Yi/5FfxJ/wBfif8AoFAH0rXyv+28M/8ACLgdSZf6V9UV8sftuMyHwsyHDAykH8qAPnPU/Ct9psNjLM8Li7cLGI23EH3Haujn8a68l8thJ4ht2t4ovKExtxtUD+DpntXHDVL69vLb7VdzS7ZVYbm6HI5qpqH/AB/3Hf8AeN/OgD0VPGGrDeD4stBuXB/0Und04PHt+lYevXTa88Tan4itJTHnbiBl69TwK48ZJwKKANz+yNO25/t213Z6eU/T8qb/AGRYf9By1/79v/hWLzjNJQBunSNP/h121PHP7px/SrkShPKUeKVRYyNuBJ8v4Vy4NLmgDqYyYpHaLxUqlm3kgSDcR3+tVo9M0yR5nutdhZ2UlSI3OX9+OnWsAn5cfjTKANv+yLD/AKDlr/37f/Cnf2Rp2zP9u2u7PTyn6flWGMYNFAG1/ZFh/wBBu1/79v8A4UraRpwxt121PHP7pxg/lWK3pSUAbY0jT8jOuWoHc+W/H6UHSNPyca5akevlv/hWJjilzQBtjR9Owd2u2o44/dOcn8qb/ZFh/wBBy1/79v8A4VitjtSUAdAdI0r7MuNbt/P3nP7t9u3Ax265zUf9kWH/AEHLX/v2/wDhWPIACPpTeq8DpQOxtHSNPzxrlqf+2b/4Uh0nTwCf7btuBniN/wDCsSlB5oEfoV+zl/yRrw3/ANcD/wChGvSa82/Zy/5Iz4a/64H/ANCNek0AFFFFABRRRQAUUUUAFFFcfrviO9sfiV4X0GEQmx1KC6knLKS4MagrtOeOvPFAHYUV5H4d+KWozeGtCnudI/tLVtVnvooorV1hUC33HkuePlHr26dqrap8Xbm98LapPpul3GmXf9i/2vYzzvHKHQSLG2VGcYY8Z6jnA6UAey0V5Ze/Ee4TdY3lldaZqVvd2CPsaOYTRXDYBz0HQgjqOxNQaH49vW8SJa6rdv5B13V7MCOFNvkW0e9Qxxu4A6jknrQB61RXnkPxEupPC7+IJfD7W2lyxJLZy3F9EnnBpFVQw52EhtwA3ZAx1wKy9E+JN14j8TeFbezt5LCC4v7+xv7aUBiXhthIu1iAQMsp6A9QRQB6vRXE+N/iDaeENQe21CzncNYtd27owxcOJFQwr/t5dT9DWbP8U4I/FY0ZdGu5VjuorK5nRgxhlcAn5QPmRdwBbI74BoA9IorynSPiZcvomifZdKvNa1HUYr2dMyQwELBMynd0UcdMZPA969A8Ja5D4l8NadrNrG8UN7Csqxv95c9Qce9AGtRRRQAUUUUAFeB/tU2gv5PBVsRkPez8f9sxXvleEftQarHod54G1CaA3EcV9MDGGC7sxgdTwKunVlRmqkd1r9xhiozlRmqfxNO3rbQ+UviXpg0vV7eILt3Qhv1rj69C+M+s2+teIbWa1jjjRLcIQkokGcnuK89qq2IniZutNWbM8BCpDDwjW+K2oUvWpbe3luN4hTdsUu3I4AqSCAgLIcg56VkdZNp8O1lmDMrqcitOFyOQMk+veqcHGMKd+eK2bHT97kzDJPIwaAHWttNOoJOFPHNTvZCLA3k/0rSWMRRrtYFc+n9aYM7mJwFz0A/zzQBniI7wu1lA4JPQVuafas0R8gCQg8nPH513vhTRtHsPDMXiTxLuksi7x2tgow144Pc/3RV1fibqEACjRtHt7EnH2RbYYKdhk/zoA4yawkkstkasrnqM9QfesS70kwWwkZSsykqgUjOfYf1r0bVX0rWdAuvEfhCFoJbciPU9MJ3C3B481PVc15idZitnUXib55JP3m48le30oCxy3iPTliuN8IdpGG9wOQPfP1ql4eieXWIEjIDHI5fbxg55rX8XajBcXipZNuCgbpFPf0FZ2hadHqWs21vNOYUlfDSZA28dcnigDqZtB1K51CN9K8iGS3zFK32sZcDnJJ9sCtHwLNZWcsmn6tawXMsk5nj3yLtVR8pGSeCSalHw/wBAKuT4imVwCcFovmIxx97vnj6UmoeBvDitNLJr87LHgF1EXznHUDdzQAzUfFPhSW4k+06Y5uVO0v5CNkgEHr17V73+x/cW13p3i2exiEVs99GUQKFA/djsOlfOXibwdoul6LcXdnrElxcRhSsZ8shskejZ7179+xF/yK/iT/r8T/0CgD6Vr5W/bf6eGP8Atr/Svqmvlb9t/p4Y/wC2v9KAPl3TZGi1C2eMgMsikZGe9GoHN/cn/po386TTmC39uSoYCReD0PNF/wD8f1z/ANdG/maAIFOGBpW6/Wm04kkgmgBCeKSlzxSUAFLSU4YHWgBCc9aSiigBR0NApUALYNGKAEPWkpT1pKAFooo7dKAEoopaAJHw23kZximdqNvyBvekNIbEpaSimI/Qv9nL/kjPhr/rgf8A0I16TXm37OX/ACRnw1/1wP8A6Ea9JoAKKKKACiiigAooooAKxfEfhfSPEZtW1e1aWW1ZmgmjmeGWIsMNteNlYAjqM4NbVFAHP2/g3w/bR6PHbabHCmkLKtksbsoiEilZOAfmLAnJbJyc9eapn4d+FjZranS/3C2B0sL9ol/49i4cpndn7wBz198V1lFAHK23w+8M21tJDHppKyXMN27yXMskjyRf6sl2YsQvZScdeOas23gzQLbUor+HTwt1Fd3F8jmWQ4mnXbK2C2DuHGCMDsBXQ0UAccPhp4SFvNbjSiIJMYjF1MFiw4ceUN+IvmAPybataR4D8OaRd2t1YaeyXFtczXcUj3MshEssYjkc7mOSVUDnPr15rp6KAMfX/DOj+ILnTbjWLFLqbTZxc2rMzDy5Bg54IyOBwcjgcVVvPBeg3euNq8tk637sjyPFcSxLKyY2l0VgrkYH3geldFRQBzmm+CvD+mmwNlp/lfYY54rf99I2xZm3Sjluck55zjtitXQ9KstD0m10zS4fIsrZPLij3s21fTLEk/iavUUAFFFFABRRRQAV80ftv/8AIt+GP+vuX/0AV9L180ftv/8AIt+GP+vuX/0AUAfIVL16UlaNnalVWZiVYdB6UAFpbqqJKWcP3GMVajg8x8bgB6mmse+TVm0t3kV22MUA4I9aALeg2ReVpJUIToK6eztpZSGEZEYJAIHSszw67qroVO3g57V2cTiO1LBdwPIAx29qAOZ1LyYLcsoU7TgDtn3rmzLeJfQSQELJJIqBCQwyTj+ta/iXUF+0TQhGAdfu8f5xWL4fsbqfULd4EkMcUySnjjCsDQB6T8f9TfT/ABZpehW6hYNJ0+GNWGThmXcx29M5NY91BELewNveNeCRBId0fO49s/0rqPjro0dz8Qm1B5cJe2kM8SgEmQbQCB+Ncqt8miNBdXVuB5KMyIOVLkYUV3YOPs41MZZt0loraOT2u/LyM6tpShh20lN6u6ukt/vOg+F2sW9n8U7LSfllt9XjewvMfdw6nAA9j3ry/wAYQTQaxeQzNmS0ne1fH+ySFP4ium+B9rLrHxh0SZgAsVw15OR0RFBYn6VzviHUI9S8X63cn/j3vbuU59MsdprilOdR81R3k92ayUE7U1ZdEc+i8+9WoI9xAxk01kKOykYZTg1PAQjBjwewzzSEWNT0TZYi6hYmQnLR47dzWPPg2ducHK7lP55rp47hzZ8Y9AOpFV9Q0O5fSvOiickOZGXHUYGSKAOXr6//AGIv+RX8Sf8AX4n/AKBXyBX1/wDsRf8AIr+JP+vxP/QKAPpWvlb9t/p4Y/7a/wBK+qa+Vv23+nhj/tr/AEoA+XtL8v8AtK28/d5fmLu29evbNamo6JKPEa2IngZrh9yurZUAk9ay9NVX1C2V3EamRcsRnHNdLcQO/jm0iYSRmSRQCowSDnkZqanuwcua1v6/AXNZpWuMn8FXm1xY3NteTRn544mwQPXnrVKDwjrs0yxjTplycbmGFH416DLot/c38cE8iRJGDFFIoALKMkcdzVZPtZ02K1e7cQi4EQiwd3mf4c1y+1Ur+xrRktN076+S316feyfrEU/eh+Nvwd/zMb/hXvl2pa51qxjnK7wmcjHfms688C6nA6tDJbT2xXP2hZAE+mT3rum8L3JuZI4o1X96DFlvlK9+euRVk+G7h4pHv79EhRwy7BlW7E49e1c0cZQjFSeJu9NOXo+1nuvPz7G6q8yd6X5/m3/Xc8wn8I6uib4oEuAOG8hw+0+9La+EdVd/9Lh+xRYz5k/A/AdTXaanZm0dLKIOlzLKV3BSgkX+HNQWUd9eXYggZhK2UXzCeR0IGewr0KLjUi6kqyUO/K72772Of6zBOzjr6/p/wTITwIjo5GuaeWHCgE/MfSq0Xga7kjyL/TxIOqNNggetdXpej3Chpi7wz2imVV29Cp61BcafPJZPc3NtNJK2HEi8hi54/wA+9RF0Zc0YYnVNbpddNNVfuUsUnG7pr8f8zkbnwbrEDARQLdDOCbdw4X6+lPi8FamU8yd7SCLdt3vMP6V1+oQ6lbJDp7xNAVhwTEcb1zn5yOuKScI9nCZLbEkcPlqsA4fsGJ7knNXJRjb9/GSdrcqu3/5NZCliacXbl1+e/wDXmc3d+Ar23Yob6wMmzzAplwSvrVdvA2rrG0h+y7Au8N564I9q6aSyn2RSgTTTsUEbgZGBVnULWZbu7E9m806xHzWxiNGPORj8sVlRalaLrpPrePRLV7rroKOLjK7cLfecT/whuuFiIrJpkwD5kZDIc+9WpfAup2zRC9ms7YSDILyj16cV0kF3frF9ihkdUZRGkasAD9au3OjXk+nzuFUGF9ojJLNuxzg+hp1VUoNe3qxSb2W9ns9dF0+TK+sRcbwhd+v9fmclf+ANTt2YW89pdBMbjHKAVz6g07UPh5q9papOJLSRG67ZQMH0rbvIJp3hMC+atyAAyJgF+6n3FWrrSriFrJbl44Y55AsY3ZC54PB96VuVQc8QtenLq9Nba7p+g/rUGn+7/F/1+JxEXg/XXBxp8gAIG5iAPzrYTwEyWXm3eq2cUm4goDuAx15Hetcma0a7spTcS/JjBztGDkNg9uK1PD+hajOVl3fZ4PlMbyDkg8/KPfNTKXKlUxFZQh3UdWrX0u3v6Do4mM5qMad/XX8rHG/8IUskmyDWbJmK7huBXNVY/CE620st3e2kBVSVTduLAd+Ogrtdc0dbN2+W4nl53lVAQd/yrOlg8iWdLuRC4tywRRnJ28Zx6VVGpSqU/aKs32XKrtLr5dN0ZPFcjanBX+f+Z9f/ALOX/JGvDf8A1wP/AKEa9Jrzb9nL/kjPhv8A64H/ANCNek11GoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzR+2//AMi34Y/6+5f/AEAV9L180ftv/wDIt+GP+vuX/wBAFAHyxoUdo1wpnlxKPuqRxn61s3UB5wO/pXIVr6drDwgRXOZIuxH3loAsvAWbCg5PYVv6Ck0SSRGLckiEHI6UaJaR6k4kt5QyrycHkfWu/wBGtFgt3LInmSLtKsOCPWgDyj7Vc2OoHyJGGDyD0I9CK9D8OXenX5FxqSSxQFQGEPIHvzzj6VxPiXT5I72WTyyjISroeoPrS6FrL2Ns8ckIlQ8ZztZfagDpfEXgq3kd7zTNVt7iAncFZ8OB6Yp1mby0jT+z3aIqvKkgq30FYS+IhHlBGpQjaCeCBUdxrMvk7YnKqfQ8gUAeyaBc2vjnT7bSNRnjh8UaVGfsjSHatzE3JQnpkHpXKeNfB/iK7jWwttCvmnDYKC3JJ9MHp+teb3OsRPcCVY5RKoA3pKVzittPib4nSx+xwatqItwNu03bnj0zmuynjqkKMsP9l/gclTA0p1o4jXmX3HTS20Xwk8IajDPdQP451qL7M0ELh/7Ptz97cR/G3TFeSxWs7JkRP5ePvN8o/WujsLDUb4m5Eccfm/MZGX5j7knk10Vr4GN1D511cyScZwM4ArjOs4G8CmSMh0eUriTZyN3rVvTtHvbzc0cZCJ952GAtdxaeBxG6FSMDLMTyQO1b39jSxPCRNmBDnySMKPcjuaAMLRfCKqE89WmlPAAbAX3NdleWGn6VpZkurlJbkL8kEK5APuah1bU7LTLNptQZIYtvykHaW9Qo6mvL/FnjJtUsRHpcBtLZXKZzl2GO5oAxPFkdkLoyW0g+0OxMkaj5V/H1r6g/Yi/5FfxJ/wBfif8AoFfIJ5PNfX37EX/Ir+JP+vxP/QKAPpWvmX9sPSrjWr/wtZ2ZiWUrO+ZXCLgYzya+mq+Zf2y9N1O/Pho6VZ3dwyeaGNvGzbc464oA+aG8NX9hNZSShCXuVgKBhuV+uD+HOa7DxTbTt8V9ORlBKpEwww4UDrXIR+HvErXMb3Gk6u4Egdt1vIenfp6U+90HxNNqD3I0nVmYMSjNbPkDPHauetQ9pJPya++xpCSjv3R7pHaNJ5bxpH50RGJJsZP0waLSxJuZ99hElxvMmFYHJ7E+hrw0aT4vDA/2brG4dD5En+FSSad4wkuTM+n60JDjLrBICcdM8V4ryPdKX4/8A9D61h7WUPw/4J7wz+RLHBcER3EnIG8cev4UxIJJEkS1gilQPj7wPHfP414TNpPii5kEt3pWsSzLgLIbdywH1xSWmmeMLORntdO1iIt97bBIAfrxU/2BG2ktfw/Ip46m3eUb/L/gnvP2SS6tpV8hWdQQqsQcN6Bqo3mmLbwWkxt5Q8LAZRl+X1XPua8mtZvHdraSW8Gn6qiO/mFhavnP1xWe2n+M2jdHsdaZGySpgkIJPOelFPI5RfxWXr/wBTxOHk7yjf5fPv3Panmgv1KGGVG3FNpIDOMY9ehp0kRspRDb2RaNEBZSwwMfdxXhP/CP+KTIrnStX3L0P2eTI/SrT6d4wM28afrJOMfNbvyPfitHkUVpGTt2v/wAji8Pzc8oa+n/AAT2ZYHhTzLeyEs8j4ZfMGz5hkkk9qmhS1RIg0SBInyhBXhu/wCVeJ/2b4v2hf7M1cALtAW3cf0qKPRPFCReWNI1bbksR9nfBJ79KHkae8n9/wDwA+s4bpD8PTzPdbuOGC2fy41Kg+ZyRtyfxqURGG2BuGAVzk+cy8DsK8HfR/FDAo2k6uyEglTbyY+nSrGq2vjLVMC60vVSgVV2i1cDA6dqz/sFOy5n56/8AHiaFtI6+n/BPUrvRNNgllmtbNrq7B3+UsgB55yBngZrSsroy2yJdQfY9rbCN6nb7/SvE/7I8WNcm4fTNYExXYXW2cEr6dKhPh/xMzEPpOrshOSDbvz+ldE8nVVJVJttdb3M6eIw9JPkhv8A13PcV0yB/K8pFSBJRKIxgHeP4ic1Vv8ATrecJFeGCYt5hWSNh+7B/HrmvIf7H8TGGYHS9ZDswZcW8n09PSqsWgeKIpFdNI1UMOh+zPx+lKGT2d+d3X9b2IlPDX+HR/13+49wbTYTHALpmd44iVZyFLDGDmnWYiurdLcH5I1UIrOASQc8c14pcaV4uuIhHNpusOg4Gbd+np0pkGg+JLe4jkh0bVV8shl/0Z+D+VT/AGInH3pO/wDXkVGvh4N8kd9H/Vz3eWK2uJnikkTeIyHBkHA9DzVWXSLQ2U90tqguUgfDNjcflIrxG40LxPcNJJLpGqmWQ5Y/ZnGf0qVNM8YKhUadrAUjaf3D9PypLI+Ve5N/f/wAdfDyd5Ru+9v+CfcH7Of/ACRvw5/1xb/0I16TXnf7PttPZ/CHw7BdwyQTJCQ0cilWHzHqDXolfQHngxCgknAFFR3P+ok+lSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzR+2//wAi34Y/6+5f/QBX0vXgf7W/hTXfFWheH4fDumXGoSwXMjyrCAdgKgAmgD4norvv+FPfEH/oVNS/74H+NH/CnviD/wBCpqX/AHwP8aAOItLqe0mEtrK8Ug6MpxXofhX4ny2ASDWbGO7gAA3rw498dDVP/hT3xB/6FTUv++B/jR/wp74g/wDQqal/3wP8aAPRtX1Xw34x0qSPTLq3F4QCqSfu3x6YP+NeXX2myWbyRupBB9Ktj4P/ABBByPCupAjuFH+NWo/hd8TI8bfDmrY9CAf60AcrJDliMAZ4+lNW2ckhc56dOtdtF8OPiQpzL4QvZf8AeiA/ka0bLwH46hIM3gTUGI7qcfzNAHAW+j3M5X92yo38RU4FdVoHhQJdxvNgg9d3Su9t9I8aQWH2ZPhzqeMDLeYP5VJJZeOo1P2T4bXe7Aw0rZ59eDQBradpcNpFHE8Udw46lcEgH1roI7OYl0W1ijjdeFTkDHb0rz+5HxhLZsfBz2ZxjKWysfzYmuZ1bwl8Y9W3i+0vXXRuqAhV/IGgD1bVfEHhvw9bMdY1C2hn5DxRkSyt7AL0/GvJfEvxhmnaWLQdPggiJO2WdQzAew6CsNvhB8QmYs3hXUyx6kqOf1pP+FPfEH/oVNS/74H+NAHG6nqV5ql01zqFxJcTN1Zzmm253208RJ6b1+ortP8AhT3xB/6FTUv++B/jUlt8IviBFMrnwnqRXkEbRyPzoA89r6//AGIv+RX8Sf8AX4n/AKBXz8fg98QM8eFNSx/uj/Gvpv8AZK8K654V8P69B4i0y40+Wa6R41mABYBMZFAHvdFFeNftEfEvW/h5Hoh0CGyka9eRZPtSMwG0AjGCKAPZaK+WNE+M3xF1fTxdxJ4ejQqzBXtpuQvXndisM/tFePvs4m+z+HNpONoV935b80DsfYdFfGx/aR8ebQfsug8nH+pk/wDiqT/hpPx5/wA+mg/9+ZP/AIqlcR9lUV8a/wDDSfjv/n00H/vzJ/8AFUf8NJ+PP+fTQf8AvzJ/8VTuB9lUV8a/8NJ+O/8An00H/vzJ/wDFUf8ADSfjz/n00H/vzJ/8VRcD7Kor43b9pDx6hw1poIP/AFxk/wDiqT/hpLx5/wA+ug/9+ZP/AIqlcdj7Jor41/4aT8d/8+mg/wDfmT/4qj/hpPx3/wA+mg/9+ZP/AIqi4j7Kor41/wCGkvHn/PpoP/fmT/4qj/hpPx5/z6aD/wB+ZP8A4qncD7Kor41/4aT8d/8APpoP/fmT/wCKo/4aT8d/8+mg/wDfmT/4qlcD7Kor41/4aS8eYz9k0H/vzJ/8VR/w0n47/wCfTQf+/Mn/AMVTuB9lUV8a/wDDSfjv/n00H/vzJ/8AFUf8NJ+O/wDn00H/AL8yf/FUrgfZVFfGv/DSfjv/AJ9NB/78yf8AxVB/aS8eDg2mhZ/64yf/ABVFwPsqivjX/hpPx5/z6aD/AN+ZP/iqP+Gk/Hf/AD6aD/35k/8AiqLgfY1z/qJPoakr5V+H3x68X+IvHGiaNqdto62d/cCGQwxOHAwTwS2O1fVVMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIBHIzRRRQAUUUUAIxwpI9K+JNS+PHxBj1O+ih1W1WKK4kjQG1U4AYgV9tv9xvpX5q6p/yF9S/6+5v/AEM0Aej/APC+/iL/ANBe1/8AARaP+F9/EX/oL2v/AICLXl9FAHqH/C+/iL/0F7X/AMBFp8Px2+I8sqxpq9puY4H+iLXllbuiaS9xbm4wGOcLHnDEeo9qAR6HL8Z/iUg+XWLUnuptEBqlJ8dviOhw+q2wPvaLXOSJG8v7kvHOmMxygfNj3qG4XD4mtdxznYrAn8KdirHTf8L7+Iv/AEF7X/wEWl/4X18Rf+gva/8AgItcY9nC+XNsyrnAAUgH8aWLSo5ZB+7KoSAPm5osKx2Q+PPxGP8AzF7X/wABFq5Z/Gn4m3TAR6pa5Jx/x6LXPQeH7W3iDSkc988Ut3dwoPItQuQOCOn/ANeiw+Xubuo/G74k2M4jk1e1ORkH7GvNVv8AhfXxF/6C9r/4CLXIazD5lrumkBmAyij9Riud7UmJnqH/AAvr4i/9Be1/8BFo/wCF9/EX/oL2v/gIteX0ooEen/8AC+/iL/0F7X/wEWvb/wBmb4g+IvHEmvL4kuorj7IY/KKRBMbgc9K+QK+lP2L/APj48V/WH+RoA+oK+ZP20Pu+E/8ArrN/6CK+m6+ZP20Pu+E/+us3/oIoA+blvLlIVhS5nWJc4jEhCjPXA96s6Lpcuq3S21oQ1y/CRAHLcZz6Vu+FrHQbvTg2psqXIWbO+fYGwPlIHt2Het34BR258f27mXdItvKfLZDgDHXP0qajai2jSnFSmk9jzqRTHIyN1UkH6iuw+Fvhd/FHiFoQo8m2QTSMR8uAeh+tTfELw09r451yC3XCeb5kSgddxGB+terfs96OumeFr7U7rKm9kMRDDGApK/rmsJ1E4aM6KVFqpqtEeOfEXwtL4Y1wwYYwSKHR8cc9q5QZJwBkmvqr40eHl8Q+EHFoF+02DCZcdSuDmvAvh74cl1fxRpIkjLWZuFMhHtzj+VKFRKHvPYKtBup7q0Zys0MkLlJUZGHUEYIrQ8M6VJrev2OmQELLcyBAT09f6V6l+0VoEGnajo1xp8AQXCSrJtH3mBz/AFrH/Z70z7b8QYrmRD5dpC8oOON3AH86vmbhfqR7JRqcu6N34vfD200PwxY6nZxkXSEQ3AHQ8cH868V719xatp1rq9obW+iWWBuqn6EV8aalolxBqGqQIpUWkxjII55bAxUUpcvus1xNPmalFGX5TiISFT5ZOA2OM0w8A19AfF/wlp2kfCy0lsrcRz28kO9gOpK4JP6V4sNDuob63SWPfEZY1cr0wxH9KuNS610Mp0GnaOp7Np/wqin+GHmiINrM9sJY8jkHrj8a8EkRo3ZJBh1JVh6Eda+6LbZBFbxIMIkahR6ACvkb4taG2ieOtTiRD5E0nnxkDjDc4qKTs7X3NsTD3U0tjmLOxuLyO5e2jZ1t4/NkI/hX1qqK+g/gP4Yt7j4f6vc3sasNSLwjI5CKMfz5rwy/02Sxa6jmBWSJwAp7jJq41LyaZhKi1FSR6R8DfBlr4jXULnUYyYI3REJHHIOSPzFcL450Gfw34mvtPuEKKrloj/eQng19FfCGxGm/DHS92Elug0vTBYsSVz+Vcf8AH7QrjUrWHWY0+azRUmwOWVuQfwrBVbVdep1So3oq3T+meFQQyTzJFAjPI5wqqMkmkljeKQpIjI6nBVhgivTP2f8AQY9V8bPcXSHy7CHzR/vngfpmqHxg03yviJq6xQlIWCunGB05/rW/tPf5Tl9jenz9TD+H/hxvFXiaDTAxRCrSu4GcBef/AK1b/wAZvCsPhzX45bLi0uQQqY+4VAGK7H9mPSla41fV3HzxgW8Z+vJ/pXT/ABh0qHVfB7hl33tuRLG3fOcMPyIrGpU5aid9DppUeai1bXf+v66nzMMZoZSuCQeRke9aPh7TZNU1+w09RzcTrGcdgTz+ma9R+PPhfTdEt9GbSohBHChtiM/exyD9etbyqKMlHucsKTlBy7HF/B3/AJKz4S/6/h/6C1foDXwJ8KYTB8YPCkbAjF6p5/3DX33Wq1Ri1Z2CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEf7jfSvzV1T/kL6l/19zf+hmv0qf7jfSvzU1T/AJDGpf8AX3N/6GaAK9FFFAFvS7KTUL2O3iVmzy2B0Xua9SsdOiit4za7twG372CK5bwgU0u0eZ0zdXA+U9wtacusOwIJwCc7emapaFx0Na9s7Uk/aWLrjglRkGsZzZ22UdPMGcnDVVaW6vMqiO24jn0rRSyZpik6W7RfdUkEHj3Hek32QN9jON1agIsUMgRck4Oce1RPczfciCRhuQRyRXS2mkaazH93cPjghHGPzIrct9F062UOsGGPzb2cE0a9g1OBgtrm5O2TLduMnNSx2M8cbv5MhOcA7cV3Ms8SymMLyRwVAz+J6YrMIFzeyxXckhSVSAA5PTpgCht72DU468sLlowxt9nGNyDJP1Ncpew+TOQFdV/2xjmvTp7CARsFLoCcfM2Aa5vWbPzbOSMAyOvIY9QabQNHHGg0dODxRUkBX0p+xf8A8fHiv6w/yNfNdfSn7F//AB8eK/rD/I0AfUFfMf7aXEfhT/rrN/6CK+nK+bf2vpLWK98GPfxmS1W4lMiDuMCgD5ayK9L/AGfHtx8Q4jcOQTbyqOPlOR3rGfVvDAtrcR6conjlDMwjYCRd3IPJ4xWdpWuJovi6fU9HhJtldvKj+6dh6DvSmnyuxdNpTTZ7X8U7Lb4ij1SNQrIA5b+8FFdv4KsUi8BaTaMwfzV8xmHru3ZryaF/FPjCx8tbHzfMQkt5wG1SAcdO9W9C1zxAmmCx2rbR2ZMTZlyflAPp7YrytYpttHtaSasmev6UyXWo6pG7AK0awhO+NvP865D4eeGRoPjPVLFTm2skWWEn+Lf3/SvK77xnrWn6/MIVkWd3bEqy8MD83p6Cprj4t6hHqlxdCxZJ5YEgkIk67c89PetY05NLS5lOtBN626bHpvxoigvY9HgmdRIxmZG9MKDn+dN+FFtY6dDqN9HsjaNVhb6nn/CuBa/1f4izWNg9m1vNawlldZsFsjjt3rf0fw1q+laZqukXLmMNLDPLKJdx3EYwDjtiom7e838jSHvaJfM9tLqGVP74zivMfGHhSA+NbO8AAiu5UlkXHUo2Tn9K5rWvGWu+F/ENvYI39oN5OQ7v0BPfj2qnqvxT1G7u0L6I++NZRFtfvgA54pyvUjePyEnGErM9q8U2sOsaBqFg6q3mQMQDzjg4NeS/DrRRqGrWSyFXjimDzI3XCrwfzrM8L+NvEk189m9nvubxhCrSSf6sH8OgzWpo+ha14E8TS3W5bp54JBzKdvGT0x7Up95PYcH0ij1z+0Y4SpndRJMSIh0zg9BXnvx80tbnw7ZarDGHuLaYxkgdUZT/AFrzPXfGmtDUrHUr62kWKCXdHEkvy8E+3emat8TNR1zRJLOayYwpOsjFZO2cgdK0hCej0ZjOpT1jr9x754Mjh0Lw/oOm4VFe18w+7Yy3868i+Kvh6G18R2zXEy75yxTHG7Jzj9aw9c+J2qajfWrQWbW4ji8uFVk5xjk9K6rxF4U1TxjNba7cS7Ifs3nxqJceXgcjpUuLi05OxanGcWoK+x3d/dw2NpommW+Ps9vFHllPCEKcg1tXCW+taZe6fcAPFcDb+fH6V4prc2rRvNnHzWYncLL1D+nHbFc2njnWbC5SIx3CzKhUfveu45z09qzhTnNtpoudWFNJNM9h+DmlJpHhi8ul+eaW9kjLdCQvy/0rlfjLGZYra4dMSyuCxXqIwSOfzrlNP+JOq2FounxWbLEC4KGTku5JJ6e9b+mQax8QNGXZAYXt1C/NJ/rAzeuParlCUZqctiIVISg4R3O/+FlkmieDIJ0ISK6c+ZxyW6Aj8q6tFs2lFtPiQOhYZ565H9K8YuNX1mHwra6XBGNkN69qpEvzMyZ56e9ctD4311GnijhnaaMb2bzclV5z2+tJU5Td1b5lOpGCV7na+CvDtro/xVngYKyxq08fH3QMj+ZrX+JsKeIPCt/LOmyazvmRCeeFOSa8sh8X6nb3kuvfY5SbmP7MXMvH4ce1bHh7xDqfihb7TfK2icOzbpOrN+FOdOatJvYiFWnK8Et79CP4YpNffELwhqrquxdTFvuHc7W/wr7lr408BeHdU0Dxx4RtryHybZ9XTaDJu+by3JPSvsuu6i046PQ86umpe8tbBRRRWpgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACP8Acb6V+amqf8hfUv8Ar7m/9DNfpW/3G+lfmpqn/IY1L/r7m/8AQzQBWNT2cBnmAAO0cmoa1LIeVbYGCznJFA0X4HaQgDdj+VaMIhAA3kt64rPtncOEXbg9cCrayow2gAFep6iqKNXT3Z7tFjQELyXzwMU6/wBSgjI8sBnznGflBrKl1E/ZLjyG2IFEeRwWJPNYw+8MncM5IPaknqxXOkGq3LqAkhPzY+UYH51amvpGgVZnk3gHGTnFW9F8E+JdatI7qy0yRLVvuPK6xiT/AHdxGfwrM1myvtNvjaalZy2tyg5jlXafr7j3p3HcIdSdZSEMnzDk560TahPBdI4Y/Lhhk9BWfCfn3HOM4IIqe8QMgeEMQBg56/8A6qANW51m2jR1e13S9dxPHrXOS6g28vhcHsOmPapdSLGzjc8kfITjJ46fpWPEPMYoMHPHXApJ6CuVtUVPPEsYKiQZKk8g1Uq3dLjC55x3OaqdDz1pEhX0p+xf/wAfHiv6w/yNfNdfSn7F/wDx8eK/rD/I0AfUFfMf7af+q8Kf9dZv/QRX05XzF+2rgQ+Fc8DzJuf+AigD5oitbiZA0MEsikE5VSRx1/Kp9MuktjNujjcsh2seoPbFbWjeNJNNthB9nhdAjoArFANwxnA/X1rnvt2bYQHyNuc7ggDfn1oaTVhp8ruj3r4PeN7G1i1KK+mWKNYleLdwSVQAj8xXleq+Lb2e/uJInCpNIzsB05z/AI1ynnKOkgH0NJ5iY++ua540Ip67HTLFTaSWjN231Ca8uI0kb5liIVj1yEIqeeSOXS4wFCzxP8zH+Jdozn8651ZlVgVkAI6EGp5L7KKm9RhSp565q3T10IjW0dz0z4c+Jf7L8Ux300q/Zy32dl9V9R+ldd8QPH8Vv4m8q1YPZOYi7D+IgEH8sn8q+flnVRgSAfjUt3fNdPumlDHsM1lLDKTs9jaOMcY6LU6XXtYm1C9lu0mPAEYbPPytx/Otx9VS2vYY4lzcFmIB6c8n/wBBH515x5qYxvGPrVh9Rd3jdpvnRdobPNOWHTSS6Cji2m2+p2KeJrjSfEcd6cSSxyptUdBg816b8XPG0atoz2bK0csBuMr1CsuMH8c189NMpbJkBPXOasXWoPdKgmmDCNdq5PbOcUPDp2XQFi2rvr0NLVvEF3qSRpJtCIB8oHfGM1a8N3SWsM8UoVhdqp5/hCkn/CuZ8xP760vnL0Eg/OtHTjy8qMVWlz88tWaYv90wlkY7kJCYH8NfRnhjxLAvwkurlhmaysyrDsd/T+Yr5hMyHaNy8DHWtCHXLmHSZ7CO6ZbeYgugbggf5FRUpc1rGlHEcl+Y1dS8WXl5MxJIj+zi1XHXYKZHqwv9asnmQDiKJm/3eprnPNTH31/OhZU3DEgHvmrVKKWiI+sTbu2dN4hvElv5JrcqBATyO7buDXqn7PXijfdX+n3rxoFjEkPb7vJFeCmVOhce/PWrWn6g1iZZLebZIy7AVbBwetTKl7tlui44h8/M9nudjrfii4g8RXkaYW3ivnuIR7seT+VV9O1u1tJrq5wXlu1MLj0BBGa5C4uvtMryyyKWPJ5qISp/fWl7CLVmH1qSd0eg3OrRr4dWB0j8pZBhQO5HWo/B2qQ2fiWS4RtlvHsOP9lTz/KuGe63xojSDagwOaUXKxqoRwrjOSD1zS9guVruU8U3JO2x9K3viC31L4t/D6zglEhW6jnJHfcjmvqCvz++Cs5m+MXhAvIXb7aBycnG1q/QGtaUOSNjCtU9pLmCiiitDIKKKKACiivLvih4ih8O/Er4eXGo6k1jpLf2j9qJkKxt+5QJvA4OGYYz0JoA9RorxHxb8R9cg8ZGHSbzT7bShHaXFj9pUKmpRSKGdlY/MepACcgjnOa5WX+2dPg1bX/+EiltpR4zFjdXgjYbIElIJc78eVyvyH5cDGeaAPpiisrRdasdTmurS0uxdXNiI1uWWNlUM6BxgkYOVIOATjPNeTR+LvGGoeKEtLbWLO2tbrXtQ0aNDYCQxLCCyyZ3Dc2BjHA9c0Ae3UV4Dovj3W7yG21tbO2utW/4Q+4vBsiOXkS6CdAfu4G4qO/TFZ1l4w1OzvfFWr6drkOrTNZ6YkmpfZx5Vsruwkk8teCEyfy56GgD6Por5w0PUJbjxFazQ6k2qBvGOFuFwi3A+ycEAcAH24rqvhT468ReIPE8dtrV1Y7ZoZTPp+wRz2citwAn3guODv68EHtQB7LRXzP8Utev9L+K+p3qz6gE097SaC1Fy6SShYmJWBMhWhdtokOGYcnGM4+hPC2rJrvhzTNUQwn7XbpKwhkEiKxUblDDrg5H4UAalFFFABRRRQAUUUUAI/3G+lfmpqn/ACGNS/6+5v8A0M1+lb/cb6V+amqc6xqX/X5N/wChmgBtpH5kmcZC81eDEOVI25756U20VUQJtO85znvVmFBuAJGSMAdSKYyaMusbHcMr37VFPKUh2JkZ5b3NSSoEthmUNg5x/erPuJCxJ24+hoGWppdthbo3HmOZOnXHFdV8KNJtNY8VB9WXdpthC99cp/z0WMZC/icVxeoswnjiJOIkVQPTvXoPwXX7XqeuaXGf9IvtIuIoRnksBuwPripjsSjP8U+I9R8T602oahKyxkkW8KkhIEH3VUdBxiuv029fxv4D1TTtRPm6tocQu7K4bl2hzh42PfFee+TKdGSXYwaCQxyeg+td18IrZzb+KL5EJjXTmtRx9+WUgKv1rrxNONNx5dmk/wANfxuRTnzp+TaOBgPIYfMCcdP6Vpyu4tJJN28DGVUDI/xrubqbR/h7MNIstLttZ1uNB9tu70b4onxkxxp049aswxaZ46029fT9Pg0vxBZxmfyLcYiuox97AP3WFYRaTTaNTzIAyWdwhDZxvXHqP/rVzsm5JcHIH866ufasqM+QmeV9j1zXM6khjuZEK7dpwMelQ9xPcZcbWQ84PGOKzn5YmrsaGTJBA2iq84AY7c7fegCCvpX9i/8A4+PFf1h/ka+a6+lP2L/+PjxX9Yf5GgR9QV82/ti31zZxeFxbSBPMkmDfIrfwj1Br6Sr5k/bR+54T/wCus3/oIoA+dP7X1D/n6H/fmP8A+Jpy6rqJz/pQwOeYY/8A4mpfD8ulw3MjavC8sew+WACRu9wCD+Oah1KSxkvrprCGRIGbMIJxtX3HP86Bi/2tqH/P1/5Bj/8AiaP7V1DH/H1/5Bj/APiaqKAzdQOtaTaFqK2MV21uwgk5Ukde/wDWockt2VGDlsiH+1dQ/wCfr/yDH/8AE0LqmoscC6/8gx//ABNUjQOhOadyS6dVv88XXb/njH/8TQNWv+f9K/8AIMf/AMTWp4H0MeINeis3Dm2UF5XTqowcfqK2/iV4F/4RZLO8tGaTTpxsLseRJ/8AXrJ1oqfs+psqEnT9otjj/wC1dQ/5+v8AyDH/APE0f2rqH/P0P+/Mf/xNUqCcAmtTEu/2tqH/AD9f+QY//iaX+1dRxn7Tx/1xj/8Aia9L0v4VvceHbaZ33XV7AJlYf8sj1C49xivLLy3ls7ua2uFKzQuUdfQisoVo1G1HobVKEqSTl1J/7W1D/n6/8gx//E0f2tqH/P1x/wBcY/8A4mqfYetegfBbwpZeK/EV5Bqas1vb25kABxlicCrlLlVyIQ55KJxf9rah/wA/X/kGP/4mlOq6hjIuv/IMf/xNep/GD4bx6Lo9vrmkqVgQCK6h/uHorD+teP8AbHalCfOrjq03TlysunVr/PF1/wCQY/8A4mk/tbUP+fr/AMgx/wDxNUieCa+gfBXwr0+fwpbvqWDc3sW5m7x5HykUqlX2aKo0XVbSdjwwarqHP+lfT9zH/wDE0f2pqAJBusEf9MY//iadrmlXGjareWF2u2W2lMTZ747/AJVSJCyH+LHQ1ad9UZONnZlr+1tQ/wCfof8AfmP/AOJpf7W1DHF1/wCQY/8A4mt74a+H4/EXiGWG45htrZ7l1/v44A/M10nxU8FWWj2Ud7okT+SjfvyTn72CMew6VnKvGM1B9TaOHlKm6i2R55/a2of8/X/kGP8A+JpRq1//AM/X/kGP/wCJqlmjIrUwPob9kfbqnibX31KO3untIIZbZ3gj3RMWYEqQMg19VV8s/sdxeV4m8TgggtZWznPfLMa+pqaB6MKKKKYgooooAKxte8UaH4fmgi1vU7aylnBaJZn2lwCAcevLDj3rZrn9R8N/bfGuj+IPtWz+zreeDyPLz5nm7ed2eMbemDnPagCpF460eLTzdapd21orXstjEqSGYyOjEHAVc54yRjjuay734reG7LWbW3uLyFdMutPa/i1HeSj4l8vYFAyT9459FNc/rXgPWNCbStQ8NPNqGq2mo312hSGEKqXX3lZZJVzjAAYNn/ZIOKm8FfC67sNCsl1K/jiu/wDhHZ9FlhSLzFQyymTfu3DO3OMY59aBnS+G/FvhibxZqGgaO2L6ULfvIozHcmRN25WySTtC9QBjGKjvPiVoWmeLdV0PW7iLTmsvs4jmmficyqT0A+ULgAknHzDpSeEfAk/hrWrS9ttXWWBdLtdNuYHtcGUwIVV1bf8AJnOSuG+tV/FHw4/t3/hNM6p5H/CRxWcX/Hvv+z+Rnn7w37s+2PegR0cvjDQItfXRJNUt11NnEQh5++RkIWxtDEc7Sc+1V9N8eeGNTkdLHWbaYrbtdfLnBiX7zAkYOO4HIrnG+F8a+MZdZt9QhNtNqKam9tcWnmusqkE+XJvAXO3urEdqwfAfww1lfDGjr4i1WXT73T9PurSzgtY1V7N5yQ0hlV28w4wRjGPrzQB1+q/FLwtYaFe6ot7JcxWckUUsMURWZTIcL8j7eMZOfRTjPSr1v440h31eae8tIdN0+G3mN0Z+qzAldy4BXOAB1LZri7b4Nsmka/Zz67GZdVgtYvNhsdgjeCTeHIMjFyxAzkjvz6bGofDSXU5tcur/AFrN9qRsJVlhtAiwzWoOH2lmDKxP3T0HGT1oA62z8T6Pd6JdavBeqdOtd3nysjL5W0ZbcCARgEHp0qG58Y+HraK5km1a2VLaOKaU7s7Vl/1f1LdgOTU+maZeHSbq08RX0GqPcl1kaO1ECeWyhdgXcxxjPJYnn0wK8/sPg3b2/g640ebWp7i9e8gu4r9oQCggUJDGU3fMqqMdR17UAdbH450i5n0n+z7u1uLS+e4RpTKUaIwxl3GwjJIxyDggc0unfELwnqLXQs9espPs1v8AapTv2hYuhfJ4IB4OOh4rnLP4WGGTT5X1S2WS1mvZ3FvYmNZTcW4g6GRiCMbsknPTinf8KuH2PTIP7Vif7FojaMfNsg6yhip8wqX6fL9336igDtfD/iHS/EMUsmkXX2hYiA+Y2QrkZHDAHkd61q5H4c+DpPB1lewSapLei4lEixBXSGAAY2xq7uRnv8x7YAxXXUAFFFFACP8Acb6V+bN7GW1jU2A4F3Nz/wADNfpM/wBxvpX5v6iAL6/ZTybucH/v4aAGwEBgZCRnjcKtoV2rtYbieCeKzQ3AOce9TIxDjLBlz0oGWp4niVNxDBsjHpVS3jMl7EnDAuM/SrU02/ALr0wGz2pLVPLaSTcBtiOGHPzHgUpbAylNJ513I7Hh3P5dq19B1C60XVLXUtPl8m7tnEkbDsR/PPcVkJC6EgKWA6lRmrfl7gDkjHGBTQI9n0a98FeLL95Z5bjRdQvebqyWHzLeWTu6Htn0NW9C1vTB460Lwr4etzbaLb33mzPIcyXk6gkM3sD0FeJAzoqmCPcQehNaWh6rd2GtWV+IFSa1mWZQOAcHp+NdUq7nRVKXR6f1/wAExjQ5a0qi6r8e+/by+ZrXq3d9qepTkkym4kaWRhnB3Hj61vfCCWZfiJpQUuw87yjxwVIO7P4V0nifQn1y1OteB7aS9s9QcyzwxY8y3kP3lK9evQ1H4d0yTwDaXGua9GLfVGhaLTbEkGQuwwZGHYD3rtq1cJTwapU1epKzb7eRnS9tKpJ1NIrRL9ThfEixR6rqUMIBiS4kC4HA+Y965nWEEnlTHAaRcNx1I4zWxcPIwZmYhjks3UsTWbcDfZypgHy2D57gdDXkS7nWzE3sF2ISB/OkkhbaScHA7GlfAOTnPYYoJ7AcYwfagRUYYr6T/Yv/AOPjxX9Yf5GvnKWPY3PSvo79jAYuPFefWH+RoEfT9fMn7aP3PCf/AF1m/wDQRX03XzH+2n/q/Cn/AF1m/wDQRQB866TZR30zpNdR2yquQXPLH0A/rWjp/h64v/E40TTLmKaWWTykbON/Gc1mWWj6lfw+bZ2M88fJ3IuRx1rrPhOy6B8StHm1iM20YV3UvxjKEKfzpS0i2XBXkkzkltnGprZyAiQTiFh77sGvr+DRdKaLyvIRmtoBEit0BCjoK8T8S2uhaZ8VNH1GM/6EZjJeKFLBHGTk/XivSYPHmhXWoS/ZjM7qDIcRnDemPz/SvOrT9ooysenhqfsnKN9Txv4yeFF8N63ay2sOy0vIt/HQOPvCuImsriKwt7ySJhbTlljcjhiOoFe4/FPWtA8S+H7sQ3LyX9nGZYRgjlj90flTdUttBvfhhYaSrKJ4LD7QjbCSkpxkD3OK0hX5YpMzqYbnm2h/7NGmR/2frGpSKpZpVhQn2GT/ADruPHXhtfEPhjUrRpN1xIhkgUDrKvPT17V518NvFlh4f8D2WnpHJ/aDzSNcqIzlCSdhP5CuotviPYQ3Je/Wa0ZXOFeM7m/2iO1Y1W3U2N6KSpJN9D560PRrvWddt9ItYz9smkMe0/wkdc/TFRW9jK2tRae6ETfaBCykdw2DXrehXOi6P8WNc1qGZBZw2huIDg4MjgbgPesXx4+mW/xM03WdN3PazxpeS7QSBIc8e3aupVm3ZLocTw6Su31/A9bjMkd9b2Vvc5dpCpVeBFHjgflXlvx88M/2ZrEGs26KLW+zG+ztKo5J+tbsPjO0juYr7yLvj555fJPCHjj8ah+IniTRtc+Gs9pBctLeRzJLboyHcT3/AENcWGUoTu0ehiuWdNpM8kuNGu4PD9prEi4tLqZ4Y8jklcZP05r2X9nK3EGia5qZUbjMkSsT2ABP86va9oaax8H9G0vTLWW5ltbYTIY1xhwOfzyfyrK+F/iXT/D+hWWi3kT295cSSvciRCNp4C/mM10zq88GkctKh7Oom+x7Pr1kmseH9TsW2SG5tmVR2yQcH88V8gaH4fvNS8TwaH5TrdNN5LrjlMHk/gK+k4viBodnIlvNchEhKw7gCf8AI5riLfXPDFp8WG12GeRU2yySnYSpcgAY/wA96VOq7bb+RdakpNXex49Po8yeJJNG5Mq3X2bJGP4toNfYdtBHp+nRoFP7mJEJXvtA/rXhvj7U/DkvxL0jVbJ2aFdrXTRodu8MCG966q6+J1kJbsrMzKI/OhAQjzASOD6HvilWk5W0ChCNPm1Rzf7RXhkQT2viO3Hy3R8u4Udmxwfy4rzSfwxdQ+CbTxGcm3uLhoAuOgH8X55r3f4geKtB17wTdwi4jkW4icKpHzI6jKkD6iqfh+98M3Hw9tfDep3aRhYPLXg5D7clvbljVRq8sbLoTKgpzv3X4nNfs26Y8msajqpI8pI/su09ycMa9f1LT7PxHpepaYqeXDNCIWbHIGN2R+NeR/DnxHpnhTwNNBLOw1CXUHIjCHLICACfQEV6JYeONJvTMtg+ycKDICuPlHX9KyrSfPd7GuHivZqK3PmP+yLtvEA0eKMm8a4+zop4y2cCo9e0y40bV7zTLsD7TbOYn29M+1e16/q3h9vjNpmsWxEkVvaNJMyrhTKB8v44NTfEu18O6/D4f8Q6eUWQ38a3IVcF0ZgWLD29a6VW1VzkeGum13Oz+AFqlj8UPF1tENqR6bYAL/d+U19A14L8EtQtdT+M3j65sG3W5tbRVYdDjcOK96roh8KOWr8bCiiiqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBH+430r8370gajqIzz9rm4/7aGv0gf7jfSvzdvsf2pqI7m7mzx/00NADQAxAVQMHvTzCY4mk6ZOKYDwTwRUjznykRhgjv7UDIhgjJXIHQ+lWS5jsGHGXlHvwoz/Oq/Ix0x6VPeoUt7aIgBtm8gerUn0Ey1Z3xMeRJ5UoG0lRgsv8AWmNdJdzLGIxG56so6++Kp2ixCb/SvMCngbeTUksaW9wjwO5IP8QxVq3UouQr5TFdrP8AN1Bx+dben3Vppd5581ol5A8ZR45G4GeuD61z+85xISoPJ96ck4HyBvk6+wqJxU4uLNKc3Takj3DwnrWna48GlaOLiCeRCEihyjJgddy9veqHib4ceI43luYDHqmxdz/v/MuMe4J5x7VlaHdSeDfhpaatYkR6xrlyyCYj5kto+qj03GugudTmv9Hh1XSbloL+NRJG8Zxhhzg+1eLJLK6kXG7jJ63ei/D9T26SlmsZJ2Uortq/x2PKpSQpVWbIJDKwwQaqgKtwoYHEgMbFunPFdx8T7WCSTR/EVpGkS61bCaVFGAJ1OHwO2TzXDEgyncRHnkHOea9x6o8B6mPcxMkhVuWU7TVc5AwPXtWvqsa+aJlA/eqHz796oEIMFz36d6S1QiKVMruCBPqck19E/sZ8XXiwEY5h/ka+eLgng9jxj2r6I/Y0/wCPrxX9YP5GgGfTtfMf7af+r8Kf9dZv/QRX05XzH+2n/q/Cn/XWb/0EUCPnKy1rUbGBYrS7kijUkgADjNQ3N9c3rJJdXLtJFHsiPfHpkfWl0y8NheCfykmG0qUcAg5qTULz7ffXVwtrFCsrByFH+rHTj/8AVTA9p1yPTP8AhRses24/0u5hjiZ9xz5uQD/6Ca8v03xdeWEE0cRyzRpGjHqNoxUdx4nup/BNt4cb/j3guDMhHoex/E1zuK5oUVZqS6nVUxErpxfQ17XVLrzZZJZS5cqDljyQcivWPhd4tbxP4yi069tIoo3hJRU55XnmvEenIrpfhvro8NeM9O1N1JiQsjgejDH+FFWjGSu1sFCvOEkk9zvfH/ilPDPxI8QLbWqS+ZbxIFzhVkGGyR+lcF4r8YX3iO/N1OiQZCApGTg7ap+NNQXV/Fur6hGxaO4uHdCe4zxWKKcKUVaVtSatebvG+hqXmqzXLy3O5llaYvgMcAEdK90WOztPh3Fr81qs0kenwz4zgFuBj86+eCOODXod74rEvwhtNJEg+1iT7K6558lTuB/PFRXp8yil3NMPWcXJvsGsfEl77w/d6amnrEbi3SDzQ3KgEHNYa+JmuNIsdNa3UTrMAbgHkqSBiuYp0LbJo27q6kfnWiowirIzeJqSd2/I+jfh14ynbxbceEpo4ltrKCRI5V5Lsp6n864b9oC4Fr4ss7O0YqYrYSs6nBJbkD8qqeCLtIfjaolkDRXVxJCzZ4IZc/zArJ+M+oJqPxJ1iSF1eGJlgRlORhVA4rOFNKa9DapVbpu/c443E/eeX/vs1aSSZtIuH8yTKzIN285GQeP0qhipQ58loxkAkMR24rodzjiz3x9P0u8+EP8Aa7QZu/7IGJQTxIhC/nzXg8V/crbmPzXIbkksc13dp4ojh+Ct3oiTD7U94EKE8+WTu49uBXndZUo2v6m9ed+W3YsQXMqTxMZZCFdT989jXrPgOKBfjTqmm3I8y3uElVELZA+63H4Zrx5sgE+ldZ/bh0z4iRazAzAJMkjFe4IG4flmnUV9PJ/oTRly6+a/U6H4+xxWPjtLexLRItpHuCMQM44/SvOBdXC8rcTA47SGum+KOtxeIfHWp39o++2cqkR/2VAFcp6YqqatFImq7zbJWnmz/wAfEp/4Ga+kfA0dne/BOG9nCtLa2c4LHqGUMOTXzSylWwRzXceG/Fw0z4deIdCbIluyph57Ejd/L9aitHmS0uXh58knrbQ9S/Yybf4j8UsXLsbS3znPHzPX1ZXyl+xgCPEPijK4H2W3wcdfmfmvq2tznCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAR/uN9K/Ny+z/AGpqXA/4+5sf99mv0jf7jfSvzcv8jVNRIxj7XN/6GaAGptXpnP8AKlZtzncOv41Hu5yAcEUv1xn1oGPiUPIkY6sQMVNfzB7yUjqDtGOmBxS6dtFyHdciNWfj2FVCT95uTnml1F1JUxu3dAD2pZmIbhgeetRDnp09qV+ehHvimMerFwB+PB61PG7D5cDGfxqGMsOUbB7Ad6k3YJUjk9c0xnpXiEnUPhF4Svbdh/xLp5rG4x/AxOVz9aPDl3/ZXhOW5uyzQ+YQAOoB9Kwvh/4nj0KS9stQsxqGiX6hLqzY4yR0dSejCu2i1/wLYWkLW1pq2om3bzI7O52LHv7b2HUD2rjxmHeIjGn0ur+h6OW4tYOc6r3tp6lH4k7LHwz4O0liBPDavdSK3VBI2VB9OK89ZCflyGyf4a0/EmpXWu6tdanfSF7qc7jgYVR2UD0ArGKb2YZbPf2rsSsrHnyd22NuAZLTAHzwvggns3/16zxHkZPr06VoWsbm5kgfpKpXpnntVRkxId4OB1U1K3aJGMsk33QNqjHHQV9C/sajF34s5zzB/I189XEqldiE4A719C/sac3Xiv8A7YfyNMD6dr5j/bTOIvChPQSzc/8AARX05XzZ+2Ne3NpF4XW2l8sSSTbvlB/hHqDQI+aNBGmy35GqyhLYRk5DEZbt0BpNS/sxL27FhcO0AbEORkMuO5OD+lWLfV7xZlaeeSWMdUCopP47adPrF0wj8maSIhcPkI24+v3ePpTAyPMjx95fzo8xD/GPzrT/ALU1DH/H2/8A37T/AOJo/tTUP+ft/wDv2n/xNSMy/MT++Pzpxki2jDrnvzWl/amof8/jf9+0/wDiaP7T1D/n7f8A79p/8TQBmeYn98fnR5seANy1p/2pf/8AP23/AH7T/wCJo/tS/wD+ft/+/af/ABNAGYJUHRx+dJ5if31/OtT+1NQ/5+2/79p/8TR/amof8/bf9+0/+JoEZnmR/wB9aUSxgHLDPbmtL+1NQ/5+3/79p/8AE0f2pqH/AD9t/wB+0/8AiaBmebv9/wCcJdsud24HBB9aZ5qFss4OTk89a0/7U1D/AJ+2/wC/af8AxNH9qah/z+N/37T/AOJpaBqZskke44dT+NJ5kf8AfH51p/2nqH/P23/ftP8A4mj+1NQ/5+2/79p/8TTAzPMj/vj86GljJ+8o4rT/ALU1D/n7f/v2n/xNH9p6h/z9t/37T/4mgDL8xP76/nT5J0kOS4zjHWtH+09Q/wCft/8Av2n/AMTR/aeof8/bf9+0/wDiaAMvzE/vrS+ZH/fX861P7T1DBP2t+P8Apmn/AMTSf2nqH/P23/ftP/iaAsZrTIzFi65pGmRuS6+lag1O/JH+mMB/1zT/AOJpP7T1DP8Ax9t/37T/AOJoA94/YwKt4i8UlGLf6Lb546Hc9fVtfLn7Hd9dXXiDxRHczGREtoCuVUYJZvQCvqOmIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBH+430r83b4A6pqIJ/wCXyb/0M1+kT/cb6V+bt9n+09QwM/6XMf8AyIaAIsc8UmSBx26HNLkce3pQWB6jJoGWIABZ3Mp4J2oMe/Wq3y454NWpcLYQIFPzM0h9PQVWGAw4AyOlJdxIUetABxnn/GrMMcbcNnoeRSiOL7r7gw9DTGVxggZ4b6U/dubGOfWrsdtbAZLSOT/CqYIq8trbGPi2uGJ+7sQnP507DsZUAPcn3rTsXXYfnwTwR3ph0y8yWW0eJScgvgVpWmjTll814lBGcK24/jTGjNmbDAclxyMdKdbw7XMkqkcZIFbl59hsrUJagNPjLTFcsD/dFYMck1xPl85bnJNAD2zHJ5qofNP3M9gKp6q7C5dVwc4bK981NqUoGFUgkdCozVSdmezhkIBZCY2x+YqXoyXuUWwc5/Ovov8AY1/4+/Ff1g/ka+c3zzuGPSvoz9jX/j78V/8AbD+RoA+na+ZP20Pu+E/+us3/AKCK+m6+ZP20Pu+E/wDrrN/6CKBHznpOnT6peLbW2wM3V5G2oo9zVnWNBv8ASHt1u0UtOCyCNg5GOoOOh74qDSNWvNJnM1lIFJBDI6hkb6qeDT9R1vUNRa2N1cEtbqUjKAJgH6dT70x6FWdpXkJuN3m99wwajq41lfS75JIpXKpvZmOflHfNUqi42mtya3ge4k2RKSep9hTry2ktJzFKpDAZ+oPSu1+FVgl3e3bTR+ZGXihYezE5qX4t6CdJvYJtpG+SSEf7qn5f0rn9v+99mdP1f9z7U8+FFAIzzXS6b4VmvfC1zrCFgsO4hcfexjGP1rWc1BXkY06cqjaic0K0PD+lyazrFrp8GfMnfaDjp71nfhzXqfwAto5PEGozum4xQKin+6WJGf0qa03CDkiqEFUqKLPONTsZtPvJYJ42RkYr8wxnBxVSvZP2idINteaffxhRC4aM4HUk5rxvvRSm5xuwr01Tm4rYcF+QsRx0por0vSfB7Xvw2SeKPddTM9yW/uqBx/I15oKKdVVG0ugVaLpqLfVGp4a0mbW9Yis4F3E/M2P7o60niPT/AOzNUaAKQMBsHt7V6R+zjZGTxTe3roDHFB5YYjgMTn+laX7Qfh2OJbbWbSAJED5MpH949P61m6jVW3TY2jRToc1tdzxKjvRXqfg/wONd+H8rxRZvpn3xuRyozx+BrWpUVNJsxo0XVbSPLKu6RYS6nfx2tuMyODgetVriJoLiSGYbZI3KMPQg4Nenfs+6Ql/4qvbuRN62NuXXPQMTx/KipLli2hUoc01FnEeKtBuPD93DDdAK00fmbR25xj9KxK9o+NWiSy6Lb6u5H7h3VvUhnO2vF+9Th6ntIJvcvFU/Z1GlsFFei+Dvh42v+Dp9YjdjNmRIox0JXvXns0TwTPFKpWRDtYHsauNRSbiuhE6UoRUnsz6C/Yz/AORl8V/9etv/AOhPX1XXyp+xn/yMviv/AK9bf/0J6+q61MQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEf7jfSvzfvP+QnqPX/j8n5H++a/SB/uN9K/N++/5COoH/p8m/8ARhoAg7jPANBB4xjd0xS7hk7gcmlTAcNtztINAybUv+Pnyl+5Eix5+lQbQMc9egzV2X7HcruMk0MrHJVlDL+Y5/ShtPbG63lhnB/uOM/keahSSVmSnYS3ciDaRwT6dfaowqtId2R9auRWl2ifPayMo9VOKYgQbVZXRt2fpWiaZe4sIdXAicrjrzWrB9pnAiOoxx+m5ST+dV5oACHCzMxHJGDTlt7SNk89p0JHPy9PypjLMli5kG/Vrck9cBiP/wBdW7C3hRDEs5dTzuJ25P41mA2cMoxI7+qsuf8AJqOS4kkkb7JbvIB90lOBRdLcL2L84bzSglQtnBOf61l31ysJZPk3eoP+FJJFeSvm4kSNccmVwv6dariOzTd9ouXmI6CFeD+J/wAKjnXQlyXQqyMX5YgVat7Wb7JcMyOLd1yJCMDcOmKI7pIcfZbRA2f9Y/zsPz4/SoLm4nlfM0jSMe7HP/6qTuxasrSD+8OPevor9jX/AI+/Ff8A2w/ka+evKIQE4Ga+hv2Nhi78VjOf9R/I1Qz6cr5k/bQ+74T/AOus3/oIr6br5j/bS/1fhT/rrN/6CKBHzzoWlNqt2I/NWGLOHkJyRkHGF6npV3xB4cfSDYD7QsjXSFvmGwAj0J6j3rAR2SRXRirryGBwR+NOmnlm8sTSySBBtXexO0eg9BTA9M8OWdxJ4RjtlhVnk3RKykMGBJJGR+FebSoYpXicYZGKkehBr034e+ImsNMWyxDKbRhJEV5DEsMj8s1zfxN0f+y/ELXKMGg1DddR47Ak8VwUZONWUJdT0MRHmownHoj0D4I2Rt/DWo37Rb2um2x+uEYZP61s/GbSDq2hSy22XmtAkwX0QjkmtD4Zi3tfhrosaFGnbLyDPI3kmtqXfeeHbq2UK81yuwv0OBzt/pXHUqWrOSZ3UqV6Ci+x8oEnHHNfTngrRrez8G2Ok3GJnmhD4x/EecV86SWTR+IVtETcTcKqr65YV9MWU40+a3ZJUadGBMR7DBwP0rfHTvyx7nNl8LObfQ+Y9ZtzaaxfWzDBimdD+Br2n4CaO3/CO32pIAJbqUwA+oXkfqTXm3xL0uaz8S394VC29zOzLg/xdSK95+EkCaN8MtJkYgifdPz1DNn+la1ZRnRTvozKhCUK7TWqKnxz0uS/8HArGWktWEpwM5+XHFfMjHap9QK+1hcwajFeWtwqhDENwPoRxXy94/8ACyWHj1NLsQRBeyqsWe244NGHqJO3RlYuk5JS+R9EeANIiTwPplq6jaLYRuD7g8frXy34xs007xVqtnFgJDcMgx6Zr65tIvsFnc26S73jhCKvptGM181fGzThZ+Orq4hH+j3SpIp/2iozSw7SlYeLi3T9D0n9nHS2PhbUrs/KJrtQp9kHP86734laN/bXg3UrRFy4XzI17lgOK574Dyra/DTT9+FEk8zEnv8ANXoSjzInMjgiXlB6jHSlOzk7bmlJWgk9j4ccFdysMFSQR9K+s/hfavH4Q8MNGgRPseZSRyTxt/rXhfxb8JDw54wiSNg1tfSB1H93LDI/WvpsTwabY2VsihFCpGgHbAz/AErSrNSimzHD03CckfJPxJsTpvjzXLY9rlmHuG5/rXq37M9ixsNcusld8qRqf72Acj9a4/4+6dJD43k1Febe9jR1PocdDXpfwKjS3+G9nKDteW8cnB6/MR/IU5yTpJk0oNV2mbPxJ0Qap4ImsU3MwIIIHPD/AP66+VLmNreWWOQYZCQR9K+2PNUNBanYZCDJk88A18zfGjw5LYeMpZ4IQlnfuDFt6ZOAf51GHmovl6GmLpucebqvyPcvhRpEulfD3T7eUL/pCCTA/h39TXzj8S7VbLx1rFunKJN8p9iK+s9Gkt7fRNLgV1wIUjXPqoGa+d/2gdIktvGct/GgFpLFGNw/vY5p0rKd7/1uGITdO1tv+GO0/Yy/5GTxX/162/8A6E9fVlfK37GsTR+IfEzHpJaQMP8AvtxX1TXajzHoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBz8/jPwxFJJDL4h0mORCVZWu0BUjqCM18sXfwd0ya+up4viT4ZVJpnkCs6kjcxOPve9eH+O+PG2vY/5/p//QzWFQB9EH4NWBPPxL8Mf99j/wCKpT8G7AnP/Cy/C/8A32P/AIqvI/h94Zi8R3V+Jor2dbSDzjb2SgzSDODtzxx1p/ifQdLtPF1rp2mG9SzuI4iBc7TKjN1DY44NZ+1jz+z6l8j5eboesn4NWH/RS/C//fY/+Ko/4U1Yf9FL8L/99D/4quP1T4OXAuTFo+sWlwdnmBZsx5Hs3I61zV78MvFNskjpp4uY06m3kWT9Ac/pWhB61D8I7eEYh+KXh2Meiygf+z1OnwtRcf8AF0fDDf7xVv5tXz/deHdZtNv2nSr6LcSBugYZI644rOeGRGKtG4YcEFSCKXKn0Cx9ML8NUUgj4l+EsgY+6n/xVRt8MI2zu+JnhQ59Qn/xVfNOx/7rflVi2sLy6z9mtZ5scHy4y2Pyo5V2Cx9Ff8KsiAwvxP8AC6j0XYP/AGao3+E0LjD/ABT8OsPQyjH/AKHXh9p4M8SXcrRwaHqDMoy2YGGB6nI4rX0n4ZeIdRZdsdvECcHdKCy/VVyaOVdgsj1I/BuxP/NS/DHPX5l/+KpW+Dliw5+Jfhfpj7w/+KrkfEPwam0Xw1dXz6otzfQR+abeKLAx35JzwPavI6YH0bF8ILKOMovxK8LYJzyw/wDiqF+ENkoIX4leFRn3X/4qvnKigD6L/wCFO2O4k/ErwuSfVh/8VXsP7PPgy08J3GuNbeJdK1t7ryyy2LA+UFyOeT1r4Tr6g/Yg/wCQp4o/64xf+hGgD60r5j/bS/1fhT/rrN/6CK+nK+Y/20v9X4U/66zf+gigDxPQNG0C5sLafU754ndCXVJkU7s4xg8jj86h1XSdGg0S+mtLwSXttOkaDzVxIjdwOpI79q5XHegYzTuFzVsIvKFrILqWCSZsR4jyCc49a7bxb4a1qW4jtdUuN/2aAFNsRwFA6detcDc3QdrcW+9Y7cARhyCQc57e9fRXhi/XxJp9prl8VWPynWSM87jwF/ka4cTOVNqSSPQwkI1VKDb6Hi0t7e6Bci0GrzRyRbG2rESFwOB19DVy28cajbFNmqSYWQyYMB5Jznv71ymtXRvdWvLhycySsR9M8VVdizZPH0rdUoSScoq5zuvOLahJ2Ni3mjW/XUheO0kEiynMPGQcgda0p9Zvf7V/tH+0LiKWd8qDCdvXoOfeuVDNtZM4U9avanqk99HCkgVfI+5j6D/CnKCb2FGo0nqzto/DWueJ7yLTLi6kLCQsJJISBuI9c+1R6n4m1PRbYeG5r9o10/MJCxH7w4znNe3/AA61G01jw9aX1ui/bHVSxx3Xg5/Wvmzx3dx3njTWriE7o3unIPrziuWi/avlmlZHZiP3S5oN3fXyOkt/iFqEF7NcNfM3m+VvUwnGEGAOveqWueLRq/im01uSYpJaMrRoITjg59a5S5uEltYUVAsiFtx9fSqyjLAetdCowT5ranJLEVGuXmutz0HUPH+r3GojUf7SlhVyBsWE7Wx1710174M8Q/ED7PeS3EUMAiEiExnGDxj68V5DfXbXKpGeEQkgfWvrj4R3Auvh7oMwOS0ID59QcVlKmoNOKSOinUdTmjJ3R4JL4pvvDuhw+GftDQyWU5lWQQnPfjGfenxfE3VYdZjvXv3dYgAlu0R2KdoGetc/8Qroz+P9edsECeSNfoDxXLs5dgW5OPzrSNGDV5LUxnXnF2i9Edd4z8UnxVq0V9e3bqYsbEEWQMHPrWrN8SdRkFzm/bMriRCYifLwOg5rzsjGOaQ8iqdGm0k1sQsRUTck9WejeJNK8Qa2thJqFzcXUdxGssbLbnavHTrUEuq6v4NSbQJNQkiVUyEEP3d3O4HPvXtfwekGo+AtDkmw3lRyIxPOCGIrwr4v6nBqfxE1Oe1JMKbYc+u1cGsKa5n7OSVkdVX3I+1i3dlqx8e6jba1FfzalNLtH+rMJAK+nWjxx45/4Sp7EvM1uLVcYWHOTnOevtXDyS+aYeMFUCE+tQ7SN3tW6owTUrHNLEVGnG+h32o+PtRuLW1h/tB4Ui+ZdkJGTnOevtW02keI/iIjStd7oWjSQZhIU4OBg5615TKzPtLdhgD0FfU/wQukk+HOlMq7njMkcn4E1lUhGmk4pI3o1JVW4zbZR/ZS06bSvF/ie0nYuUsrfaSu3je9fTNeA/Aa/i1D4qeMTAQVgsrWEkeoZ8179XRTk5QTZyVoqM3FdAoooqzMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPzI8ef8jtr3/X9P/wChmsKt3x5/yO2vf9f0/wD6GawqAJrW5ntXL208sLkYLRuVOPTiut+GllLrPi+CS486dbZDKzZ3EAdM57ZrjK9q+AOn2IsNXvryVo5pCsEeF3ZUcsaLLcd+h63babb38VtE91BLldoglIUqO+P/AK9bSaa2kIghX76iMoo3AL/eyazBpyG9jtbdLS8jlAMc8b7ZDx710S3ENpaW8Fxa3UJwY03RBsn3I60COfl1C7uJHW2vlTy2KP5Y2lvTB/wrNtYvKOy4uLa4hZzJJcBFYsxPCsMciu2JtIYP9OurdpMDYDH5TP7dK5640+zkuGCQxzMW+UxMpUA9ePWgCzJqFlJDYvLp1m7tIMf6Oo3Y7g9hS3GsvYNJe6faGCKKbd+4fywy9w6gdKytSs7OzuYGt47uXZllIPMf9CBUQ0+4nhkkE7yKckPvCMEx0Kng80AbsniV3la6SyEhlwZ9rZCqBxluw9qpxa5ZabLMPsdsJAnysnRwTnqOeKxpvDeo2drcSR3SiDyw4AbO9sfdPoK5i9t7hsSPN5cyJuMAx+YoA7qK40+fzbm9hE6XcZiVHxkZyDknqK+RPEVgdL1y+sshhDKygjoRnj9K+hVmSY2cU9xIisCSXG4ufTFeSfFeyWPVo7uFfkceWxC4GR0/HFAHCUUUUAFfUH7EH/IT8Uf9cYv/AEI18v19QfsQf8hPxR/1xi/9CNAH1pXzH+2l/q/Cn/XWb/0EV9OV8x/tpf6vwp/11m/9BFAHzjod3HYatbXM8ayRRk7lZQ2QQR0NaviXVtL1D+zfsdmyrBEVlXaI/ooI6gdcnmsK1tprudIbWJ5pm+6iDJNOu7O5s/LN3byw+YNyeYuNwzjIpoBkrRvITDGY07KW3Y/Gux8KeLn0nQ7vT5Cf70J/PIrj5HEjbljSMH+FM4/Wm1lUpxqK0jSlVlSlzRA5Zie5JNJSkYpKszDGKDzyaMUUAesfDnxrbaD4A1S0eZY73L/Z89SSMj9a8okdpJGkc5dyWY+5pKWs4U1Btrqa1KznGMX0EoFFFaGQV7d8EvF4s9CvrK7nCi0jLwRk/wAI+Zj+teI0+OR4yTG7KWG07TjI9Kzq0/aRsbUKvspcxY1e8bUNWvL09Z5mk/M1WXOR602irSsrGTd3dh1zmjFFFMR7N8B/Ey2Vnqmn3c4RIoXkgVj1JDEgflXjtzM1xczTOSWkdmJ+pohmkgkEkLsjjOCp9eKbtyhb3xWcYcsm+5tOq5wUew2gkkknqaKWtDET617D8EfGlvoekapp19KFGTcQ7j04GR+Jrx6ndACDzUVIc8bGtGp7OXNufR/7Idx9q8a+NrjGPNjhfH1d6+pK+Uv2MP8AkY/Ff/Xtb/8AoT19W1aVlYzbu7hRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH5kePP+R217/r+n/wDQzWFW748/5HbXv+v6f/0M1hUAFfRng7QNV1Lw7ZXCW6Ws0kYkRIUEIc4/wFfPdhB9pvYIMhfMcLk9Bk19K3OsQWWkWifbLuSSIqsfkyfIFAxjHUUAWLO11JcxX0qiQHBTdyT7H2ppbVbMoSl2oztjLHdz1BU1oWGopJuaWVo0YqXR495UdiGFdO8OnTWtrdJfJ/o6OWjLYDehPpQBykfiHxDchbh1jnaL/WRS4I54+X396al9aSzGW7065WVyAyscCM+ox1FdJYQaPqrIJZoYRhdhjAIU+me5zWhqFna6bJFBJdwCLIKtsBy2Oh7fhQBitrlpYlJ7a5kWPZs8uEEkN7E9Oa4zUPEiNdsfsrfaIm8wtI5b65Fev2M+mz6dePqflukq/LJgKnyjBwK5210zS9WnZmQTW6R48qFgjMB0BJoA840zXL28N0N7Rw7CcINuT6nNR6bqkqPJ9qjYso7gZYe5PauxudHsrwPa6ZbqtyWbzGLbioXovbNc7N4UmgYWRlka6kf53RN4Cn3HSgDMMzXt1JOtucI+GkRgO3AFc340t7u68Ny2TSiVo389UQZxj1P0rXTTNQsIrq2ELR20TlWkYfMvvjvTX1ONLKWKYEswCA4wMfz5oA8Moq7rFqbPU7iAjAVzj6dqpUAFfUH7EH/IT8Uf9cYv/QjXy/X1B+xB/wAhPxR/1xi/9CNAH1pXjn7Q3wy1n4ix6KNDuLKBrJ5Gf7SzDO4ADGAa9jrG1/xToXh14U1zVrOwaYExi4lCbgOuM0AfLel/s5+ONOvUuY77QZGUEBWklA5HsKv6t8CfiFqctrJNf+HVe3BwQZG3E9SQykV7/wD8LM8E/wDQ06R/4ErR/wALN8E/9DTpH/gStFwPmu4/Zt8c3ErSSaloO49dpdR+QXFR/wDDM3jb/oJaH/33J/8AE19Mf8LN8E/9DTpH/gStH/CzfBP/AENOkf8AgStAHzP/AMMzeNv+glof/fcn/wATR/wzN42/6CWh/wDfcn/xNfTH/CzPBP8A0NOkf+BK0f8ACzPBP/Q06R/4ErQB8z/8MzeNv+glof8A33J/8TR/wzN42/6CWh/99yf/ABNfTH/CzPBP/Q06R/4ErR/wszwT/wBDTpH/AIErQB8z/wDDM3jb/oJaJ/33J/8AE0f8MzeNv+glof8A33J/8TX0x/wszwT/ANDTpH/gStH/AAszwT/0NOkf+BK0AfM//DM3jb/oJaJ/33J/8TR/wzN42/6CWh/99yf/ABNfTH/CzPBP/Q06R/4ErR/wszwT/wBDTpH/AIErQB8z/wDDM3jb/oJaH/33J/8AE0f8MzeNv+glof8A33J/8TX0x/wszwT/ANDTpH/gStH/AAszwT/0NOkf+BK0AfM//DM3jb/oJaJ/33J/8TR/wzN42/6CWh/99yf/ABNfTH/CzPBP/Q06R/4ErR/wszwT/wBDTpH/AIErQB8z/wDDM3jbP/IS0P8A77k/+Jo/4Zm8bf8AQS0P/vuT/wCJr6Y/4WZ4J/6GnSP/AAJWj/hZngn/AKGnSP8AwJWgD5n/AOGZvG3/AEEtD/77k/8AiaP+GZ/G3/QS0T/vuT/4mvpj/hZngn/oadI/8CVo/wCFmeCf+hp0j/wJWgD5n/4Zm8bf9BLQ/wDvuT/4mj/hmfxt/wBBLQ/++5P/AImvpj/hZngn/oadI/8AAlaP+FmeCf8AoadI/wDAlaAPmf8A4Zm8bf8AQS0P/vuT/wCJo/4Zm8bf9BLQ/wDvuT/4mvpj/hZngn/oadI/8CVo/wCFmeCf+hp0j/wJWgDgP2evhTrnw71TW7rXLqxnW9iijjFszHBUsTnIHrXt1ch/wszwT/0NOkf+BK0f8LM8E/8AQ06R/wCBK0AdfRWBofjHw5r14bTRdasL65CFzFBMGbaOpwO3IrfoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPzI8ef8jtr3/X9P/6Gawq3fHn/ACO2vf8AX9P/AOhmsKgDc8JWT3OsWzYfZu42ckn0Feq6fb2ayzH995jHYiAZyB3OfeuL+GI8hri4aBJA5CKf4gf9mvQLG5ZDIPsrSSREhtgyeenuKAEhv7qK4ghlliCKS27kc+9Ol1kvC8Ns6tEuSFYdTjrVTUxcSXAW5RftMih1ULnd9B3rKtrhbW6l+12+6JzjejY2++KAOjs9Ra2t2j8vlEDJI+eW7bfSrraj9u0+K5kUBfMHmiQcKfUGuVe/kgjKQz+ZCcYz3HpXQ6R+/sjvj89oBlbfqDn+LHU/SgDVn1uWeSKztr0XEQVsqFCDn0B/nUF1dGzkhMdxL5cfLOpPJ75A9PWs3U4nVUmmbcw+QkfIIz2GO1Oknll0Zn+zIwUbSBlmx656CgDqfDOvx2euOjQi4d0LLKIwe36H3rT8P+IWGrqdMt1it0fa5lHygE9c+tcVoNvJqBAt3RZOXbqoRf8Ae9fasMTTLJfQvduIzJhD5hG7396APUNWhs9ZvWhjuYvtEkj+ZMhO2P8AxrgfFuiDSiFjR5QFOODkk92qLQrm30i7LXC3ch4bIchc57j0rr01Fta1qW5WKC3s1QBVBDLn2HBJoA8E8e2PltZ3eeZE2MuOQR0/OuQr234mRpqNpcWttCj+SuVMSYO4eteJkY4NACV9QfsQf8hPxR/1xi/9CNfL9fUH7EH/ACE/FH/XGL/0I0AfWlfJf7b/APyFPC//AFxl/wDQhX1pXyX+2/8A8hPwv/1xl/8AQhQB8v16v8JtLiudBv7y5s9EuvKlAihvzGGl45AJ5AHXNeUVsX1raWumaVKPPM1wGkmO8bdu7ACjHB96APeLvQ9ExKken6IHW2VQ6R27K0uQSR8wI4yPxqlNoEETxPFYeGJYjGWMTLBvQhvulgfmYj6CvGPP8P8A/Pvq3/gQn/xFKbjw9sUC11UEdT9pTn/xygCb4gpHH4quxDbWlquFJhtABGh2jIGCR+tc5W2ZfDx622q/+BEf/wARS+d4c8vH2PVN2c7vtCdPT7lAGHRW15vh7/n11T/v/H/8RThN4c2MDZ6puJGG+0Jx/wCOUAJ4Wh0ie7nj12ZoLcxHZIv3g2R0/DPWtyTSfBiwXEia3du8Y3JHsAL8EhQcdegNYXm+Hv8An11T/v8Ax/8AxFPWbw4FYGz1Qk9D9oTj/wAcoA6Uab4IaSW5GqSKPLlZLU5wGC/IN2M9fz9q89ra83w9/wA+uqf9/wCP/wCIqa3u/DsKzA2Oov5iFPmnT5eQcj5OvH60Ac/RW15vh7/n11T/AL/x/wDxFPSbw4CS1nqjDB4+0IP/AGSgDCora8zw9/z66p/3/j/+Ip0c3hxXBez1Rh6faEH/ALJQBh0Vteb4e/59dU/8CI//AIinLL4dDAtaaoQDyPtCc/8AjlAGHRW2ZfDuTi11QD/r4j/+IoEvh3Iza6oR6faI/wD4igDEorceXw6XYraaoqk8D7QnH/jlJ5nh7/n11X/v/H/8RQBiUV0V9eeHbq6kmWw1GEN/yzjnQKPp8lV/N8Pf8+uqf9/4/wD4igDForcebw4SNtnqijAGPtCH8fuU3zfD3/Prqn/f+P8A+IoA9g/Yz/5Kpdf9g2X/ANDSvtqvi79kNrRvi5dmwjmjg/syTAlcM2dyZ5AFfaNABRRRQAUUV4/8dr7TbPWvBq3uqzWPnagkd2sd/Jbg2nO8sEYcZx83UetAHsFFeMyeM/FC641yNQtf7Mi8Xr4fNl9kG5om2/OZM5yN3GB9c9K5XStX17w1oWo6zFeLLcaj4gns73U5YR/o8cbPgksSqhjgDI2qOO4oA+kKK8d8GeLfFXiHxDo2ltqulIraZJfXNxDbeck/l3fl/IQyhSyEDI3AHJAPGMDTvG+rWHgnw60V3a6HZ3EOozG7Fr5iSTx3DiOAA5ALcn1PagD6BorzHwb4k8UeIfFotLuS1023t9Nsb26tGtC0heVGLoGLDZyO4Yjp616dQAUUUUAFFFFABRRRQAUUUUAFFFFAH5kePP8Akdte/wCv6f8A9DNYYrc8ef8AI7a9/wBf0/8A6GaoaJax3mqW9vM5RZHAyFz3oA9J8PRR6NpWnwTgR3Uo80uf+Weef8ivTfBukzeI4b1bCVIYVOZL1k2qnqC39K6jwz4atdZ0ue81WwtruCFQsEFu26dgBgZ5+XpXOeM7i/1e1j0mwUWOnxna2mxxlBER3Y9WPueKAH6vren+BHEHhu2S71VlO/VrkhlX1WNew96yrfxL4c8WxmTxZoH2fUEJX7bpZ2E+7IeD+tch/wAI/qcstzJaKtxChw+X5Wq6tJb32y+IgbGA6jGPbFAHcT+AV1KIXPgvULHVoFOWtt3lTge6HvSaHZppiH+1NOuImgciQTZjfnpjPUVyB024Uf2jY37eZGwIaKTa6+/FekeHvF2q3iNp3iS2t9WhwDGl2AH/AAf1oA5jVbOK91U/YnlmQ/8ALLj+fSnyz+RapCymCF23D5fmY9wR2x612+o6NoeokwafeyaFqEjbxHcYaM8dFccD8ax9a0W70SK3ttbV2tfuw3HylHPYBvf3oA5hPL0xY5/OTfIxUhG3fL9PWsjUJkuZ08qcCeQ7WGwDb9K1r9YPLZohbi1LbHQv86N68Vl3lnGwi8uVGcHCueAcUAZwudupGOdC7R4+8SRj39fpV9tcSz3fYbWOKYcksDn8B2qGO2E8TTeYgljOGLkk59APWrM0b29pFI9lw5y0khyT70AaPhJLNZp73UTJgDcIEG1pM9Tk9q8V8WWi2fiG+jjjaOIyl41bqFJyK9HluU86Jrg5iX5QEOOtYfxS0/bHYXqx7fl8pm3ZLdwTQB57X1B+xB/yE/FH/XGL/wBCNfL9fUH7EH/IT8Uf9cYv/QjQB9aV8mftvDOqeFwOT5Mv/oQr6zr5M/bf/wCQp4X/AOuMv/oQoA8QfwSYvDg1OW9XzDbtOYlTOwg/dY54OPbrWX4ijaLTNEVwATbluCDwWPpWKZpSGBkfDdRuPNbGtqTpOiEA48hh+O40AYdFeu+FPh5aXGgCTU0b7XOu7aTgxeleYazYSaXqlzZTDDwuV+o9a48PjqOIqSp03rE6a2FnSgpvr+HqUaKKK7DmCivSvDXw6Oo+HheXMgE06iSEKegPrXCa3pk+j6lNZXQAliOCR0PvXLRxtGvOVOEruJ0VcLUpQU5bMoUUUV1HOFFd14Q8Aza7YPdTyvbKf9XlPvD1rmPEOjXGh6k9ndgb1GQR0I9a5qeLo1KjpRl7yOieGqU4KpJaMzKKKK6TnCiu78GeBW13SZb+4doo8kRY/ix1/WuS1jTptK1CW0uB86HGR0I9a56eKpVKkqUX70dzeeGqQpqo1oyjRRRXQYBRXceC/BDa5Yvd3XmQw5IjIH3+OormvEOkT6JqctpcA5XlWx94etc9PF0qlV0Yv3kdE8LUhTVVrRmZRRRXQc4UV1PhLwnPr8MksZKqG2j39ayNf0mfRdSks7nBZOjL0I9awjiKcqjpJ+8uhvLDVI01Va0Zm0UUVuYHvX7Gf/JVLv8A7Bsn/oaV9tV8S/sZ/wDJVLv/ALBsn/oaV9tUAFFFFABWZqOvaXpt19mv72G3mFvJd7ZDj90n33+g71p1xXxN8BReOINOU6hJp81pI4aWOPeZIJFKyxdRjcMc84x0NAGhP468MwXVnby6xbLLdpHJEOcbZP8AVljjC7u27GaIvHfhiXXV0aPWrVtTaZ7YQAnPmqcMhOMBsg8E89q5nxD8KoNS8SXep2d7bwQ3iwLPa3Fn56AxKFUx4dQvyqvBDDIzirB+G2URf7WIK+Jn8Rblt+fm3fuR83bd9/2+7QB0uh+MNB1zUZLDS9RSa8RDKYijISgOCy7gNy5wMjI5pdT8W6FpmsRaXfalFHfybMQ4Ziu84XcQCFyeBuxmuS8D/DKfw14ph1q61wajLHay2xLWpSWXe4bfJIZGLMMY6D8K17rwffR+LNS1nRdc+wJqvkfboXs1mL+UNo8tyw2ErxyG9aALVv8AEDwvObvy9XhBtITcS70dMRA4LjIG5QSORkVavPGGg2n2vztSiJtfKEyxq0jJ5q7o+FBJ3AZGO1cX4a+Ev9m6xJearrI1RJbCewmD2pSWdZSCWkkMjbmwMdAPYUlh8JprHwX/AGLD4ima9a9iu5rx7c7bhI0CJBJGHBaMIqjG4cjPtQB6Loesafr2mx3+kXUd1aSEgSJnqDggg8gg9jzV+uX+HfhT/hDtAk037Wt3vupbnesHkgb2ztC7jwPrXUUAFFFFABRRRQAUUUUAFFFFAH5kePP+R217/r+n/wDQzVv4cQpL4ot3ljV0iBYhjgZxxz2qDx1FI3jHxDIqMY0v5gzAcDLnGa7L4QabaT2N/LdrmWZxFFkkDHegD2HQYbe5tYx4b1l7PUF5kR5OXI7Z9K6jVNV1C12f2xp9pqNrKmGbcFkQY5AYcmvKtE8ORR6gGYXUEaBt75PykdCKsPYX9zLHcRX8ksW7CCRiNo+lAHYxWXhC+R00XUDY6m2DHb38piz6gMeGqj44tJ447eHUtCZpWUYuNoKfUMtc/Np9tPcTS6hbC8s1Gdzy5Kn1HtWz4Y8RavpdgiWMq/2bvIVJ/wB4rL6Y/wAKAPPtT0i8sy9xHHILWU8MvzKp9x2re8Hi51a4RILRp7xPlMaYOfQgelekraaP4hsbmQwzaPJIuZZbUgxSDvmM9PwrjfEOvxeGbF9M8A2YtY5Dm51Bjmef6f3V+lAHY3WnaZobwvqdt/aGqbMxWKtmKL1LnoT7Vxmt3k3iJ7t9bRrjyATCEbCRDHARBwDWZp+vS6par5rI18vy7TwzD2PrV6GRLy8mEEq28jIMspzyODuFAGLon2BZFcwxlAn/AC1JwT3HTrUV1rMb3EzCCLbnYY04G0dx71IZrW2uRp0hW4Hm54OM/gKit7COPUZWbyFTOMPxj0HvQAySaWWBFlkjto2OUGwbiPUnuaz5LmaVGW4uHECg7Wc43D2rX1ayjtLvy7m7hkbAK+Qc4PZa5W/ga/upWnmCQqcLkYBPrQA3UrURxxSQyGTfj5SRx/hWzP4ZXWPD92bi/EUkVuWjRzne4GQornbRGidTIhZA+AwUjPpityzTUbiYyQRMFQHczEcfSgDx0gg4PWvp/wDYg/5Cfij/AK4xf+hGvnTxLYSafq80Uoxu/eLxjINfRf7EH/IT8Uf9cYv/AEI0AfWlfJf7b/8AyE/C/wD1xl/9CFfWlfJf7b//ACE/C/8A1xl/9CFAHy/Xoep2dvF4T8GyK6TNJcsrsmcEbh8vPpXnleg3WB4P8F7mOPtj/L/wMc1z4ltRVu/6M1pXu7dv8j2dIkaNiV2lxz2PTivNvi/4cE1rHrNrGzSx4ScKvVezH6dK9BhnS7BYMQyfdDDacdjU0sSyxtC8YeJgVdGPGPSvgsLiJ4Ssqi6bryPeq4dcvLL+v63Plmr+h2Lalq9pZoMmWQKfp3/TNeu6j4G0az0fVVt7d5bmQM0btkmEY3DHtx1rkPhFpQvdduLiUHyraI4I4+ZuBz+dfYLNKdShUqw05e/nseOsM1UUVr/wD2i1t4re2hjhXy0jXagX+EVw3xU8NQ3mivqdomLq2O58fxITz+vNdy77CgUDcFPPt/jUsqR3MBjlAeORdpXswr4zD4meHqxrRfX7z2Z0m4csnoz5WxVrSrRr/UrW0TlppFT8zXs83w+0i1tNUMcDSGWN2jaT/ljgZG38a4H4Vael34till+5aqZfq3QV9pDNKVajUq0/so8dYVqpGO92e5WdtHZ2sNtECscShFHXgcVwvxX8PNqemPqcKgXFmDuA/jj/APrda7mS7jwd0ig7iAP73tRJ5MimOdd8ch2sHHB9vevjMNiKmHrKst/6ue3OjzRcZLRny3UltC9xcRwxDdJIwRR6knFe2J4B0mCPU2MQkknV9mT/AKnjIK/jXn/wx0tb7xYhmBMVoDMx7ZB4/WvtKeaUqtOpUh9lHizwcqc4xbvfse16HZx6fpVtYoFVbeMR8HOTjk1xPxM8K/a9Gk1G1G66tiWcActH9PbrXb3M6mNHglVHc4IHUnvVtSpZh8u5/lZTyDxXxtDE1MPVVdb3u/Pue5Vp3puL2Z8sU6JDJKiL1YgD8a91/wCEA0mGTUZlgM81yjmOJx8sZOSMfjXmfw90Yal4tjguIt8dvukkQ9Pl6A/jX2VHNaNanOpHaKueFUwcqcopu9z23R7Yabo1vaqhEdvGI1LdSe5rl/ih4dbWtHW/tl/0y1BJQfxJ3rqJTI9yjnaIBkFRzvxU9nObiCRXi2EEqVP93sa+OpV50KqxEd73+/c96dBey5ZarqfMGDmgAlgByTxXvEXw/wBH+23F6YvMEisBCT8isR94V5b4J0gah4yt7SYYjikZ5B7Jz/hX2VDNKNeE5x+yrs8Gpg5U5Rje92e0+EdMXSNDtLdYkBWNWbH3tx5JNc98UvDq6rpbX1suLy2G7YB99O5rrnmAdZypiKghUzywqdHivEMy/NGuUwO4PXNfG08TUpV/rHW/9I96dFOHLJaNWPlykr3m28B6Na6vc32xZI5AUS2cfIpPce9eTQaI0vjMaQg4+07Pm/ug5/lX2WGzSjiebl+yru/9dDwamDlBJ3vd2Paf2TLP7F8WnjKlWbRjIwPqxQ19l18p/AYRr+0LqaQbfKTSdqhewHljFfVldeGqOrRjN9UmYVo8lSUezCiiitzIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/NnxTq1xp/izxVBbrCUurueOQvGGJXzDwM9PrXs3gHwwYfCVrfQxxErh5EgfGzIyeW714l4nt2u/iPqsCKWMmpSrgd/3hr3S5VbdUFrMkVvHCGkQgjccY20AbNysl7JasPOZF+cO56L/AHWH8X4VgapdXC3zvb7DbyqSkKnlGHXIq1p1sY7UXUkqwxxjzIUDlzg/jVeXybl5LjUFMF2+QNxI3ejKKAIbS5WOQG9iRYpQMxr8pDH1Hoa25Gh04QyWKwW8keWAbcE5HTnvVGGzuhZxbEjuMncsUpxyO+exqu11c6nP9kxtnPHkgllJ/wAKAHjxfqd1IsaaPCsfMRu1yVJ9TVDxJaXEPh6KK7ZYZZHLgblBx/Ours2tbOK60nUROmYd/wC5AKofSuK1prFdMSSKJ3mVuXd92R6YJoA5u5D6bco4lfJQMkjAHPtmrVndia4jMaqLiQY2tnv3PNZ+q3UE0MbJcFtvCxldoFZ66lNA0RaP5lORzx7UAb0mmfZruSWR2kZOf3QLHPoKINS/0w3E0Mscn3VKpkH6+9JY+MtaitXisyke3g7Y1zj69TWU8usXCEyM7b8sNg4oA6TWL77ZaxNHbRxNuALsTuf6D0rLubfdbyG2UuA253CnaD6VlR3N1bSJNcuzqvCEdB7Vv6TqASKW3uk8+Wb50jjOQD7jtQBVSc3CKLgMzIMKqL933qK0l1K4aW3tXe3U8F2wMCo9QubgXhSCHyh3VOuPftWTLezN+5t22qTyD1NADfiHo9raafY3UFy1xcklJjjgDtXsf7EH/IT8Uf8AXGL/ANCNePanarLp8kVwrmUrkEcAHtXsX7EIxqvigHqIYv8A0I0AfWdfLn7YMOnz+J/CUerzyQWRhm3vH94cjGODX1HXyX+2/wD8hPwv/wBcZf8A0IUAeGX9h4aitbyO1v5JJVjM1vIf4jnAjbjrjJ7Ve1J9Pj8PeEI0uGadZi8pKlQqFx7/AFrha2td/wCQVon/AFwb/wBCNTOCmrMqE3F6HrepeMvDVmkkFpqUrSlv9YsJdR+Oafo/jTQZ7R/tWsFCh6PAVJ9O5zXg9JXlvJcM48tte56H9qVr67H0Do/izStZ1k6bHfmTeGVf3BUOMdAc/Wn29t4f8MXYs0uktI9Qcvtcf3RjGc8c14To2oSaXqltewgGSBw4B7+1XfFev3HiLVWvJ1Ea42xxjog9KwllCVXkp6U2tdXutuvzNI5h7nPL4umi/wAj1rUvF3he3Jjt9SladWA3iIsPfPNRR+NdG3IX1nAjHIW3Izz25rxCkroWTYZKzVyP7VrHvlp4x0XUtVktTqe2NlwuYiFfjkZzV2zg8OeH7pI0mgspbw/3NobHpk8V8+2dw1rdQzpgvE4cZ6ZBzV/xLrt34g1Nry8IDYCqi/dQegrCeTw5lCnpBrXV7rbqVHMPd5pfEttrW+49m1jxH4VVpc6qDcJgAohYAg1T03xPocwuopNdYrkyKXgI2+wya8QoraOT0FHlEs1qrToe7ab4x0u81aHT01QyLIdu5rcgN6AHNaEdl4f8P6nzcw2Nzep5Z2rtVsH3PFfP9ncPaXcNxEf3kTh1+oOa1PFXiG58R6it3dBVKoEVF6CsamUR9oo09INa779OoLHtrnl8S2X9Lc9iu9c8J2V1JEupiO6UffVSwU9+fWqOk+KdFN5dCXXjtLFlZrcgcDHXNeI0lbLJ6HLZ6h/atZHv1j440S6vo7f+1ihVuGMJCufTOaui20Pw/dCW4nt7K41D5C6x7d/OfXjrXzxFI0UqSL95WDDPqK3vGfiWXxLe288kXlLDEIwuc89zWFTJ4Koo0laDWu/y69wjj7rnl8S2X9I9d1bxN4Y05JYRqrfaQhUNEhcqfzxWRpHi/RkDl9ZdZXbeWa2I5xj1rxjNFdEMnw6jyvUX9q1k/LzPcbfxzpEmrRwPqbmNiFDLbkLyehOa0b2z0DQNWj1AslpJeHyDIY+GJ5z14+tfPqkggg8iug8WeJ7jxEbQTRiJLeMIFBzlu7VjUymKqRVJWi01LV/LqVHMW05T3W23+R6p4i8QeFovNtTqkpmjU7GiQsFb655rJ0Txnp0QEEusukca7gxtSNzY5/i715DSV0QynDqHI1ch5pWv5HucnjvRnvYYG1PfC2AWFseCcc5zWhr1poGk3o1u4kFtNN+684xk793cDPpXz7mt7xH4nu9es9Pt7oKFs49gK/xn1NYTyiEZw9irR1UtXt95cMxbTct1srf8A+hP2fntJP2gtUbT5lmtzpZw69Ccx5r6xr4l/Yz/AOSqXf8A2DZP/Q0r7ar1qVNUoKC6Kx5tSftJub6hRRRWhAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+ethp8t18WNYnRcLDfzsGI/i8wgY9TXpmp2lyl3OLuB443wVLqSGOOxHSoPh/psD634tuby2uJGl1Gc28kT4MexzkgfWvUtLNvqwSCWZVfAlInyjlh6HpigDzW5vprcwpHY2wLINio+SPU1BFJJLdibz2d8ZIAJK89D6V6D4j8M6b9lad4wl27bSZQCG/3T0Arl7uxa2Y2xMMcoISXZnK+mD3oAGsZILp2nuJH82MmKKVsBs+hHQ1zdvBM90zRWzxNBwwV/wD0I1d1Ge4nihtPs7SfZvmeRWIOPyqf+1DLKsQuEjjb5XaNcEfXsaAG3D3RjgWa2S2vJj+7ZujD13dMVz/iqIiyla9O+TOJAOx7Yx1Fd5b3r2em288L20yLuUNNlmQf7vYVyE8UcrEzyJcWznzGXBQfQUAeco8LAQEKo6gEf1NKlukiS7tuB9x2FejP4VtNUWKPT1aKRvm2MOo9ATXOahoE+m3NxAJWXyzyhAxQBJ4KNss8hkto3CpwSuQD61oBFuLmdZFeO3YZ3hM/hxTPCGkTxTm4aAyRsD904U11s1rLdW8WIfs9ujYCqMhj9c0AcjZ2tu0hhFp5asf9YDk49faks9KP9pNFZpJsAyZCMkj6Vr6q8ljqbCKNtxwDtQHHp7VJcxz2iObqZVZk3hh1Ht7UAN1DS0ktJbma9bO3Z88eAvtXK6hpJXy5ItrcZLovAFbOqXUElinkGUQ9cSS/ebvwKyrSQSW0i3ZZIT9z5yTmgDnby2meAvwcv95m5Ptivb/2P7dLbxT4uji3bPJgYBhgjJPavE7iA2sjzHdJCThG3YGa9u/ZDbf4p8Vnn/j3g6nPc0AfUNed/FT4TaL8Sbiwm1q5vYGs1ZEFuygEMcnOQfSvRKKAPn//AIZY8G/9BHWP+/if/E1LL+zB4Tmjijl1XWmSIbUBkT5R1x92ve6KAPn/AP4ZY8G/9BHWP+/if/E0f8MseDf+gjrH/fxP/ia+gKKAPn//AIZY8G/9BHWP+/if/E0f8MseDf8AoI6x/wB/E/8Aia+gKKAPn/8A4ZY8G/8AQR1j/v4n/wATR/wyx4N/6COsf9/E/wDia+gKKAPn/wD4ZY8G/wDQR1j/AL+J/wDE0f8ADLHg3/oI6x/38T/4mvoCigD5/wD+GWPBv/QR1j/v4n/xNH/DLHg3/oI6x/38T/4mvoCigD5//wCGWPBv/QR1j/v4n/xNH/DLHg3/AKCOsf8AfxP/AImvoCigD5//AOGWPBv/AEEdY/7+J/8AE0f8MseDf+gjrH/fxP8A4mvoCigD5/8A+GWPBv8A0EdY/wC/if8AxNH/AAyx4N/6COsf9/E/+Jr6AooA+f8A/hljwb/0EdY/7+J/8TR/wyx4N/6COsf9/E/+Jr6AooA+f/8Ahljwb/0EdY/7+J/8TR/wyx4N/wCgjrH/AH8T/wCJr6AooA+f/wDhljwb/wBBHWP+/if/ABNH/DLHg3/oI6x/38T/AOJr6AooA+f/APhljwb/ANBHWP8Av4n/AMTR/wAMseDf+gjrH/fxP/ia+gKKAPLfhn8E/D/w88QSavo93qE1w8DQFbh1K7SQc8Ac8CvUqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5a8DX7W1prAsobWa6TUrzfHI2HYeYeBniukW4tryMTQxSWk7IBIjDqO4HavO/Cjv8Ab9YIjYvHql0Y3GBj94c89/pXUaFfNK13BqtzbhZCWR+gQ++OmaANa9v2j0iOOCQStG5EPmYIT2bNZ0d5cOJi0iyzhAwVVBGf8KIBDAksdx9lZO8iyHk9sg1PLNeBdrLbW7LjaeCSvoPrQA8F7+OP7ZJbFnwGG/yvwDAc/jVo+HNIsrkG70p9sy58yGbIx7npUkNpEmmoLqSGMP8AdU/KQfRgetVI7QW5uNrTRKVx5cR+U/nx+VAEZ0y1eRINMvLW2tixCpdnfj/gVV9e8OQyxM1xren3N0nIghAX88dq2dDn082E1vf6f5Eyg4VkyWB/iGa55/BWn2tzLdW2qCWSRDI0TOBsHpwevtQBSj0PVHhtDBDI8bfKkkLfKCaux+FNSivYbbUBbLFnOWcblz79xW3aWunJp9gEkRGMgPLucDvnBrc1m00q8lge1uoDJG2VMUJxn0LGgDndX8P6TpFlMLvVkSyVC2yOT52b0GO1cXqWp6Tb2kEVlc3VzGRuEZY4B/3u1emS2NrrqrDdLAnlEs0UIBkYfh2rlXi03T79oLbT1eK0y7LdLtC++Mc0AcdJqomnFtpulTv5uMJlm3N67q2dT0O88hEvLK0t3KjfGbkmQ/qa0tS8RWEaLJHE6sziSQhlRMDptArMXXNMS4nu5rN7o9VeIZPPqxoAxL3w75kCwKFMatyxfGT6Vja5pa2lqhSUwyKcFG5IrobrUpLzUYZhAtrAOEU8j659az7mZrO4nmYJdLzgM+SD7UAcvqVxNcW8cSQK0EfAOMEn1Nev/sggjxR4rBKki3gztGB1NeSySmWX/Ro1VpDypbp716/+yZF5Pi/xam4MRbwZI9cmgD6cooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+U/CEQuftUUccRlj1O8csRkkeaeDW9dnTvtUlubFFMifvgj7SR649K6tPgbDb6hcXWn+K9atPNuJLgRxrEQjO2TjK9KSb4H+dd/aZPGWttP037Ic/8AoNAHBXGkxXP+k6cRIkAKOkzcAfXpSCzurmFbqe3eZUXaZIjwB2yOhr0H/hSbiKSMeM9cVH+8qxwgH/x2p7X4PXNpD5Vt431yOPG3ascOMfTZQB5neXV/HtaQNNYRsGCqMsh9AaS+1W6nuYkhcQwgCT5sE/j6V6LH8E3jiaNPGuuhGOSNsPP/AI7UcXwMWKKSNPGGtbJPvAxwnP8A45QBwup6vNqlrC9zJ57xqREIlC4Pue9ZWqXcmmafGfsUZndSxkeDDKf5GvT4vgWsVr9mi8Ya2sH9wJDj/wBBovfgYL5Y1u/GeuyrGMKGWLj/AMdoA800z4mf2ZosAh0qza4HBaVCSaybv4uatb3TyWVtZ2okOXRIsjPrzXph/Zr0kvuPifWs9ekf/wATSf8ADNWkZJ/4SXWCSc8rEf8A2WgDxa88d689800V0Y/NGSwAQgfhVWPUbq7vWkmu7h1b/WOWyDXuMn7M+jyPufxLrJP0j/8AiatWv7O2n2seyDxRrCqTu+5Eef8AvmgDyGz8NR3F5aeZFLi4bbAGICk+pzXf6p4KvPD+nQyXM1o0Pckc/T0rs7j4KyXKxibxnrbeXwn7uH5f/HKj1T4HtqsaR6h428QTon3VbysD/wAdoA8iv7fTrmzWb7eVl38I2Nv4AVQXTpp4prGHylY/M8wYDj0Neuwfs8WEEokj8U6yHHQ7Ij/7LU0XwAtopfMj8Wa0H652Q/8AxNAHzbqml3Fpd7GmaQL1Ma4AH416/wDsilT4r8WbFIH2eAc9Tyea6q8/Zz0+8JNz4q1xyeTxGM/+O12Hwq+FGnfDq91G5sNSvb2S9REf7Rt+UKTjGAPWgD0aiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top panel shows the isthmus of the ductus venosus, which is identified by the sudden acceleration of blood flow visible on color Doppler. The second panel shows a segment of umbilical cord (color coded in blue). The directionality of blood flow of the hepatic veins can be assessed in a transverse view of the upper abdomen as seen in the third panel. Red indicates blood flow towards the transducer while blue indicates flow in the opposite direction. The inferior vena cava is best imaged in a coronal plane above the renal vein and below the infundibulum. All precordial veins show the typical triphasic waveform pattern, although the relationship of forward and reverse velocities varies according to the pressure difference to the right atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14823=[""].join("\n");
var outline_f14_30_14823=null;
var title_f14_30_14824="Diagnosis of Hymenoptera venom allergy";
var content_f14_30_14824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of Hymenoptera venom allergy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14824/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14824/contributors\">",
"     James M Tracy, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14824/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14824/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/30/14824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of serious sting-related reactions are caused by insects belonging to the order Hymenoptera. Within this order, three families are medically important:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Apidae family (honeybees and bumblebees).",
"     </li>",
"     <li>",
"      The Vespidae family (yellow jackets, yellow hornets, white faced hornets, and paper wasps).",
"     </li>",
"     <li>",
"      The Formicidae family (fire ants, harvester ants, bulldog ants, and jack jumper ants). Allergy to fire ant venom is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=see_link\">",
"       \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of Hymenoptera allergy (except ants), which is based upon the clinical history and testing for the presence of venom-specific IgE antibodies, will be reviewed here. Accurate diagnosis of venom allergy is important because patients with venom allergy are candidates for venom immunotherapy, a treatment which can dramatically reduce the risk of recurrent severe reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/1\">",
"     1",
"    </a>",
"    ]. The indications and protocols for venom immunotherapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most people develop only minor local reactions to Hymenoptera stings. A local reaction is defined as any reaction in which the signs and symptoms are confined to tissues contiguous with the sting site. These reactions are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link&amp;anchor=H4#H4\">",
"     \"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management\", section on 'Local reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, systemic reactions cause signs and symptoms throughout the body and include a spectrum of manifestations, ranging from mild to life-threatening. Mild systemic reactions may be limited to the skin and consist of flushing, urticaria, and angioedema. More severe systemic reactions (ie, anaphylaxis) can involve bronchospasm, laryngeal edema, and hypotension. Venom-induced anaphylaxis can be particularly severe and is a leading cause of fatal anaphylaxis. Systemic reactions are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link&amp;anchor=H10#H10\">",
"     \"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management\", section on 'Systemic allergic reactions/anaphylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in diagnosis is to determine whether the patient's reaction was local or systemic. The following questions need to be addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How long ago did the sting event occur?",
"     </li>",
"     <li>",
"      How many stings were sustained?",
"     </li>",
"     <li>",
"      After the stings occurred, how much time elapsed before symptoms first appeared?",
"     </li>",
"     <li>",
"      Where on the body did the sting occur? As an example, a sting on the face could cause extensive facial angioedema as part of a local reaction, but the same symptom from a sting on the leg would indicate a systemic response.",
"     </li>",
"     <li>",
"      Patients should be asked specifically about symptoms affecting various organ systems, as the most memorable symptom is typically reported while other symptoms are overlooked.",
"     </li>",
"     <li>",
"      Which insect does the patient believe stung them (although often not reliable)?",
"     </li>",
"     <li>",
"      Was the patient taking any medications that might have worsened the response to the sting, such as beta blockers? This information is relevant to risk assessment.",
"     </li>",
"     <li>",
"      How was the reaction treated and were there any delayed symptoms?",
"     </li>",
"     <li>",
"      Were there any previous stings, and if so, did those result in normal, large local, or systemic symptoms?",
"     </li>",
"     <li>",
"      Have there been any subsequent stings, and if so, what symptoms developed?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If possible, any records that can be retrieved from emergency medical services or emergency departments should be reviewed.",
"   </p>",
"   <p>",
"    Patients with systemic reactions should be evaluated further with testing for venom-specific IgE. Testing of patients with local reactions is not usually necessary. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Testing for large local reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hymenoptera stings are acutely painful and patients are usually aware that a sting has occurred, although they may not have visualized the insect clearly. Testing for venom-specific IgE is essential for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Hymenoptera allergy requires both of the following elements [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of a sting event that resulted in a systemic allergic reaction",
"     </li>",
"     <li>",
"      Evidence of venom-specific IgE, either by skin testing or in vitro testing (ie, IgE immunoassay)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Identification of the culprit species",
"    </span>",
"    &nbsp;&mdash;&nbsp;A culprit species can sometimes be identified based upon the patient's geographical location or setting in which the sting occurred. In addition, nests may be seen. Physical features and behaviors of the different Hymenoptera species are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9271?source=see_link\">",
"     \"Bees, yellow jackets, hornets, and wasps: Biology and identification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TESTING FOR VENOM-SPECIFIC IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for venom-specific IgE can be performed by skin testing or in vitro testing. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Skin testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'In vitro testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The indications for testing for venom-specific IgE vary with the patient population and are different in adults and children. One limitation to testing is that up to 27 percent of the general adult population has detectable venom-specific IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/3\">",
"     3",
"    </a>",
"    ]. The presence of this antibody, without the history of a systemic reaction to a previous sting, is not sufficient to predict that the patient is at high risk for a systemic reaction to a future sting. Thus, venom skin testing is NOT indicated in an individual who has never experienced a sting event or who has been stung and experienced only a local reaction. One possible exception to this statement is the patient with unavoidable exposure and frequent large local reactions who finds these reactions sufficiently disabling that venom immunotherapy would be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link&amp;anchor=H14#H14\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\", section on 'Patients with large local reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any person older than 16 years of age who has experienced a",
"    <span class=\"nowrap\">",
"     systemic/anaphylactic",
"    </span>",
"    reaction to a suspected Hymenoptera insect is a candidate for skin testing with venoms. This includes older adults in whom the stinging event and systemic reaction occurred decades earlier, because the risk of another reaction can persist for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, skin testing is generally NOT indicated in patients 16 years of age or younger and who have had systemic reactions limited to the skin (ie,",
"    <span class=\"nowrap\">",
"     urticaria/angioedema).",
"    </span>",
"    These patients have only a 10 percent chance of a future systemic reaction, and a less than 3 percent chance that it will be more severe than the index reaction. The natural history of cutaneous reactions in children is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link&amp;anchor=H2#H2\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\", section on 'Natural history of systemic allergic reactions to venom'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On occasion, an individual who has never been stung will present with concern about the possibility of developing a severe reaction to a sting because one or more family members has Hymenoptera venom allergy. Testing for venom-specific IgE is not indicated in this situation. The best approach to assisting such patients may vary. Many people can be simply reassured that they are not at increased risk for a serious reaction despite their family history. Others are reassured by the advice to carry an epinephrine autoinjector, accompanied by clear instructions on how and when to use it. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"     \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"     \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SKIN TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing should be performed by an",
"    <span class=\"nowrap\">",
"     allergist/immunologist",
"    </span>",
"    who has training and experience in the diagnosis and treatment of insect allergy. Skin testing is preferred over in vitro methods for initial testing in most cases because it is somewhat more sensitive and usually less costly. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Interpretation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Timing of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the sting event was recent, at least four to six weeks should be allowed to elapse before skin testing is performed. Many patients demonstrate reduced skin sensitivity to venom within the first few weeks after a systemic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/7\">",
"     7",
"    </a>",
"    ]. If skin testing is nevertheless performed during this period, a negative result (ie, lack of response), even with a good response to the histamine control should be interpreted with great caution, and the test should be repeated at a later date,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a serum test for venom specific IgE could be done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of venoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that recombinant allergen-based IgE testing may have a potential role in distinguishing between bee and wasp allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/8\">",
"     8",
"    </a>",
"    ]. However, often the insect that caused the sting cannot be identified. Therefore, testing should be performed with venoms from all potentially relevant insects for the geographic area in question. In the United States, skin testing should include all of the following venoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Honey bee",
"     </li>",
"     <li>",
"      Yellow jacket",
"     </li>",
"     <li>",
"      Yellow hornet",
"     </li>",
"     <li>",
"      White-faced hornet",
"     </li>",
"     <li>",
"      Wasp",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allergy reactions to bumblebee field stings are rare compared to other hymenoptera because of their nonaggressive behavior. However, allergic reactions have been reported, including during occupational exposure in greenhouse workers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Specific bumblebee venom would be optimal for skin testing and immunotherapy, but is currently not available in the US. There is some cross-reactivity between honeybee and bumblebee venoms and some individuals are sensitized to both. When honeybee venom sensitivity is detected in patients with bumblebee sting allergy, honeybee venom immunotherapy would be indicated.",
"   </p>",
"   <p>",
"    Clinicians practicing in areas inhabited by venomous ants should also be mindful of these insects as a possible cause of systemic reactions to stings. Patients can usually tell ant stings from other Hymenoptera stings, but the history is sometimes ambiguous (eg, a sting on a child's scalp may not be noticed until well after an event) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/11\">",
"     11",
"    </a>",
"    ]. If there is uncertainty, then the patient should be tested for ant venom allergy also. The geographical location of fire ants and testing for fire ant allergy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7752?source=see_link\">",
"     \"Entomology and control of imported fire ants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=see_link\">",
"     \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing with Hymenoptera venoms is most commonly performed using the intracutaneous (intradermal) technique. Unlike skin testing for other types of allergies, prick (epicutaneous) testing is not routinely done first, although this may be prudent in patients who experienced severe anaphylaxis and may be highly sensitive to venom. A concentration of 100",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is used for prick testing.",
"   </p>",
"   <p>",
"    Intradermal testing should be accompanied by appropriate positive and negative controls. Intradermal testing should begin with venom concentrations between 0.001 to 0.01",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Testing then proceeds at intervals of 20 to 30 minutes with incremental 10-fold increases in concentration until a positive skin test response occurs or a maximum concentration of 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is reached. Higher concentrations may result in irritant reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A general discussion of allergy skin testing, including medications which may interfere with interpretation of the results, is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive skin test response at a concentration &le;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    confirms the presence of venom-specific IgE antibodies. Approximately 25 percent of patients are positive only to the 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Venom skin testing is positive in 70 to 90 percent of patients with a convincing clinical history of a systemic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/7,15-18\">",
"     7,15-18",
"    </a>",
"    ]. If skin testing is negative in a patient with a suggestive history, then in vitro testing should be performed. In addition, skin testing should be repeated after 6 to 12 weeks. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'In vitro testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Various patterns of cross sensitivity are seen, and patients may test positive to species to which they have no known exposure. Many patients show sensitivity to both yellow jackets and hornets, whereas cross sensitivity between honeybee and other venoms is unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, positivity to both honeybee and yellow jacket venom is occasionally observed and is believed to be due to cross-reacting carbohydrate determinants, which are not believed to be clinically relevant. Choice of venoms for use in immunotherapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H3#H3\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Venom selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with positive venom skin tests, neither the size of the wheal and flare reaction, nor the concentration to which the patient reacts, reliably predicts the severity of future systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/15,22\">",
"     15,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing to venom allergens rarely results in systemic allergic reactions, although this adverse effect is possible with any type of skin testing, as discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     False positive and false negative results",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive or negative results may arise from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-specific irritant responses may result in false positive results with intradermal injection of venom at concentrations above 1",
"      <span class=\"nowrap\">",
"       mcg/mL,",
"      </span>",
"      as mentioned previously [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      False negative results may occur if a patient is tested too soon after a systemic reaction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Timing of testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mastocytosis may experience anaphylaxis in response to insect stings, as well as a variety of other triggers. These individuals usually have demonstrable venom-specific IgE, but some do not [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/23\">",
"       23",
"      </a>",
"      ]. Those without apparent IgE may be reacting non-specifically to vasoactive components in venom. Elevations in serum tryptase may be used to screen for systemic mastocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"       \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IN VITRO TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro testing for venom-specific IgE is indicated for purposes of diagnosis in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/15,22,24\">",
"     15,22,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a convincing clinical history of systemic symptoms to a sting and negative skin testing.",
"     </li>",
"     <li>",
"      Patients who cannot be skin tested because they have dermatographism or severe or active skin diseases.",
"     </li>",
"     <li>",
"      Patients who cannot be skin tested because they are unable to discontinue medications that can render the skin unreactive (eg, high dose tricyclic antidepressants).",
"     </li>",
"     <li>",
"      There is a need for evaluation in the initial weeks following a systemic event and concern about skin reactivity being suppressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Commercially available immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many commercial laboratories perform venom-specific IgE testing, but the assays used are not necessarily equivalent and the utility of different tests, even within one system, is variable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ImmunoCAP&reg; is recognized as a reliable commercial assay that retains reasonable accuracy in patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      therapy. Other commercial assays may also perform well, although it is important to obtain information about the sensitivity and specificity of the assay used.",
"     </li>",
"     <li>",
"      The Johns Hopkins laboratory performs a higher-sensitivity assay, which can detect up to 6 percent of cases not detected by the ImmunoCAP&reg; (when both assays are performed in parallel) and &gt;10 percent of cases not detectable with other assays [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/25\">",
"       25",
"      </a>",
"      ]. This high-sensitivity assay should be considered if standard commercial immunoassays are negative in a patient with a severe past sting reaction and negative skin tests [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is considerable cross-reactivity between honeybee and vespids (specifically yellow jacket). This may present a problem in distinguishing the relevant insect species for venom immunotherapy. Component resolved diagnostics using recombinant venom assays, though not FDA approved and not widely available in the United States, show some diagnostic promise in distinguishing true double sensitization from cross-reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/26-28\">",
"       26-28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of skin testing and in vitro testing, with the high-sensitivity assay if necessary, should detect 98 percent of patients who will have a systemic reaction to a subsequent sting. The remaining patients pose a diagnostic dilemma that is discussed below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Systemic reactions with no evidence of venom IgE'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of elevation of venom-specific IgE antibodies cannot be used to accurately predict the occurrence or severity of a systemic sting reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/15,22\">",
"     15,22",
"    </a>",
"    ]. In vitro tests and skin tests are similar in this respect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPARISON OF TESTING METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing and in vitro immunoassays for venom-specific IgE are complementary. Up to 20 percent of skin-test-positive individuals have undetectable serum levels of venom-specific IgE. On the other hand, 10 to 20 percent of patients with negative skin tests may have positive in vitro results when high-sensitivity assays are included [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/25,29\">",
"     25,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER DIAGNOSTIC ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Screening for occult mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe anaphylaxis to insect stings is one of the more common presenting signs of indolent systemic mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Screening for mast cells disorders should be considered in any patient who experienced hypotension as part of a systemic reaction to a sting, particularly if",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    were absent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/34\">",
"     34",
"    </a>",
"    ]. This can be accomplished by obtaining a baseline serum tryptase level after the systemic reaction has fully subsided and the patient has returned to their baseline state. Further evaluation for systemic mastocytosis (ie, with additionally laboratory studies and bone marrow biopsy) is indicated in patients with baseline serum tryptase &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and should be considered for levels &gt;11.4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    if the patients has signs or symptoms suggestive of a mast cell disorder. The threshold baseline tryptase that is considered abnormal is evolving, and other experts may use slightly different values in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Systemic reactions with no evidence of venom IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A negative test result for venom-specific IgE should be interpreted with caution, especially when done within the first few weeks following a sting reaction, as mentioned previously [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/15,22\">",
"     15,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Timing of testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Rare occurrences of anaphylaxis have been reported in individuals with negative skin testing in addition to negative in vitro methods [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/22\">",
"     22",
"    </a>",
"    ]. The pathogenesis of these reactions may involve non-IgE mechanisms such as mast cell disorders, although no specific evidence for this mechanism exists [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/24\">",
"     24",
"    </a>",
"    ]. Such patients should have baseline serum tryptase levels to exclude the presence of occult mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient has no clinical features or elevations in baseline tryptase to suggest mastocytosis, then we repeat skin testing and in vitro testing in three to six months. Some European centers have experience with basophil activation assays for detecting venom allergy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/23\">",
"     23",
"    </a>",
"    ], although this testing method is not widely used in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3879086\">",
"    <span class=\"h2\">",
"     Basophils/basophil activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our understanding of the role of basophils in the diagnosis and management of insect anaphylaxis continues to evolve. Although not commonly used in the United States, the basophil activation test may play a role in the future in managing individuals with a history of systemic reactions to insect stings but negative venom tests [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the patient is waiting to be retested, they should carry one or more doses of epinephrine for autoinjection at all times and avoid contact with Hymenoptera. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/22/6502?source=see_link\">",
"     \"Bees, yellow jackets, hornets, and wasps: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, a patient with a history of a severe sting reaction will not have demonstrable venom-specific IgE, even upon repeat testing. Of those patients who have a history of a past systemic reaction and react again to a subsequent sting, 98 percent have demonstrable venom IgE by skin tests or in vitro tests, and 2 percent do not. We counsel this remaining group of patients in Hymenoptera avoidance and instruct them in how and when to self-administer epinephrine.",
"   </p>",
"   <p>",
"    This 2 percent is probably made up of individuals with mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    disorders, other disorders that predispose to anaphylaxis that have yet to be defined,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venom allergy that is not detectable using currently available assays. Patients with these characteristics also account for some portion of the 98 percent with detectable venom IgE, although there is no way to distinguish most of them at the outset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Sting challenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sting challenges are rarely performed outside of research settings. However, some investigators have proposed that a sting challenge be used to diagnose venom allergy and select patients for VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/1\">",
"     1",
"    </a>",
"    ]. However, challenges carry risk and are impractical in most settings. In addition, challenge results are not always reproducible or representative of the outcome of field stings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/1,40\">",
"     1,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Testing for large local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large local reactions are usually caused by an IgE mediated late-phase response and carry no more than a 5 to 10 percent risk of a future systemic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Therefore, venom testing and venom immunotherapy are generally not indicated. Despite this, data suggest that venom immunotherapy can successfully prevent future large local reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14824/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Patients with extreme and debilitating, or progressively worsening, large local reactions may want to pursue venom immunotherapy for this purpose, in which case testing is indicated. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/42/25250?source=see_link\">",
"       \"Patient information: Insect allergy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Hymenoptera allergy requires BOTH a history of a sting event that resulted in a systemic reaction, AND evidence of venom-specific IgE, either by skin testing or in vitro testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial step in diagnosis is to determine whether the patient's past sting reaction was local or systemic, based upon the clinical history. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, skin testing is the preferred initial method for demonstrating venom-specific IgE. Venom skin testing is positive in 70 to 90 percent of patients with a history suggestive of venom allergy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications for testing for venom-specific IgE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin testing should be performed using the venoms of all the Hymenoptera insects known to reside in the patient's geographical area. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If skin testing is negative, venom-specific IgE immunoassays should be obtained. The combination of skin testing and in vitro testing can detect about 98 percent of patients who will suffer another systemic reaction if stung again. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'In vitro testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Comparison of testing methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We screen all patients whose systemic reactions to Hymenoptera stings involved hypotension for mast cell disorders, by obtaining a serum tryptase level when the patient is in a stable baseline state. Any elevation in serum tryptase should be evaluated further. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Screening for occult mastocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If both skin testing and in vitro testing are negative, serum tryptase is normal, and yet there is a convincing history of a systemic reaction, then the patient should be re-tested for venom-specific IgE in three to six months. In addition, the patient should be educated about appropriate sting avoidance and treatment of reactions. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Systemic reactions with no evidence of venom IgE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the people involved in the writing, editing, or review of this topic have any financial interest in the diagnostic tests discussed.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/1\">",
"      Franken HH, Dubois AE, Minkema HJ, et al. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol 1994; 93:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/2\">",
"      Freeman TM. Clinical practice. Hypersensitivity to hymenoptera stings. N Engl J Med 2004; 351:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/3\">",
"      Golden DB, Marsh DG, Kagey-Sobotka A, et al. Epidemiology of insect venom sensitivity. JAMA 1989; 262:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/4\">",
"      Golden DB, Breisch NL, Hamilton RG, et al. Clinical and entomological factors influence the outcome of sting challenge studies. J Allergy Clin Immunol 2006; 117:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/5\">",
"      Light WC, Reisman RE, Shimizu M, Arbesman CE. Unusual reactions following insect stings. Clinical features and immunologic analysis. J Allergy Clin Immunol 1977; 59:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/6\">",
"      Reisman RE. Unusual reactions to insect stings. Curr Opin Allergy Clin Immunol 2005; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/7\">",
"      Goldberg A, Confino-Cohen R. Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J Allergy Clin Immunol 1997; 100:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/8\">",
"      Mittermann I, Zidarn M, Silar M, et al. Recombinant allergen-based IgE testing to distinguish bee and wasp allergy. J Allergy Clin Immunol 2010; 125:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/9\">",
"      Hoffman DR, El-Choufani SE, Smith MM, de Groot H. Occupational allergy to bumblebees: allergens of Bombus terrestris. J Allergy Clin Immunol 2001; 108:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/10\">",
"      de Groot H. Allergy to bumblebees. Curr Opin Allergy Clin Immunol 2006; 6:294.",
"     </a>",
"    </li>",
"    <li>",
"     Regularly updated maps of the fire ant range and agriculture quarantine areas within the United States. www.aphis.usda.gov/plant_health/plant_pest_info/fireants/downloads/fireant.pdf (Accessed on September 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/12\">",
"      Georgitis JW, Reisman RE. Venom skin tests in insect-allergic and insect-nonallergic populations. J Allergy Clin Immunol 1985; 76:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/13\">",
"      Bil&oacute; BM, Rueff F, Mosbech H, et al. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/14\">",
"      Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/15\">",
"      Golden DB, Kagey-Sobotka A, Norman PS, et al. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001; 107:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/16\">",
"      Golden DB, Marsh DG, Freidhoff LR, et al. Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol 1997; 100:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/17\">",
"      Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/18\">",
"      Parker JL, Santrach PJ, Dahlberg MJ, Yunginger JW. Evaluation of Hymenoptera-sting sensitivity with deliberate sting challenges: inadequacy of present diagnostic methods. J Allergy Clin Immunol 1982; 69:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/19\">",
"      Hoffman DR. Allergens in Hymenoptera venom. XXV: The amino acid sequences of antigen 5 molecules and the structural basis of antigenic cross-reactivity. J Allergy Clin Immunol 1993; 92:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/20\">",
"      King TP, Joslyn A, Kochoumian L. Antigenic cross-reactivity of venom proteins from hornets, wasps, and yellow jackets. J Allergy Clin Immunol 1985; 75:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/21\">",
"      Reisman RE, Mueller U, Wypych J, et al. Comparison of the allergenicity and antigenicity of yellow jacket and hornet venoms. J Allergy Clin Immunol 1982; 69:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/22\">",
"      Reisman RE. Insect sting allergy: the dilemma of the negative skin test reactor. J Allergy Clin Immunol 2001; 107:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/23\">",
"      Niedoszytko M, de Monchy J, van Doormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/24\">",
"      Golden DB, Tracy JM, Freeman TM, et al. Negative venom skin test results in patients with histories of systemic reaction to a sting. J Allergy Clin Immunol 2003; 112:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/25\">",
"      Hamilton RG. Diagnostic methods for insect sting allergy. Curr Opin Allergy Clin Immunol 2004; 4:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/26\">",
"      Eberlein B, Krischan L, Darsow U, et al. Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants. J Allergy Clin Immunol 2012; 130:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/27\">",
"      Koro&scaron;ec P, Valenta R, Mittermann I, et al. High sensitivity of CAP-FEIA rVes v 5 and rVes v 1 for diagnosis of Vespula venom allergy. J Allergy Clin Immunol 2012; 129:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/28\">",
"      Koro&scaron;ec P, Valenta R, Mittermann I, et al. Low sensitivity of commercially available rApi m 1 for diagnosis of honeybee venom allergy. J Allergy Clin Immunol 2011; 128:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/29\">",
"      Hamilton RG. Responsibility for quality IgE antibody results rests ultimately with the referring physician. Ann Allergy Asthma Immunol 2001; 86:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/30\">",
"      Gonz&aacute;lez de Olano D, Alvarez-Twose I, Esteban-L&oacute;pez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/31\">",
"      Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/32\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/33\">",
"      Bonadonna P, Zanotti R, M&uuml;ller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010; 10:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/34\">",
"      Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012; 130:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/35\">",
"      Haeberli G, Br&ouml;nnimann M, Hunziker T, M&uuml;ller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/36\">",
"      M&uuml;ller UR. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy 2009; 39:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/37\">",
"      Kosnik M, Korosec P. Importance of basophil activation testing in insect venom allergy. Allergy Asthma Clin Immunol 2009; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/38\">",
"      Korosec P, Erzen R, Silar M, et al. Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin Exp Allergy 2009; 39:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/39\">",
"      Peternelj A, Silar M, Bajrovic N, et al. Diagnostic value of the basophil activation test in evaluating Hymenoptera venom sensitization. Wien Klin Wochenschr 2009; 121:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/40\">",
"      van der Linden PW, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994; 94:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/41\">",
"      Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr 1984; 104:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/42\">",
"      Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/43\">",
"      Golden DB, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 2009; 123:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14824/abstract/44\">",
"      Walker R, Jacobs J, Tankersley M, et al. Rush immunotherapy for the prevention of large local reactions secondary to imported fire ant stings. J Allergy Clin Immunol 1999; 103:S180 (Abstract).",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4095 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14824=[""].join("\n");
var outline_f14_30_14824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Identification of the culprit species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS FOR TESTING FOR VENOM-SPECIFIC IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SKIN TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Timing of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of venoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      False positive and false negative results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IN VITRO TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Commercially available immunoassays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPARISON OF TESTING METHODS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER DIAGNOSTIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Screening for occult mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Systemic reactions with no evidence of venom IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3879086\">",
"      Basophils/basophil activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Sting challenges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Testing for large local reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=related_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/22/6502?source=related_link\">",
"      Bees, yellow jackets, hornets, and wasps: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9271?source=related_link\">",
"      Bees, yellow jackets, hornets, and wasps: Biology and identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7752?source=related_link\">",
"      Entomology and control of imported fire ants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/42/25250?source=related_link\">",
"      Patient information: Insect allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_30_14825="Screening for inherited thrombophilia in children";
var content_f14_30_14825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for inherited thrombophilia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14825/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14825/contributors\">",
"     Lisa A Michaels, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14825/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14825/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/30/14825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia (IT) is defined as a genetically acquired predisposition to venous thrombosis. Screening for IT is now available because numerous genetic disorders associated with hypercoagulability have been identified. Although venous thrombosis (VT) is uncommon in children, the significant morbidity and mortality resulting from venous thromboembolism (VTE) has led to a desire to identify children with IT. However, there is debate about whether screening for IT is clinically beneficial for both the pediatric and adult populations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of screening children for inherited thrombophilia will be reviewed here. The diagnostic approach and treatment of the child with thrombosis and of the infant with purpura fulminans are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H10#H10\">",
"     \"Protein C deficiency\", section on 'Neonatal purpura fulminans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism (VTE) is uncommon in children but is associated with significant morbidity and mortality. It has been proposed that identifying children with IT may be beneficial by helping to reduce the likelihood of primary or recurrent VTE, or to modify therapy in children with VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of any screening program is dependent upon the prevalence of the disorder in the population of interest, the cost of screening, and the availability of a safe and effective intervention if the disorder is detected.",
"   </p>",
"   <p>",
"    In children, the overall reported incidence of pediatric VTE is sufficiently low (ranging from 0.1 to 0.5 per 10,000 children), so universal screening would not be cost effective. However, it has been proposed that screening may be useful in selected pediatric populations with a higher prevalence of thrombosis, which is similar to guidelines for select adult populations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/8\">",
"     8",
"    </a>",
"    ]. Such groups of children include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children with an initial episode of venous thrombosis (VT)",
"     </li>",
"     <li>",
"      Children with a stroke",
"     </li>",
"     <li>",
"      Asymptomatic children with a family history of thrombophilia or VT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One also needs to weigh the risk and benefit of a possible intervention. In the case of children with IT, the benefit of preventing VTE must be balanced against the risk of bleeding from anticoagulation. If one accepts that the benefit of thrombophilia testing outweighs the risks of preventive therapy for a selected pediatric population, other issues to be considered include the ethics of childhood screening, optimal timing for screening, test selection, and interpretation of test results.",
"   </p>",
"   <p>",
"    Negative test results may not rule out the possibility of an inherited thrombophilia in families with a strong history of thrombosis, especially when an affected family member is not available for testing. &nbsp;It is likely that the current suggested battery for IT is incomplete and that other tests may become available in the future. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Pretesting consultation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts in the field agree that the basic screening panel for IT includes assays for the following proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor V Leiden (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prothrombin G20210 A (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein C (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein S (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antithrombin&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other centers may also include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fasting plasma homocysteine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"       \"Overview of homocysteine\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lipoprotein (a) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"       \"Lipoprotein(a) and cardiovascular disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fibrinogen (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H11#H11\">",
"       \"Disorders of fibrinogen\", section on 'Thrombotic variants'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thrombin time (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Activated protein C (APC) resistance (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Factor VIII",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing for common methylenetetrahydrofolate reductase (MTHFR) polymorphisms is no longer included in the evaluation of patients with VT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, the screening panel of IT includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor V Leiden",
"     </li>",
"     <li>",
"      Prothrombin G20210 A",
"     </li>",
"     <li>",
"      Protein C",
"     </li>",
"     <li>",
"      Protein S",
"     </li>",
"     <li>",
"      Antithrombin",
"     </li>",
"     <li>",
"      Fasting plasma homocysteine",
"     </li>",
"     <li>",
"      Fibrinogen",
"     </li>",
"     <li>",
"      Activated protein C (APC) resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Challenges in interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for IT in children should be done under the guidance of a pediatric hematologist because of the following major challenges in interpreting test results in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Need for age appropriate reference values &mdash; With the exception of the DNA based assays for factor V Leiden and the prothrombin gene mutations, each test requires age appropriate reference ranges. In some cases, normal pediatric values overlap values considered pathologic in adults. Thus, a screening result in a child may be misdiagnosed as a deficiency based upon adult normative values when the level is actually normal for age. Pediatric reference intervals are not available for tests that are performed in most laboratories.",
"     </li>",
"     <li>",
"      Variability of normative reference values &mdash; If age appropriate normative values are used, they often differ between laboratories because of the use of different reagents and measuring instruments when the assays are performed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/11\">",
"       11",
"      </a>",
"      ]. Direct comparison of test results from different laboratories or published reference ranges is not feasible and should be approached with caution.",
"     </li>",
"     <li>",
"      Nongenetic factors &mdash; Nongenetic factors may alter screening test results. These include the use of oral contraceptives, pregnancy, vitamin deficiencies, nephrotic syndrome, liver disease, and malabsorptive disorders (eg, celiac disease and cystic fibrosis). As an example, elevated homocysteine may be observed in response to deficiencies in vitamins B12, B6 and folate, or due to high level of methionine in the diet. Lipoprotein (a) is an acute phase reactant and may be elevated during episodes of inflammation.",
"     </li>",
"     <li>",
"      Negative test result &mdash; A negative test result may not rule out the possibility of an inherited thrombophilia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pretesting consultation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all cases, any abnormal result should be confirmed with repeat testing. When repeat testing is not possible, the hereditary nature of IT may be confirmed by testing the parents and other family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IT is more common in children with VTE than in the general pediatric population. This was illustrated in a meta-analysis of 35 cohort or case-controlled studies, which demonstrated that children with a first episode of VTE had a three- to nine-fold increased likelihood compared to controls of having a specific thrombotic genetic disorders, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antithrombin deficiency (OR 9.4, 95% CI 3.3 to 26.7)",
"     </li>",
"     <li>",
"      Protein C deficiency (OR 7.7, 95% CI 4.4 to 13.4)",
"     </li>",
"     <li>",
"      Protein S deficiency (OR 5.7, 95% CI 3 to 11)",
"     </li>",
"     <li>",
"      Increased lipoprotein (a) concentration (4.5, 95% CI 3.3 to 6.2)",
"     </li>",
"     <li>",
"      Factor V Leiden mutation (OR 3.8, 95% CI 3 to 4.8)",
"     </li>",
"     <li>",
"      Prothrombin G20210A mutation (OR 2.6, 95% CI 1.6 to 4.4)",
"     </li>",
"     <li>",
"      Children with VTE had about a ten-fold increased risk of having two or more thrombotic genetic disorders (OR 9.5, 95% CI 4.9 to 18.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, over 70 percent of these children had one or more clinical risk factors for VTE. In younger children and infants, these risk factors included sepsis, congenital heart disease, and central venous catheters. In older children, cancer, immobilization, rheumatic diseases, local infections, and the use of oral contraceptives in adolescent girls were associated with VTE. There were no data comparing the relative contribution of IT to these other risk factors for VTE. This study did not attempt to analyze the relative contributions of IT and the various medical disorders present to the development of VTE.",
"   </p>",
"   <p>",
"    VTE may develop in children with a co-existing medical condition or arise spontaneously in a child who appears otherwise healthy. The prevalence of IT differs in these two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a child with a pre-existing medical condition and VTE, the prevalence of IT ranges from 10 to 30 percent.",
"     </li>",
"     <li>",
"      In contrast, the prevalence of IT may be as high as 60 percent in children without apparent medical disorders who develop spontaneous VTE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The studies supporting these conclusions are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pre-existing medical condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of pediatric VTE occurs in hospitalized children with underlying medical conditions, such as cancer, congenital heart disease, trauma, or renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/9\">",
"     9",
"    </a>",
"    ]. These children have multiple risk factors for venous thrombosis (VT), including in-dwelling central venous catheters, which are the single most common cause of thrombus formation.",
"   </p>",
"   <p>",
"    The reported prevalence of IT in children with a pre-existing medical condition and VT ranges from 10 to 30 percent as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/13-19\">",
"     13-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series of 171 hospitalized Canadian children (median age 2.3 months, range 1 day to 16.5 years) with VTE, the prevalence of IT was 13 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/13\">",
"       13",
"      </a>",
"      ]. An underlying medical condition was present in 91 percent of patients. The specific genetic disorders that were screened included increased plasma lipoprotein (a) concentration (8 percent), factor V Leiden (5 percent), prothrombin G20210A polymorphism (2 percent), protein S deficiency (1 percent), and protein C deficiency (1 percent).",
"     </li>",
"     <li>",
"      A similar rate of 16 percent was reported in a case series of 100 Dutch children, 96 percent of whom had an underlying condition [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of IT is similar in children with malignancies and central venous line (CVL)-related thrombosis with a reported range of 23 to 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of IT as a primary causative factor for VTE in children with underlying medical disease is not fully defined. It also remains unclear whether IT increases the risk of VT when other thrombotic risk factors are present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously mentioned Canadian case series (91 percent of patients with an underlying medical condition), 77 percent had a central venous line (CVL) compared to only 13 percent with IT, suggesting that CVL had a much greater impact on VTE than IT.",
"     </li>",
"     <li>",
"      In a prospective study of 163 children with CVL placement, 18 patients developed thrombosis, of which 15 had IT and 3 did not [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/20\">",
"       20",
"      </a>",
"      ]. In comparison, the control group of 155 children undergoing elective surgery without CVL included 18 children with IT, none of whom developed VT. Thus, CVL placement again appeared to be the dominant risk factor for VT.",
"     </li>",
"     <li>",
"      In children with cancer, the drug regimen appears to pose a greater risk for thrombosis than the presence of IT alone [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the current available evidence, routine testing for IT in children with a single episode of VT, and one or more identified thrombotic risk factors (including an underlying medical condition) associated with VT is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testing may be appropriate if there is a strong family history of thrombosis, or if the patient has a history of recurrent events. In these patients, screening should be considered only if the information is expected to affect medical management decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spontaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous VT is uncommon in childhood and accounts for a minority of all thrombotic events. The prevalence of IT is greater in children with spontaneous VT than those with a pre-existing medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/13,23\">",
"     13,23",
"    </a>",
"    ]. This is especially true in adolescents with spontaneous VT, in whom IT may be present in up to 60 percent of patients. Many of these adolescents may have more than one inherited defect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to realize that the presence of IT does not exclude the presence or influence of other coexisting thrombotic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/24\">",
"     24",
"    </a>",
"    ]. Children with presumed spontaneous VTE should be evaluated carefully for possible predisposing causes by performing a thorough history and physical examination. The evaluations should include a history of recent travel, surgery, or trauma; sports participation, especially weight training; and concurrent use of medications, such as oral contraceptives. A complete review of systems may uncover previously unrecognized illnesses that may increase the risk of VT, such as diabetes or inflammatory bowel disease. When clinically suspected, additional radiological imaging for anatomic defects, such as May-Thurner syndrome, thoracic outlet syndrome, or atresia of the inferior vena cava, should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the causes of venous thrombosis\", section on 'May-Thurner syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inferior vena cava abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adult patients with an unprovoked thrombotic event are at increased risk of recurrence, regardless of whether they have IT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Although similar data are lacking in children, it is presumed that children with spontaneous VT are also at a high risk of recurrent VT, regardless of whether or not they have IT. However, there are no guidelines that recommend chronic prophylactic anticoagulation therapy in children with spontaneous VT, because it is generally accepted that the risk of bleeding from prolonged anticoagulation in children is greater than the potential benefit of preventing VT. As a result, the decision to administer chronic anticoagulation therapy is generally based upon clinical judgment, and primarily used in selected cases of recurrent thrombosis or following a life-threatening VT episode. Thus, screening for IT in children with spontaneous VT is not recommended because the results of IT screening in children with spontaneous VT are unlikely to affect the decision for anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, if a child is found to have IT, other family members may decide to undergo screening based upon a positive test in the related child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that the presence of IT should change the initial management of a child with VT. Decisions regarding anticoagulation agents, duration, and intensity of therapy should be identical in patients whether or not they have IT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     What should be ordered?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to screening for IT, a complete search for acquired causes should be performed. Testing during an acute thrombotic event should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count. Elevations in the hematocrit and platelet count may predispose to venous and arterial thrombotic events. An increased risk of VT is also associated with iron deficiency anemia and thalassemia.",
"     </li>",
"     <li>",
"      PT and aPTT &mdash; Prolongation of the prothrombin time (PT) and activated partial thromboplastin (aPTT) time may be caused by inhibitors of clotting factors, the presence of antiphospholipid antibodies, or disseminated intravascular coagulation (DIC). In addition, vitamin K deficiency and liver disease may also prolong PT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical use of coagulation tests\", section on 'Causes of prolonged PT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical use of coagulation tests\", section on 'Causes of prolonged aPTT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening for lupus anticoagulant and anticardiolipin antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If screening for IT is performed, a comprehensive panel should always be obtained. This is true even if a specific genetic thrombotic disorder has already been identified in the family. Selective testing for a single mutation may overlook the presence of another thrombotic disorder. In one series, 3 percent of children with IT had more than one defect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/15,27\">",
"     15,27",
"    </a>",
"    ]. In addition, the previously discussed meta-analysis demonstrated that the rate of VTE was greatest in children with two or more inherited thrombotic disorders with a nine-fold increased risk compared to children without IT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The list of screening tests performed in our practice is discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Screening tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Timing of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;If screening for IT is performed, the timing of testing is important. With the exception of DNA based assays, testing may reflect transient changes resulting from acute thrombosis, nongenetic factors (eg, medications and other comorbid conditions), or anticoagulation therapy (",
"    <a class=\"graphic graphic_table graphicRef76966 \" href=\"UTD.htm?43/22/44396\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute thrombosis &mdash; During acute thrombosis, plasma levels of antithrombin, protein C, and protein S are transiently decreased, whereas factor VIII levels are increased. Testing for these plasma proteins should be delayed six weeks or longer to allow levels to return to baseline. However, most patients will remain on anticoagulant therapy for three months or more, far beyond the six-week time frame need for recovery. In such instances, measurements may need to be delayed until planned anticoagulation is completed.",
"     </li>",
"     <li>",
"      Anticoagulation &mdash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       Heparin",
"      </a>",
"      may lower antithrombin levels. Warfarin reduces vitamin K dependent factors including proteins C and S. Protein S levels may not return to baseline until four to six weeks after discontinuation of warfarin.",
"     </li>",
"     <li>",
"      Other nongenetic factors may affect test results and are discussed above. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Challenges in interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, we recommend testing for IT after completing the initial course of anticoagulant therapy following a thrombotic event. If, however, plasma levels of antithrombin, protein C, and protein S are obtained earlier and are well within the normal range, then a deficiency of these proteins is essentially excluded. A low concentration of protein C or S must be confirmed by repeat testing at least four to six weeks after anticoagulation has been discontinued.",
"   </p>",
"   <p>",
"    The waiting time period between the thrombotic event and IT screening can be used for pretesting counseling, which is discussed below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Pretesting consultation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although studies have not shown an increased prevalence of IT in adults with arterial thrombotic or embolic stroke compared to the general population, there is evidence that suggests a higher prevalence of IT in children with arterial ischemic stroke than in the general pediatric population. The screening for IT in children with arterial ischemic stroke, and the management of children with IT and arterial ischemic stroke are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link&amp;anchor=H5#H5\">",
"     \"Ischemic stroke in children: Evaluation, initial management, and prognosis\", section on 'Hypercoagulable state evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=see_link\">",
"     \"Ischemic stroke in children: Secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of IT in cerebral sinus venous thrombosis (CSVT) also remains uncertain. Acquired prothrombotic abnormalities are more common in patients with CSVT, and include anticardiolipin antibodies and antiphospholipid antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NEONATAL PURPURA FULMINANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal purpura fulminans is classically described in infants with protein C deficiency, although it has also been reported in patients with protein S deficiency, including those who are compound heterozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Neonatal purpura fulminans usually presents within the first days of life with necrotic skin purpura, extensive venous and arterial thromboses, and laboratory evidence of disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of thrombosis in the newborn\", section on 'Neonatal purpura fulminans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All neonates with purpura fulminans or severe spontaneous thrombosis need to be screened for proteins C and S deficiencies, as the administration of exogenous protein C or S is critical for the treatment of these disorders. In a neonate with purpura fulminans, the diagnosis of an inherited deficiency of either protein C or S is based upon an undetectable level of protein C or S in the patient, and documentation of reduced levels in the parents. The diagnosis may be difficult to make, as normal levels of these proteins are low in neonates, especially preterm infants, and remain low through much of early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/11,34-36\">",
"     11,34-36",
"    </a>",
"    ]. The diagnosis in the infant should be confirmed by repeat testing at a later date, but may be difficult to obtain due to the high mortality associated with this disorder and the need for ongoing therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC CHILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;As IT is more frequently diagnosed, families with a history of thrombosis and thrombophilia are increasingly inquiring whether or not their asymptomatic child should be screened for IT. In making a decision for screening, the benefits, and risks of screening for the individual need to be consider. In the case of IT, it remains uncertain whether or not the benefit outweighs the risks of screening in this group of children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Potential benefits of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several potential benefits of screening for IT in asymptomatic children with a family history of IT, VTE, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Education of the family about thrombophilia, which allows implementation of lifestyle changes (eg, smoking avoidance) that may reduce the risk of thrombosis",
"     </li>",
"     <li>",
"      Information for health care providers to avoid thrombogenic medications, such as oral contraceptives",
"     </li>",
"     <li>",
"      Information for health care providers to tailor anticoagulation therapy during high-risk clinical settings for thrombosis (eg, surgery, immobilization, or pregnancy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"       \"Inherited thrombophilias in pregnancy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Potential drawbacks of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arguments against IT screening in asymptomatic children include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening may not warrant the cost of testing, and may be associated with an increase in anxiety and parental guilt.",
"     </li>",
"     <li>",
"      As discussed previously, interpretation of screening tests can be challenging and may result in misdiagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Challenges in interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening panels for IT are likely incomplete, and thus, negative testing may provide a false sense of security. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are ethical issues of genetic screening in children who may lack the maturity and understanding to make an informed decision, especially when there currently is no demonstrated benefit to IT testing during childhood. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ethics of screening'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thrombotic risk with IT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of IT does not appear to significantly increase the low clinical risk of thrombosis in childhood, which ranges from 0.1 to 0.5 per 10,000 children, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from the European Prospective Cohort on Thrombophilia (EPCOT) that followed asymptomatic carriers of a thrombophilic defect (ie, Factor V Leiden, and deficiencies of antithrombin, or proteins C and S) and controls over a mean of 5.7 years, an initial deep VT or pulmonary embolism was diagnosed in 4.5 percent of asymptomatic carriers compared to 0.6 percent of controls [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/38\">",
"       38",
"      </a>",
"      ]. However, the first thrombotic event occurred at a mean age of 40 years in patients with IT. The annual incidence of a thrombotic event was 0.8 percent in patients with IT compared to 0.1 percent in controls, which is lower than the reported 1 to 3 percent risk of bleeding with long-term anticoagulant therapy.",
"     </li>",
"     <li>",
"      In a smaller prospective cohort study of children (age range 1 to 14 years) from families with a known inherited single thrombogenic defect, there was not a single episode of VTE in 81 children who were carriers of an inherited defect or 62 children who were free from known genetic or acquired causes of thrombophilia over a mean observation period of five years (range 1 to 8 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from families with specific prothrombotic defects demonstrate a small but not clinically significant increase annual risk of VTE in carriers compared to noncarriers for both factor V Leiden mutation (0.45 versus 0.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/40\">",
"       40",
"      </a>",
"      ] and for prothrombin 20210A mutation (0.37 versus 0.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/41\">",
"       41",
"      </a>",
"      ]. In both studies, bleeding from long-term anticoagulant therapy outweighed the risk for thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest routine screening in asymptomatic children with a family history of IT is not warranted because IT does not substantially increase the rate of thrombosis in childhood. Because the initial thrombotic events in families with IT typically occurs in adulthood, the decision for individual screening generally can wait until the patient is old enough to understand the implications of screening and participate in the decision making process. In most countries, the legal age for independent medical decision making is 18 years of age. In some cases, screening may be considered in patients younger than 18 years of age with a family history of IT who have other thrombotic risk factors (eg, pregnancy) or prior to the start of thrombogenic medications (eg, oral contraceptives). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although, a diagnosis of IT is not an absolute contraindication for the use of oral contraceptives, there is an increased risk of thrombosis associated with oral contraceptives in individuals with IT compared to those without thrombophilia. The risk is dependent upon the specific thrombophilic disorder. Contraception in women with or suspected to have IT is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=see_link\">",
"     \"Contraception for women with inherited thrombophilias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ethics of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric genetic screening is a controversial issue, as children, especially young children, generally have non-existent or limited ability to participate in the decision making process. The American Medical Association (AMA) Code of Ethics (E-2.138), American Academy of Pediatrics (AAP), and American College of Medical Genetics, all recommend that testing for genetic conditions that do not present until adulthood or may affect future choices over contraception or reproduction should be discouraged until the child is mature enough to participate fully in the decision making process [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Testing should be offered if knowledge of the genetic condition results in preventive or other therapeutic interventions that are in the child's best interests.",
"   </p>",
"   <p>",
"    In the case of IT, routine genetic screening in an asymptomatic child with a family history of thrombosis does not meet these criteria for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As discussed above, the risk of thrombosis during childhood is low, so that the decision for screening generally can be delayed until the patient is mature enough to participate fully in the decision making process.",
"     </li>",
"     <li>",
"      There are no preventative or therapeutic interventions that would be routinely given to a child with IT to prevent thrombosis. As previously noted in the EPCOT report and other studies, the risk of bleeding from long-term anticoagulation was greater than the risk of a thrombotic event in asymptomatic individuals with IT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Requests for screening for inherited thrombophilia in children have risen with the increased availability of testing for genetic thrombotic disorders. There are no published guidelines for the pediatric population, and recommendations are frequently extrapolated from general guidelines, which currently promote testing individuals with an episode of thrombosis prior to the age of 50 years of age and first degree relatives of individuals with IT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For asymptomatic children with a family history of IT, we do not routinely recommend screening for IT because there is a low risk of thrombosis in childhood, so testing can be deferred until the individual is old enough to participate in the decision making process [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, management is unlikely to be changed in a child with VT whether or not they have IT.",
"   </p>",
"   <p>",
"    Our approach to these requests for testing includes the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pretesting consultation",
"     </li>",
"     <li>",
"      If appropriate, testing performed at a family's request",
"     </li>",
"     <li>",
"      Posttesting consultation to review test results",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to offering testing, the clinician should be aware of the local and state laws governing genetic testing, especially as they pertain to minors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pretesting consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretesting consultation is used to obtain the history about the family and the individual child, apply this information to determine the benefit of testing for the child, and educate the family on whether or not testing is beneficial for the child. The discussion should include the risks, benefits, limitations, and implications of testing for not only the child, but also for the extended family.",
"   </p>",
"   <p>",
"    If possible, it is most helpful to identify a family member with IT and review",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    medical history and laboratory record. In many cases, this family member may not have a history of thrombosis, and may have been identified due to evaluation for another disorder. &nbsp;When testing was obtained as part of an evaluation for VT, the review or prior testing should be evaluated for completeness, especially as assays for the factor V Leiden and the prothrombin gene mutations were not routinely available prior to the mid-1990s. The timing of screening also needs to be considered, as transient deficiencies of antithrombin, and proteins C and S are often observed in close proximity to an acute thrombotic event, and may be altered by concurrent anticoagulation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Timing of screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If there is not an identified proband, the use of testing to provide risk assessment for subsequent thrombosis is less reliable. As an example, in one study of 314 patients with a VTE and a positive family history of one or more first-degree relative with VTE, IT was diagnosed in 42 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/47\">",
"     47",
"    </a>",
"    ]. The rate of identifying one of the currently identified thrombophilias only increased to 46 percent in patients with a strongly positive family history of two or more first-degree relatives with VTE. These results suggest the current panel of tests is not complete, and yet, unidentified predisposing defects may exist [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some families with a clearly defined, highly penetrant predisposition to thrombosis, there may be benefit in identifying family members with the prothrombotic genetic predisposition from those who are not carriers, as it can directly impact clinical decisions (eg, choice of oral contraceptives). In other cases when IT has been identified in families with either no or a sporadic history of VT, the risk of future thrombotic event may be low, and there is less value for screening. In addition, a positive test result may impact negatively on subsequent insurance eligibility and future employment.",
"   </p>",
"   <p>",
"    The impact of a positive test result on family members also should be considered. Some family members may decide to undergo screening based upon a positive test, while others may refuse screening based upon their individual wishes and moral beliefs. The family needs to be aware that testing is optional, and the pros and cons of screening for each individual family member must be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;After discussion with the family, the clinician may decide that testing is not indicated or should be deferred until a later time. Later testing may occur when the patient is mature enough to participate in the decision because",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    understand the implications of testing, or when deciding upon the use of medications that increase the risk of thrombosis.",
"   </p>",
"   <p>",
"    The local and state laws vary regarding genetic testing, and in some locales, formal written consent may be required.",
"   </p>",
"   <p>",
"    If screening for IT is performed, a comprehensive panel should always be obtained even if a specific genetic thrombotic disorder has already been identified in the family. Selective testing for a single mutation may overlook the presence of another thrombotic disorders. In our center, the panel of tests used in asymptomatic children with a positive family history of IT is the same as that used to identify genetic thrombotic disorders in children with VTE. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Screening tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Postconsultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-testing counseling is equally important for patients who test positive or negative [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14825/abstract/37\">",
"     37",
"    </a>",
"    ]. Negative results may cause a false sense of security and families should understand that current testing may not have identified all inherited risk factors. In contrast, positive results may elicit excessive anxiety and parental guilt.",
"   </p>",
"   <p>",
"    Families should be educated regarding the estimated risk of thrombosis, the symptoms of thrombosis, the avoidance of acquired risk factors, and the pros and cons of long-term anticoagulation or intermittent prophylactic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia (IT) is the genetically acquired predisposition to venous thrombosis. Screening for IT is now available because of the identification of genetic disorders associated with hypercoagulability.",
"   </p>",
"   <p>",
"    Because venous thrombosis (VT) is uncommon in children, screening for IT has been proposed for select pediatric population with a thrombotic risk that is higher than the general pediatric population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of children with venous thrombosis (VT) have a pre-existing illness. Although IT may be detected in as many as 30 to 40 percent of these patients, other risk factors (eg, central venous catheters) likely have a much greater impact on the risk of VT.",
"     </li>",
"     <li>",
"      In children with VT and a pre-existing illness, we suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      to screen for IT, as test results do not alter patient management (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pre-existing medical condition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although children with spontaneous VT have a higher rate of IT than those with VT and a pre-existing illness, we suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      to screen for IT because the risk of bleeding from long-term anticoagulation therapy outweigh the risk of recurrent VT during childhood in these patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Spontaneous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an asymptomatic child with a family history of IT, we suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      to screen for IT because there is a low risk of thrombosis in childhood (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Testing can be deferred until the individual is old enough to participate in the decision making process or prior to the start of thrombogenic medications (eg, oral contraceptives). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Asymptomatic child'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although neonatal purpura fulminans is classically associated with deficiency of protein C, it has also been described in neonates with protein S deficiency. Patients with this disorder should be tested for protein C and protein S because the administration of protein C or S is critical for the treatment of purpura fulminans caused by either protein C or S deficiency. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neonatal purpura fulminans'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The screening of children with ischemic stroke is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link&amp;anchor=H5#H5\">",
"       \"Ischemic stroke in children: Evaluation, initial management, and prognosis\", section on 'Hypercoagulable state evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In our practice, we use the following approach when screening for IT in a child is requested or being considered. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretesting consultation is used to obtain a history of the patient and family, determine the benefit of testing for the child, and educate the family on whether or not testing is beneficial for the child. &nbsp;(See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pretesting consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If testing is deemed appropriate, testing should be done under the guidance of a pediatric hematologist and in a laboratory that uses age-based normative reference values. A comprehensive panel of tests should be used. In children with VT, testing should be performed at least six weeks after completing the initial three to six month course of oral anticoagulant therapy following a thrombotic event. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-testing counseling and education is equally important for patients who test both positive and negative fot IT. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Postconsultation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/1\">",
"      Michaels LA. A response to: laboratory testing for thrombophilia in pediatric patients. Thromb Haemost 2003; 89:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/2\">",
"      Tormene D, Pagnan A, Prandoni P, Simioni P. Screening for thrombophilia in children: a puzzling decision with unclear implications. J Thromb Haemost 2004; 2:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/3\">",
"      Kamphuisen PW, Rosendaal FR. Thrombophilia screening: a matter of debate. Neth J Med 2004; 62:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/4\">",
"      Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003; 1:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/5\">",
"      Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 1:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/6\">",
"      Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/7\">",
"      Baglin T. Thrombophilia testing: what do we think the tests mean and what should we do with the results? J Clin Pathol 2000; 53:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/8\">",
"      Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Laboratory testing for thrombophilia in pediatric patients. On behalf of the Subcommittee for Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH). Thromb Haemost 2002; 88:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/9\">",
"      Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation 2008; 118:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/10\">",
"      Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C-&gt;T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 2007; 167:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/11\">",
"      Flanders MM, Phansalkar AR, Crist RA, et al. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr 2006; 149:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/12\">",
"      Junker R, Koch HG, Auberger K, et al. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999; 19:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/13\">",
"      Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/14\">",
"      van Ommen CH, Heijboer H, B&uuml;ller HR, et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/15\">",
"      van Ommen CH, Heijboer H, van den Dool EJ, et al. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003; 1:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/16\">",
"      Bonduel M, Hepner M, Sciuccati G, et al. Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism. Thromb Haemost 2002; 87:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/17\">",
"      Albisetti M, Moeller A, Waldvogel K, et al. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. Acta Haematol 2007; 117:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/18\">",
"      Kn&ouml;fler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines. Eur J Pediatr 1999; 158 Suppl 3:S147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/19\">",
"      Ruud E, Holmstr&oslash;m H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer--a prospective study. Med Pediatr Oncol 2002; 38:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/20\">",
"      Nowak-G&ouml;ttl U, D&uuml;bbers A, Kececioglu D, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 1997; 131:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/21\">",
"      Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res 2003; 111:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/22\">",
"      O'Brien SH, Smith KJ. Using thrombophilia testing to determine anticoagulation duration in pediatric thrombosis is not cost-effective. J Pediatr 2009; 155:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/23\">",
"      Mazzolai L, Duchosal MA. Hereditary thrombophilia and venous thromboembolism: critical evaluation of the clinical implications of screening. Eur J Vasc Endovasc Surg 2007; 34:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/24\">",
"      B&uuml;ller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:401S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/25\">",
"      Brouwer JL, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 2006; 145:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/26\">",
"      Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/27\">",
"      Kosch A, Junker R, Kurnik K, et al. Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 2000; 99:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/28\">",
"      Somma J, Sussman II, Rand JH. An evaluation of thrombophilia screening in an urban tertiary care medical center: A \"real world\" experience. Am J Clin Pathol 2006; 126:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/29\">",
"      Mahasandana C, Suvatte V, Chuansumrit A, et al. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990; 117:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/30\">",
"      Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/31\">",
"      Pegelow CH, Ledford M, Young JN, Zilleruelo G. Severe protein S deficiency in a newborn. Pediatrics 1992; 89:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/32\">",
"      Pung-amritt P, Poort SR, Vos HL, et al. Compound heterozygosity for one novel and one recurrent mutation in a Thai patient with severe protein S deficiency. Thromb Haemost 1999; 81:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/33\">",
"      Adcock DM, Brozna J, Marlar RA. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis. Semin Thromb Hemost 1990; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/34\">",
"      Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/35\">",
"      Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/36\">",
"      Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992; 80:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/37\">",
"      Thornburg CD, Dixon N, Paulyson-Nu&ntilde;ez K, Ortel T. Thrombophilia screening in asymptomatic children. Thromb Res 2008; 121:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/38\">",
"      Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/39\">",
"      Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002; 100:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/40\">",
"      Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/41\">",
"      Coppens M, van de Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006; 108:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/42\">",
"      Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet 1995; 57:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/43\">",
"      Committee on Bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics 2001; 107:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/44\">",
"      Arbour, L, Byrne, P, Harrison, C, et al. Bioethics Committee. Guidelines for genetic testing of healthy children. Paediatr Child Health 2003; 8:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/45\">",
"      Grody WW, Griffin JH, Taylor AK, et al. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3:139.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines on the investigation and management of thrombophilia. The British Committee for the Standards in Haematology. J Clin Pathol 1990; 43;703.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/47\">",
"      van Sluis GL, S&ouml;hne M, El Kheir DY, et al. Family history and inherited thrombophilia. J Thromb Haemost 2006; 4:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14825/abstract/48\">",
"      Turchetti D, Romeo G. Problems related to counseling in genetic thrombophilias. Pathophysiol Haemost Thromb 2002; 32:254.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5920 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14825=[""].join("\n");
var outline_f14_30_14825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Challenges in interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VENOUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pre-existing medical condition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spontaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - What should be ordered?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Timing of screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STROKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NEONATAL PURPURA FULMINANS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ASYMPTOMATIC CHILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Potential benefits of screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Potential drawbacks of screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thrombotic risk with IT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ethics of screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pretesting consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Postconsultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/22/44396\" title=\"table 1\">",
"      Thrombophilia test interference",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=related_link\">",
"      Contraception for women with inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=related_link\">",
"      Ischemic stroke in children: Evaluation, initial management, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=related_link\">",
"      Ischemic stroke in children: Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_30_14826="Bacterial arthritis: Clinical features and diagnosis in infants and children";
var content_f14_30_14826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial arthritis: Clinical features and diagnosis in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14826/contributors\">",
"     Paul Krogstad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14826/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14826/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14826/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14826/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/30/14826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/30/14826/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/30/14826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections of the joints may be caused by bacteria, fungi, and viruses. Bacterial joint infections are most common. The term septic arthritis includes joint infections caused by pyogenic bacteria; it encompasses bacterial arthritis, pyogenic arthritis, suppurative arthritis, purulent arthritis, and pyarthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of bacterial arthritis in infants and children will be reviewed here. The epidemiology, pathogenesis, microbiology, treatment, and outcome of bacterial arthritis in infants and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of bacterial arthritis in infants and children varies depending upon the age of the child, the site of infection, and the causative organism (",
"    <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Site of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial arthritis typically affects the joints of the lower extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/2\">",
"     2",
"    </a>",
"    ]. Infections of the knee, hip, and ankle consistently account for at least 80 percent of cases, with the hip and knee most commonly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Bilateral bacterial arthritis of the hip occurs in a small number of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 10 percent of cases involve more than one joint [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. Polyarticular infections are more common in neonates and with certain pathogens (eg,",
"    <em>",
"     Neisseria meningitidis",
"    </em>",
"    ,",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    , and occasionally",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonates and infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial arthritis in neonates and young infants deserves special attention for a number of reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/10,12-16\">",
"     10,12-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signs and symptoms can be subtle",
"     </li>",
"     <li>",
"      More than one joint may be involved",
"     </li>",
"     <li>",
"      The different microbiology (eg, group B streptococcus,",
"      <em>",
"       N. gonorrhoeae",
"      </em>",
"      , and gram-negative bacilli in addition to",
"      <em>",
"       S. aureus",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      The potential catastrophic consequences of untreated disease, particularly when the hip is involved (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H37#H37\">",
"       \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Outcome'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In neonates and young infants (&lt;2 to 3 months), the typical presentation of bacterial arthritis is that of septicemia (eg, irritability, apprehension, poor feeding) or fever without a focus of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/1\">",
"     1",
"    </a>",
"    ]. Subtle features of joint involvement may include positional preferences, lack of use of the involved extremity (\"pseudoparalysis\"), evidence of discomfort when handled or having the diaper changed, and extremity swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hip arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of bacterial arthritis of the hip in neonates and young infants may include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/7,13,16\">",
"     7,13,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of femoral venipuncture (usually five to nine days before bacterial arthritis, but may be as recent as one day or as remote as 28 days before) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Swelling in the region of the thigh or buttock",
"     </li>",
"     <li>",
"      Holding the leg flexed with slight abduction and external rotation",
"     </li>",
"     <li>",
"      Irritability on passive movement of the hip (eg, during diaper change)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Left untreated, bacterial arthritis of the hip may spontaneously drain along the obturator internus, manifesting as a lower-abdominal mass just above the inguinal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Older children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with bacterial arthritis usually have fever and constitutional symptoms (malaise, poor appetite, irritability, tachycardia) within the first few days of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/1,11,14,20\">",
"     1,11,14,20",
"    </a>",
"    ]. Although these findings are not always present, septic arthritis should be considered seriously in all children with the acute onset of fever and joint pain.",
"   </p>",
"   <p>",
"    Findings related to the involved joint (eg, swelling, tenderness) are generally present but may be subtle. Pain with active or passive movement is a cardinal feature. When bacterial arthritis involves the lower extremity, children may present with limp or refusal to walk or bear weight.",
"   </p>",
"   <p>",
"    When the hip or sacroiliac joint is involved, the pain may be referred to adjacent structures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Patients with bacterial arthritis of the hip may complain of knee pain; those with bacterial arthritis of the sacroiliac joint may have symptoms that mimic appendicitis, pelvic neoplasm, or urinary tract infection. Arthritis of the sacroiliac joint usually occurs in late childhood (average age of 10 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Underlying arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial arthritis should be considered as a possibility in children and adolescents with underlying juvenile idiopathic arthritis (JIA, formerly juvenile rheumatoid arthritis) if there is unusual worsening of one joint during an exacerbation of arthritis or there has been a recent injection of the joint in question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of infants and children with suspected bacterial arthritis should occur promptly. Diagnostic joint aspiration should be performed as soon as possible so that surgical drainage (if necessary) and appropriate empiric antimicrobial therapy can be instituted. Early diagnosis and treatment is associated with improved outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H37#H37\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of the child with suspected bacterial arthritis includes a careful history and physical examination, laboratory and imaging studies, and synovial fluid analysis. The goals of the evaluation are to confirm the presence of bacteria in the joint and to exclude other conditions in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elements of the history in the child with suspected infectious arthritis that should be reviewed include (",
"    <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75773 \" href=\"UTD.htm?8/60/9165\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57993 \" href=\"UTD.htm?37/0/37899\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/14,25\">",
"     14,25",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H5#H5\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Microbiology'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression of symptoms &ndash; The pain of untreated bacterial arthritis tends to worsen over time; it does not wax and wane. The pain may awaken the patient at night, in contrast to inflammatory arthropathies such as juvenile idiopathic arthritis (JIA), where symptoms tend to be worst upon rising in the morning. Complaints of knee or thigh pain may represent referred pain from pathology in the hip (bacterial arthritis or other hip pathology).",
"     </li>",
"     <li>",
"      Direct inoculation (eg, kneeling on needles, puncture wounds, or lacerations over a joint).",
"     </li>",
"     <li>",
"      Rash &ndash; Rash may occur in bacterial arthritis due to",
"      <em>",
"       N. gonorrhoeae",
"      </em>",
"      or",
"      <em>",
"       N. meningitidis",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/26\">",
"       26",
"      </a>",
"      ]. Rash also may provide a clue to several considerations in the differential diagnosis (eg, Lyme disease (",
"      <a class=\"graphic graphic_picture graphicRef62480 graphicRef57414 \" href=\"UTD.htm?25/29/26067\">",
"       picture 1A-B",
"      </a>",
"      ) and JIA (",
"      <a class=\"graphic graphic_picture graphicRef62959 \" href=\"UTD.htm?13/24/13711\">",
"       picture 2",
"      </a>",
"      )). Skin and soft tissue infections (eg, impetigo, cellulitis, abscess) may provide a portal of entry for",
"      <em>",
"       S. aureus",
"      </em>",
"      or group A streptococcal (GAS) bacteremia.",
"     </li>",
"     <li>",
"      Recent use of antibiotics &ndash; The recent use of antibiotics may attenuate symptoms. It also may provide a clue to an antecedent infection that may be associated with postinfectious arthritis (eg, poststreptococcal reactive arthritis) or predispose to infection with a resistant pathogen (eg, penicillin-resistant pneumococcus) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/27\">",
"       27",
"      </a>",
"      ]. Serum sickness also may follow exposure to many antibiotics, including penicillins, cephalosporins,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , and sulfonamides.",
"     </li>",
"     <li>",
"      Recent or concurrent illness &ndash; Upper respiratory tract infection may precede bacterial arthritis (predisposing to bacteremia) or transient (or toxic) synovitis. Enteric, genitourinary, and respiratory infections may precede postinfectious reactive arthritis. Concurrent varicella zoster virus (VZV) infection may provide a portal of entry for",
"      <em>",
"       S. aureus",
"      </em>",
"      or GAS (",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      ) bacteremia; VZV also rarely causes primary arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H4#H4\">",
"       \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Pathogenesis'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H29\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Onset of most recent menses (for pubertal females) &ndash; Disseminated gonococcal infection usually occurs in the first seven days of the menstrual cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exposures &ndash; Reviewing the history for various exposures may suggest particular pathogens or other conditions (eg, hepatitis B, Lyme disease, histoplasmosis). (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Immunization status &ndash; Arthritis due to",
"      <em>",
"       Haemophilus influenza",
"      </em>",
"      type B,",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      , hepatitis B virus, measles, and mumps may occur in unimmunized children; receipt of rubella vaccine virus is associated with joint symptoms two weeks after immunization.",
"     </li>",
"     <li>",
"      Family history of rheumatologic disease (eg, psoriatic arthritis) or inflammatory bowel disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful physical examination may confirm the presence and location of acute arthritis and may also identify a source of bacteremia or entry point for direct inoculation. Examination also may help to exclude other considerations in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef75773 \" href=\"UTD.htm?8/60/9165\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57993 \" href=\"UTD.htm?37/0/37899\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Particular attention should be paid to growth parameters and examination of the skin, eyes, and extremities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation is an important aspect of the physical examination of the infant or child with suspected bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/25\">",
"     25",
"    </a>",
"    ]. Infants and children with bacterial arthritis usually appear ill. They tend to maintain the joint in a position that maximizes comfort. Knees are held moderately flexed. Hips are flexed, abducted, and externally rotated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/14,23,29,30\">",
"     14,23,29,30",
"    </a>",
"    ]. Children with bacterial arthritis may refuse to bear weight on or use the involved extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;All bones should be palpated and all joints moved [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/31\">",
"     31",
"    </a>",
"    ]; the area(s) of suspected involvement should be examined last. Finding several abnormal joints makes septic arthritis less likely than viral, reactive, or inflammatory arthropathies, which are more commonly polyarticular. If the child is frightened or uncooperative, the parent can be instructed to perform the joint examination while the clinician observes from a distance.",
"   </p>",
"   <p>",
"    The involved joint is typically swollen, red, warm, and tender to palpation. External findings may be absent when the hip is involved, although asymmetric buttock creases or swelling of a buttock or the genitalia may provide a clue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/31\">",
"     31",
"    </a>",
"    ]. Severe swelling may indicate extensive infection or venous thrombosis (sometimes associated with",
"    <em>",
"     S. aureus",
"    </em>",
"    osteoarticular infections) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/18,25,32\">",
"     18,25,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in the adjacent soft tissue are variable and depend upon the duration of infection and the depth of the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Subtle soft tissue findings may include loss of normal concavity and skin markings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active and passive range of motion are usually decreased. Pain is increased with maneuvers that increase intracapsular pressure (eg, compression of the head of the femur into the acetabulum). Pain through any range of active or passive motion is suggestive of bacterial arthritis. In contrast, children with traumatic injuries and other types of arthritis usually have some pain-free range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/25\">",
"     25",
"    </a>",
"    ]. In patients with bacterial arthritis of the sacroiliac joint, maneuvers that twist the pelvis cause pain (eg, the FABERE test (",
"    <a class=\"graphic graphic_figure graphicRef79475 \" href=\"UTD.htm?5/55/6015\">",
"     figure 1",
"    </a>",
"    )), whereas gentle hip motion is not painful [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/14,23,24,35\">",
"     14,23,24,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When appropriate cultures are obtained (synovial fluid, blood, and other sites as indicated), the bacterial etiology is confirmed in 50 to 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/5,8,36,37\">",
"     5,8,36,37",
"    </a>",
"    ]. For non-neonates, joint fluid should be injected into blood culture bottles to enhance the recovery of",
"    <em>",
"     Kingella kingae",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    The laboratory evaluation for children with suspected bacterial arthritis typically includes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/14,25,38\">",
"     14,25,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC) with differential",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Blood culture",
"     </li>",
"     <li>",
"      Synovial fluid white blood cell (WBC) count and differential, Gram stain, culture, and susceptibility testing (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Synovial fluid'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional laboratory studies may be necessary in patients in whom particular organisms are suspected (eg,",
"    <em>",
"     N. gonorrhoeae",
"    </em>",
"    , GAS). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Other studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral WBC count, ESR,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CRP are usually elevated in patients with bacterial arthritis. However, in some cases, they are only mildly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/8,39-41\">",
"     8,39-41",
"    </a>",
"    ]. ESR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CRP are better negative than positive predictors of bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/42\">",
"     42",
"    </a>",
"    ]. When elevated, they can be used to monitor the disease course and response to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H30#H30\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ESR is &gt;20",
"    <span class=\"nowrap\">",
"     mm/hr",
"    </span>",
"    in most children with bacterial arthritis (mean 55",
"    <span class=\"nowrap\">",
"     mm/hr)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/8,34,39,43\">",
"     8,34,39,43",
"    </a>",
"    ]. The ESR may rise for three to five days after institution of appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/43\">",
"     43",
"    </a>",
"    ]; continuing to rise after three to five days may be an indication of treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to ESR, the CRP is elevated in most patients with bacterial arthritis (mean 8.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/43\">",
"     43",
"    </a>",
"    ]. Normal CRP is a good negative predictor for pyogenic arthritis. In a retrospective series of 133 children who underwent joint aspiration and in whom CRP was obtained, 39 children (29 percent) had bacterial arthritis. A CRP &lt;1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    was associated with a negative predictive power of 87 percent for positive synovial fluid culture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/42\">",
"     42",
"    </a>",
"    ]. CRP is more useful than ESR for monitoring response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]; the CRP peaks within 36 to 50 hours of onset of infection and usually falls to normal within a week of successful treatment, whereas ESR may remain elevated for up to 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/25,43\">",
"     25,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that aerobic blood cultures be obtained in all patients in whom bacterial arthritis is a consideration; anaerobic cultures should be obtained if anaerobic infection is a concern (eg, direct inoculation). Blood cultures are positive in approximately 40 percent of cases and sometimes yield the pathogen when joint fluid cultures are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/11,14,25,45\">",
"     11,14,25,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serology for",
"    <em>",
"     Borrelia",
"    </em>",
"    antigens should be sent when Lyme-disease-related articular disease is suspected based upon the geographic location, or the possibility of exposure to vectors of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional laboratory studies may be necessary in patients in whom particular organisms are suspected (",
"    <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If gonococcal arthritis is suspected in adolescent patients, cultures from the oropharynx, rectum, cervix (females) or urethra (males), and skin lesions (if present) or nucleic acid amplification tests of the urine for gonococcal DNA should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link&amp;anchor=H12#H12\">",
"       \"Disseminated gonococcal infection\", section on 'Laboratory studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If gonococcal infection is suspected in the newborn, culture of the cerebrospinal fluid should be obtained in addition to cultures of blood and eye exudates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link\">",
"       \"Gonococcal infection in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If GAS arthritis, poststreptococcal arthritis, or rheumatic fever is suspected, throat culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antistreptolysin-O (ASO) titer should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cultures of the stool",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine should be obtained if septic arthritis due to gram-negative enteric pathogens or reactive arthritis following gastrointestinal tract infection is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H5#H5\">",
"       \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Microbiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiologic evaluation of children with suspected bacterial arthritis usually begins with plain radiographs. Plain radiographs are helpful in identifying fractures, foci of osteomyelitis, and other causes of osteoarticular pain and swelling. Plain radiographs may demonstrate signs of joint effusion but are not particularly sensitive for this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/40,47,48\">",
"     40,47,48",
"    </a>",
"    ]. Ultrasonography (US) is sensitive for detecting joint fluid, but the presence of fluid is not specific for joint infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/40,49,50\">",
"     40,49,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic findings of bacterial arthritis are related to capsular swelling. Radiographs add little to the diagnostic evaluation of joints that are readily accessible to physical examination, but may be a valuable adjunct to the examination of the hip.",
"   </p>",
"   <p>",
"    When reviewing radiographs, it is helpful to compare the involved extremity with the opposite side [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/31\">",
"     31",
"    </a>",
"    ]. Radiographic findings suggestive of joint effusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacterial arthritis include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/11,16,31,48,51\">",
"     11,16,31,48,51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soft tissue swelling",
"     </li>",
"     <li>",
"      Displacement of muscle surrounding the joint",
"     </li>",
"     <li>",
"      Widening of the joint space",
"     </li>",
"     <li>",
"      Increased opacity within the joint",
"     </li>",
"     <li>",
"      Distension of the joint capsule",
"     </li>",
"     <li>",
"      Subluxation",
"     </li>",
"     <li>",
"      Erosion or disappearance of the epiphysis or metaphysis (present two to four weeks after the onset), suggesting adjacent osteomyelitis",
"     </li>",
"     <li>",
"      Erosion of subchondral bone (present two to four weeks after the onset)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5301190\">",
"    <span class=\"h4\">",
"     Hip radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the child with suspected bacterial arthritis of the hip, radiographs should be obtained with the child in the \"frog leg position\" and with the legs extended at the knee and slightly internally rotated. It is better to request an anteroposterior and frog lateral radiograph of the pelvis than views of a single hip. Subtle changes (described below) may be more apparent when the opposite hip is readily visible on the same image.",
"   </p>",
"   <p>",
"    Hip radiographs may demonstrate findings suggestive of bacterial arthritis, as described below. Hip radiographs also are necessary to exclude other conditions that cause hip pain (eg, Legg-Calv&eacute;-Perthes disease, slipped capital femoral epiphysis, fracture) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hip pain in childhood\", section on 'Specific causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic signs of hip arthritis may include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/7,11,30,51-54\">",
"     7,11,30,51-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Swelling of the capsule",
"     </li>",
"     <li>",
"      Obliteration or lateral displacement of the gluteal fat lines (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81582 \" href=\"UTD.htm?21/53/22352\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elevation of the femoral portion of Shenton line, with widening of the arc",
"     </li>",
"     <li>",
"      The obturator sign (the margins of the obturator internus are displaced medially into the pelvis as its tendon passes over the capsule of the hip joint)",
"     </li>",
"     <li>",
"      Lateral and superior displacement of the femoral head with relatively normal acetabular development (in contrast to developmental dysplasia of the hip, in which the acetabulum is abnormal)",
"     </li>",
"     <li>",
"      Concomitant osteomyelitis of the femur (this is a late sign, since bone destruction takes a minimum of a week to become apparent on routine radiographs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography (US) is helpful in identifying and quantifying joint effusions, particularly for deep joints such as the hip (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60427 \" href=\"UTD.htm?26/22/26981\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/29,40,55\">",
"     29,40,55",
"    </a>",
"    ]; however, the presence of a joint effusion is not specific for infection. Increased blood flow with power or color Doppler suggests infection, but normal blood flow does not exclude it [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    US should be performed in children with suspected bacterial arthritis of the hip; it has a high negative predictive value and can be used to guide diagnostic aspiration. In a series of 96 children who underwent hip US for possible bacterial arthritis, none of the 40 who had normal US findings had a discharge diagnosis of bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/40\">",
"     40",
"    </a>",
"    ]. However, false negative US has been reported when imaging was inadequate or performed less than 24 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If US demonstrates fluid in the joint, diagnostic aspiration should be performed. The sonographic characteristics of the fluid (ie, echolucent versus echogenic) do not correlate with infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/40,49,50\">",
"     40,49,50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Synovial fluid'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H7#H7\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    US guidance may be used for joint aspiration and is recommended for diagnostic aspiration of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/55,58,59\">",
"     55,58,59",
"    </a>",
"    ]. Imaging guidance is not always necessary for aspiration of joints other than the hip. However, if guidance is required for children younger than eight years, US is preferred to fluoroscopy because US demonstrates cartilaginous structures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=see_link\">",
"     \"Joint aspiration or injection in children: Indications, technique, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide bone scans generally are not used in the diagnostic evaluation of bacterial arthritis unless concomitant osteomyelitis is suspected. However, bone scans may be helpful in the evaluation of deep joints (eg, hip, sacroiliac) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/11\">",
"     11",
"    </a>",
"    ]. The characteristic bone scan finding in bacterial arthritis is increased uptake on both sides of the joint during the early or \"blood pool\" phase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/60\">",
"     60",
"    </a>",
"    ]. In contrast, in osteomyelitis, the bone scan generally demonstrates increased uptake on only one side of a joint.",
"   </p>",
"   <p>",
"    Performance of radionuclide bone scan in patients in whom concomitant osteomyelitis is suspected should not delay aspiration of the joint or prompt surgical drainage when bacterial arthritis is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H7#H7\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is highly sensitive for the early detection of joint fluid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69485 \" href=\"UTD.htm?10/31/10738\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/47\">",
"     47",
"    </a>",
"    ]. However, it is not as readily available as ultrasonography and may require sedation for younger children.",
"   </p>",
"   <p>",
"    MRI may demonstrate abnormalities of adjacent bone, soft tissue, and the extent of cartilage destruction. Changes in signal intensity of bone marrow are demonstrated more frequently in patients with bacterial arthritis of the hip than with transient synovitis and may be helpful in differentiating these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/47,61\">",
"     47,61",
"    </a>",
"    ]. MRI is suggested to evaluate possible concomitant osteomyelitis or osteomyelitis-associated abscess in children who fail to respond after 48 hours of appropriate antimicrobial therapy for bacterial arthritis and initial drainage or aspiration of the affected joint. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H30#H30\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not routinely performed in the evaluation of suspected bacterial arthritis, computed tomography (CT) may be helpful in assessing areas of complex anatomy (eg, shoulder, hip, sacroiliac joint) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/11,35\">",
"     11,35",
"    </a>",
"    ]. In the later stages of the disease process, CT may demonstrate destructive changes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Synovial fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of synovial fluid should be performed as soon as possible when bacterial arthritis is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/14,25,63\">",
"     14,25,63",
"    </a>",
"    ]. The identification of organisms in synovial fluid is the primary criterion for the diagnosis of bacterial arthritis. In addition, removal of synovial fluid decompresses the joint, which makes the patient more comfortable. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hip aspiration should be performed with imaging guidance to confirm joint entry. Synovial fluid should be collected in a heparinized syringe so that clot formation does not preclude enumeration of leukocytes. The fluid should be sent for cell count, Gram stain, culture (aerobic and anaerobic), and susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/14\">",
"     14",
"    </a>",
"    ]. Additional studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    special culture media may be necessary if particular organisms are suspected.",
"   </p>",
"   <p>",
"    Joint aspiration in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=see_link\">",
"     \"Joint aspiration or injection in children: Indications, technique, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cell count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synovial fluid WBC count must be used in conjunction with clinical findings when making decisions regarding treatment of arthritis while awaiting results of the Gram stain and culture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H12#H12\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The higher the synovial fluid WBC count, the greater the likelihood of bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/66\">",
"     66",
"    </a>",
"    ]. Synovial fluid WBC counts of &gt;50,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    with a predominance (&gt;90 percent) of polymorphonuclear leukocytes (PMN), suggests bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/38,63,67,68\">",
"     38,63,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a synovial fluid WBC count of &gt;50,000 is neither sensitive nor specific for bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/9,64,66\">",
"     9,64,66",
"    </a>",
"    ]. The synovial fluid WBC count may be &lt;50,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    in patients with unusual causes of bacterial arthritis (eg,",
"    <em>",
"     Brucella",
"    </em>",
"    ) and may exceed 50,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    in children with JIA, serum sickness, or reactive arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/65,66,69\">",
"     65,66,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Gram stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of careful examination of the Gram-stained smear of synovial fluid cannot be overemphasized. Organisms that are seen on the Gram-stained smear may not grow in culture because synovial fluid has bacteriostatic effects. Approximately 40 to 50 percent of joint aspirates are sterile in patients with other clinical and laboratory findings of bacterial arthritis, including positive blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/5,8,36,37,45\">",
"     5,8,36,37,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of organisms in joint fluid is the primary criterion for the diagnosis of bacterial arthritis. Synovial fluid should be cultured under aerobic and anaerobic conditions.",
"   </p>",
"   <p>",
"    Synovial fluid cultures are positive in approximately 50 to 60 percent of patients with other clinical and laboratory findings of bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/5,8,36,37,45\">",
"     5,8,36,37,45",
"    </a>",
"    ]. False negative synovial fluid cultures may occur with fastidious organisms, inadequate laboratory techniques, or prior treatment with antibiotics. The use of cell lysis (blood culture) bottles and incubation for at least seven days may enhance the recovery of Kingella kingae and other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5301219\">",
"    <span class=\"h4\">",
"     Culture for unusual pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid should be cultured for unusual pathogens in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of tuberculosis exposure (",
"      <em>",
"       Mycobacterium tuberculosis",
"      </em>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"       \"Skeletal tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of trauma, animal bite or scratch, or a mechanism for direct inoculation (sporotrichosis,",
"      <em>",
"       Pasteurella",
"      </em>",
"      , anaerobes). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=see_link\">",
"       \"Clinical features and diagnosis of sporotrichosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=see_link\">",
"       \"Pasteurella infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Travel to or living in an area endemic for fungal infections (eg, coccidioidomycosis) or brucellosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immune suppression (candidal arthritis)",
"     </li>",
"     <li>",
"      Monoarthritis that is refractory to conventional therapy (brucella, tuberculosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"       \"Skeletal tuberculosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) testing of synovial fluid for",
"    <em>",
"     K. kingae",
"    </em>",
"    and other fastidious pathogens may increase detection, particularly in patients who received antibiotics before synovial fluid sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the evaluation of the child with suspected bacterial arthritis, consultation with an expert in infectious diseases may be warranted for children with postoperative infection, chronic joint infection, perforating injury, or suspected unusual pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/58\">",
"     58",
"    </a>",
"    ]. Consultation with an expert in rheumatology may be warranted for children with underlying arthritis (eg, juvenile idiopathic arthritis, psoriatic arthritis) or involvement of more than one joint, or failure to respond to antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bacterial arthritis should be suspected in children who present with fever and monoarticular pain, swelling, and limited range of motion and in young infants who present with clinical manifestations of sepsis (eg, irritability, poor feeding), pseudoparalysis, evidence of discomfort when handled or having the diaper changed, or fever without a focus. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Isolation of a bacterial pathogen from the synovial fluid (by culture or other diagnostic techniques) confirms the diagnosis of bacterial arthritis. Isolation of bacteria from blood cultures in a patient with characteristic clinical features and increased synovial fluid white blood cell count also confirms the diagnosis, even if the synovial fluid culture remains negative. When appropriate cultures are obtained (including cultures of blood and other sites as appropriate), the bacterial etiology is confirmed in 50 to 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/5,8,36,37\">",
"     5,8,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with characteristic clinical, laboratory, and radiographic features, a diagnosis of probable bacterial arthritis (or culture-negative arthritis) can be made in the absence of isolation of bacteria from synovial fluid or blood if other pathologic processes are excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/4,25,75\">",
"     4,25,75",
"    </a>",
"    ]. Consultation with an expert in pediatric infectious diseases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pediatric rheumatology may be helpful in difficult cases.",
"   </p>",
"   <p>",
"    Given the potential morbidity of delayed treatment, children with probable bacterial arthritis should be managed in the same manner as children in whom an organism is isolated from synovial fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H17#H17\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Negative cultures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of bacterial arthritis in infants and children includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other types of infectious and noninfectious arthritis (",
"      <a class=\"graphic graphic_table graphicRef75773 \" href=\"UTD.htm?8/60/9165\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57993 \" href=\"UTD.htm?37/0/37899\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H5#H5\">",
"       \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Microbiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other infections (musculoskeletal and systemic)",
"     </li>",
"     <li>",
"      Other causes of joint pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical features, imaging studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    synovial fluid analysis usually differentiate these conditions from acute bacterial arthritis. Consultation with an expert in pediatric infectious diseases or pediatric rheumatology may be helpful in difficult cases. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Indications for consultation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis can be caused by viruses and fungi, as well as bacteria (",
"    <a class=\"graphic graphic_table graphicRef75773 \" href=\"UTD.htm?8/60/9165\">",
"     table 2",
"    </a>",
"    ). Fungal arthritis is rare in children but can occur in neonates hospitalized in the intensive care unit, immunocompromised hosts, and with endemic mycoses. Fungal arthritis caused by opportunistic pathogens usually presents after an indolent course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Osteoarticular infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postinfectious or reactive arthritis is associated with a recent previous or concomitant extraarticular infection of the upper respiratory (eg,",
"    <em>",
"     H. influenzae",
"    </em>",
"    ,",
"    <em>",
"     N. meningitidis",
"    </em>",
"    , group A streptococcus), gastrointestinal (",
"    <em>",
"     Shigella",
"    </em>",
"    ,",
"    <em>",
"     Salmonella",
"    </em>",
"    ,",
"    <em>",
"     Campylobacter",
"    </em>",
"    ), or genitourinary tract (",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninfectious causes of arthritis in children include trauma (hemarthrosis), inflammatory, and immunologic disorders (",
"    <a class=\"graphic graphic_table graphicRef57993 \" href=\"UTD.htm?37/0/37899\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other infections may have signs and symptoms that mimic those of bacterial arthritis (eg, fever, musculoskeletal pain, refusal to bear weight, joint swelling, etc). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteomyelitis &ndash; In children with osteomyelitis without concomitant bacterial arthritis, gentle examination usually allows some joint movement and pain-free range of motion, whereas in children with bacterial arthritis, there is pain through any range of active or passive motion [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/4,25,31\">",
"       4,25,31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deep cellulitis.",
"     </li>",
"     <li>",
"      Abscess of the obturator internus or psoas muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Septic (suppurative) bursitis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/30/14826/abstract/59,81\">",
"       59,81",
"      </a>",
"      ]. Physical examination demonstrating peribursal erythema and warmth and aspiration of bursal fluid help to differentiate septic bursitis from bacterial arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33256?source=see_link\">",
"       \"Septic bursitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial endocarditis &ndash; Patients with bacterial endocarditis may have a systemic immune reaction that includes arthritis. The classic clinical stigmata of bacterial endocarditis include petechiae, splinter hemorrhages (",
"      <a class=\"graphic graphic_picture graphicRef72076 \" href=\"UTD.htm?15/63/16369\">",
"       picture 3",
"      </a>",
"      ), Janeway lesions (",
"      <a class=\"graphic graphic_picture graphicRef58380 \" href=\"UTD.htm?30/54/31585\">",
"       picture 4",
"      </a>",
"      ), Osler nodes (",
"      <a class=\"graphic graphic_picture graphicRef68796 \" href=\"UTD.htm?28/10/28847\">",
"       picture 5",
"      </a>",
"      ), and Roth spots (exudative, edematous hemorrhagic lesions of the retina). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link&amp;anchor=H7#H7\">",
"       \"Infective endocarditis in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other causes of joint pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of joint pain, limp, or refusal to bear weight in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient (or toxic) synovitis",
"     </li>",
"     <li>",
"      Trauma (eg, fracture)",
"     </li>",
"     <li>",
"      Slipped capital femoral epiphysis",
"     </li>",
"     <li>",
"      Legg-Calv&eacute;-Perthes disease",
"     </li>",
"     <li>",
"      Tumor (eg, leukemia, osteosarcoma, osteoid osteoma)",
"     </li>",
"     <li>",
"      Villonodular synovitis (a rare proliferative lesion of synovial tissue that limits joint function and may destroy adjacent bone)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the exception of malignant tumors, these conditions usually are not accompanied by fever or constitutional signs. They are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Osteoid osteoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=see_link&amp;anchor=H5#H5\">",
"     \"Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone\", section on 'Pigmented villonodular synovitis/tenosynovial giant cell tumor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hip pain in childhood\", section on 'Specific causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/63/17393?source=see_link\">",
"       \"Patient information: Septic arthritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presentation of bacterial arthritis in infants and children varies depending upon the age of the child, the site of infection, and the causative organism (",
"      <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial arthritis usually affects the lower extremity, particularly the hip and knee. Up to 10 percent of cases involve more than one joint, particularly in neonates. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Site of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In neonates and young infants, the typical presentation of bacterial arthritis is that of septicemia (eg irritability, apprehension, poor feeding), cellulitis, or fever without a focus of infection. Clues to joint involvement include lack of use of the involved extremity, aversion to or discomfort on being handled (eg, being picked up, having the diaper changed), postural changes (eg, positional preferences), and unilateral swelling of the extremity, buttocks, or genitalia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neonates and infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most older children have fever and constitutional symptoms in addition to swelling, tenderness, and limited mobility of the affected joint, but the joint findings may be subtle. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Older children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history in the child with suspected infectious arthritis include characterization of the pain, recent use of antibiotics, recent or concurrent illness (upper respiratory, skin, enteric, genitourinary), rash, immunization history, various exposures, and family history. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the physical examination include observation of the child for restricted extremity use",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a preferential position, palpation of all bones and joints, assessment of range of motion of all joints, examination of the skin and eyes, and a search for another focus of infection or source for bacteremia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radiologic evaluation of children with suspected bacterial arthritis usually begins with plain radiographs to identify fractures, foci of osteomyelitis, and other causes of osteoarticular pain and swelling. Ultrasonography is helpful in detecting joint fluid, but the presence of fluid is not specific for joint infection. MRI is also a highly sensitive imaging modality for the early detection of joint fluid but is not as readily available and may require sedation for younger children. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory evaluation for children with suspected bacterial arthritis typically includes complete blood count (CBC) with differential, erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein (CRP), blood culture, and synovial fluid white blood cell (WBC) count, Gram stain, culture, and susceptibility testing. Additional laboratory studies may be necessary in patients in whom particular organisms are suspected (",
"      <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Synovial fluid WBC count of &gt;50,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      with &gt;90 percent neutrophils is suggestive of bacterial arthritis, but the identification of organisms in the joint fluid is the primary criterion for diagnosis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Synovial fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolation of a bacterial pathogen from the synovial fluid (by culture or other diagnostic techniques) confirms the diagnosis of bacterial arthritis. Isolation of bacteria from blood cultures in a patient with characteristic clinical features and increased synovial fluid WBC count also confirms the diagnosis, even if the synovial fluid culture remains negative. A diagnosis of probable bacterial arthritis (or culture-negative arthritis) can be made in the absence of isolation of bacteria from synovial fluid or blood if other pathologic processes are excluded and the patient has characteristic clinical, laboratory, and radiographic features. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of bacterial arthritis includes other types of infectious and noninfectious arthritis (",
"      <a class=\"graphic graphic_table graphicRef75773 \" href=\"UTD.htm?8/60/9165\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57993 \" href=\"UTD.htm?37/0/37899\">",
"       table 3",
"      </a>",
"      ), other infections (musculoskeletal and systemic), and other causes of joint pain. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/1\">",
"      Nade S. Septic arthritis. Best Pract Res Clin Rheumatol 2003; 17:183.",
"     </a>",
"    </li>",
"    <li>",
"     Krogstad P. Septic arthitis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GL, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.742.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/3\">",
"      Heberling JA. A review of two hundred and one cases of suppurative arthritis. J Bone Joint Surg 1941; 23:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/4\">",
"      Morrey BF, Bianco AJ Jr, Rhodes KH. Septic arthritis in children. Orthop Clin North Am 1975; 6:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/5\">",
"      Nelson JD. The bacterial etiology and antibiotic management of septic arthritis in infants and children. Pediatrics 1972; 50:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/6\">",
"      SAMILSON RL, BERSANI FA, WATKINS MB. Acute suppurative arthritis in infants and children; the importance of early diagnosis and surgical drainage. Pediatrics 1958; 21:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/7\">",
"      OBLETZ BE. Suppurative arthritis of the hip joint in infants. Clin Orthop 1962; 22:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/8\">",
"      Welkon CJ, Long SS, Fisher MC, Alburger PD. Pyogenic arthritis in infants and children: a review of 95 cases. Pediatr Infect Dis 1986; 5:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/9\">",
"      Fink CW, Nelson JD. Septic arthritis and osteomyelitis in children. Clin Rheum Dis 1986; 12:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/10\">",
"      Dan M. Septic arthritis in young infants: clinical and microbiologic correlations and therapeutic implications. Rev Infect Dis 1984; 6:147.",
"     </a>",
"    </li>",
"    <li>",
"     Gutierrez K. Infectious and inflammatory arthritis. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.477.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/12\">",
"      Chung SM, Pollis RE. Diagnostic pitfalls in septic arthritis of the hip in infants and children. Clin Pediatr (Phila) 1975; 14:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/13\">",
"      OBLETZ BE. Acute suppurative arthritis of the hip in the neonatal period. J Bone Joint Surg Am 1960; 42-A:23.",
"     </a>",
"    </li>",
"    <li>",
"     Krogstad P. Septic arthritis. In: Current Pediatric Therapy, 18th ed, Burg FD, Ingelfinger JR, Polin RA, Gershon AA (Eds), Saunders, Philadelphia 2006. p.665.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/15\">",
"      Yagupsky P, Bar-Ziv Y, Howard CB, Dagan R. Epidemiology, etiology, and clinical features of septic arthritis in children younger than 24 months. Arch Pediatr Adolesc Med 1995; 149:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/16\">",
"      Omene JA, Odita JC. Clinical and radiological features of neonatal septic arthritis. Trop Geogr Med 1979; 31:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/17\">",
"      Asnes RS, Arendar GM. Septic arthritis of the hip: a complication of femoral venipuncture. Pediatrics 1966; 38:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/18\">",
"      Chacha PB. Suppurative arthritis of the hip joint in infancy. A persistent diagnostic problem and possible complication of femoral venipuncture. J Bone Joint Surg Am 1971; 53:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/19\">",
"      Freiberg JA, Perlman R. Pelvic abscesses associated with acute purulent infection of the hip joint. J Bone Joint Surg 1936; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/20\">",
"      Gillespie R. Septic arthritis of childhood. Clin Orthop Relat Res 1973; :152.",
"     </a>",
"    </li>",
"    <li>",
"     Fleisher G. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/22\">",
"      Osman AA, Govender S. Septic sacroiliitis. Clin Orthop Relat Res 1995; :214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/23\">",
"      Schaad UB, McCracken GH Jr, Nelson JD. Pyogenic arthritis of the sacroiliac joint in pediatric patients. Pediatrics 1980; 66:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/24\">",
"      Molinos Quintana A, Morillo Guti&eacute;rrez B, Camacho Lovillo MS, et al. Pyogenic sacroiliitis in children-a diagnostic challenge. Clin Rheumatol 2011; 30:107.",
"     </a>",
"    </li>",
"    <li>",
"     Stans AA. Osteomyelitis and septic arthritis. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.440.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/26\">",
"      Rompalo AM, Hook EW 3rd, Roberts PL, et al. The acute arthritis-dermatitis syndrome. The changing importance of Neisseria gonorrhoeae and Neisseria meningitidis. Arch Intern Med 1987; 147:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/27\">",
"      Bradley JS, Kaplan SL, Tan TQ, et al. Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG). Pediatrics 1998; 102:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/28\">",
"      Holmes KK, Counts GW, Beaty HN. Disseminated gonococcal infection. Ann Intern Med 1971; 74:979.",
"     </a>",
"    </li>",
"    <li>",
"     Frank G, Eppes SC. Bone, joint, and soft tissue infections. In: Comprehensive Pediatric Hospital Medicine, Zaoutis LB, Chiang WV (Eds), Mosby, Philadelphia 2007. p.414.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/30\">",
"      Bennett OM, Namnyak SS. Acute septic arthritis of the hip joint in infancy and childhood. Clin Orthop Relat Res 1992; :123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/31\">",
"      Nade S. Acute septic arthritis in infancy and childhood. J Bone Joint Surg Br 1983; 65:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/32\">",
"      Walsh S, Phillips F. Deep vein thrombosis associated with pediatric musculoskeletal sepsis. J Pediatr Orthop 2002; 22:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/33\">",
"      Nelson JD. Skeletal infections in children. Adv Pediatr Infect Dis 1991; 6:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/34\">",
"      Shaw BA, Kasser JR. Acute septic arthritis in infancy and childhood. Clin Orthop Relat Res 1990; :212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/35\">",
"      Aprin H, Turen C. Pyogenic sacroiliitis in children. Clin Orthop Relat Res 1993; :98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/36\">",
"      Barton LL, Dunkle LM, Habib FH. Septic arthritis in childhood. A 13-year review. Am J Dis Child 1987; 141:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/37\">",
"      Wiley JJ, Fraser GA. Septic arthritis in childhood. Can J Surg 1979; 22:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/38\">",
"      Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial fluid tests. What should be ordered? JAMA 1990; 264:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/39\">",
"      Del Beccaro MA, Champoux AN, Bockers T, Mendelman PM. Septic arthritis versus transient synovitis of the hip: the value of screening laboratory tests. Ann Emerg Med 1992; 21:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/40\">",
"      Zawin JK, Hoffer FA, Rand FF, Teele RL. Joint effusion in children with an irritable hip: US diagnosis and aspiration. Radiology 1993; 187:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/41\">",
"      Klein DM, Barbera C, Gray ST, et al. Sensitivity of objective parameters in the diagnosis of pediatric septic hips. Clin Orthop Relat Res 1997; :153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/42\">",
"      Levine MJ, McGuire KJ, McGowan KL, Flynn JM. Assessment of the test characteristics of C-reactive protein for septic arthritis in children. J Pediatr Orthop 2003; 23:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/43\">",
"      Kallio MJ, Unkila-Kallio L, Aalto K, Peltola H. Serum C-reactive protein, erythrocyte sedimentation rate and white blood cell count in septic arthritis of children. Pediatr Infect Dis J 1997; 16:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/44\">",
"      Wall EJ. Childhood osteomyelitis and septic arthritis. Curr Opin Pediatr 1998; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/45\">",
"      Nade S, Robertson FW, Taylor TK. Antibiotics in the treatment of acute osteomyelitis and acute septic arthritis in children. Med J Aust 1974; 2:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/46\">",
"      Thompson A, Mannix R, Bachur R. Acute pediatric monoarticular arthritis: distinguishing lyme arthritis from other etiologies. Pediatrics 2009; 123:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/47\">",
"      Buchmann RF, Jaramillo D. Imaging of articular disorders in children. Radiol Clin North Am 2004; 42:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/48\">",
"      Volberg FM, Sumner TE, Abramson JS, Winchester PH. Unreliability of radiographic diagnosis of septic hip in children. Pediatrics 1984; 74:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/49\">",
"      Miralles M, Gonzalez G, Pulpeiro JR, et al. Sonography of the painful hip in children: 500 consecutive cases. AJR Am J Roentgenol 1989; 152:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/50\">",
"      Robben SG, Lequin MH, Diepstraten AF, et al. Anterior joint capsule of the normal hip and in children with transient synovitis: US study with anatomic and histologic correlation. Radiology 1999; 210:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/51\">",
"      Mitchell M, Howard B, Haller J, et al. Septic arthritis. Radiol Clin North Am 1988; 26:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/52\">",
"      WHITE H. Roentgen findings of acute infectious disease of the hip in infants and children. Clin Orthop 1962; 22:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/53\">",
"      Hefke HW, Turner VC. The obturator sign as the earliest roentgenographic sign in the diagnosis of septic arthritis and tuberculosis of the hip. J Bone Joint Surg 1942; 24:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/54\">",
"      Chont L. Roentgen sign of early suppurative arthritis of the hip in infancy. Radiology 1942; 38:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/55\">",
"      Jaramillo D, Treves ST, Kasser JR, et al. Osteomyelitis and septic arthritis in children: appropriate use of imaging to guide treatment. AJR Am J Roentgenol 1995; 165:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/56\">",
"      Strouse PJ, DiPietro MA, Adler RS. Pediatric hip effusions: evaluation with power Doppler sonography. Radiology 1998; 206:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/57\">",
"      Gordon JE, Huang M, Dobbs M, et al. Causes of false-negative ultrasound scans in the diagnosis of septic arthritis of the hip in children. J Pediatr Orthop 2002; 22:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/58\">",
"      Kocher MS, Mandiga R, Murphy JM, et al. A clinical practice guideline for treatment of septic arthritis in children: efficacy in improving process of care and effect on outcome of septic arthritis of the hip. J Bone Joint Surg Am 2003; 85-A:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/59\">",
"      Paisley JW. Septic bursitis in childhood. J Pediatr Orthop 1982; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/60\">",
"      Connolly LP, Connolly SA. Skeletal scintigraphy in the multimodality assessment of young children with acute skeletal symptoms. Clin Nucl Med 2003; 28:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/61\">",
"      Yang WJ, Im SA, Lim GY, et al. MR imaging of transient synovitis: differentiation from septic arthritis. Pediatr Radiol 2006; 36:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/62\">",
"      Wilson DJ. Soft tissue and joint infection. Eur Radiol 2004; 14 Suppl 3:E64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/63\">",
"      Kunnamo I, Pelkonen P. Routine analysis of synovial fluid cells is of value in the differential diagnosis of arthritis in children. J Rheumatol 1986; 13:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/64\">",
"      Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA 2007; 297:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/65\">",
"      Baldassare AR, Chang F, Zuckner J. Markedly raised synovial fluid leucocyte counts not associated with infectious arthritis in children. Ann Rheum Dis 1978; 37:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/66\">",
"      Coutlakis PJ, Roberts WN, Wise CM. Another look at synovial fluid leukocytosis and infection. J Clin Rheumatol 2002; 8:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/67\">",
"      Ropes MW. Examination of synovial fluid. Bull Rheum Dis 1957; 7 Suppl:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/68\">",
"      WARD J, COHEN AS, BAUER W. The diagnosis and therapy of acute suppurative arthritis. Arthritis Rheum 1960; 3:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/69\">",
"      Press J, Peled N, Buskila D, Yagupsky P. Leukocyte count in the synovial fluid of children with culture-proven brucellar arthritis. Clin Rheumatol 2002; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/70\">",
"      Yagupsky P, Press J. Use of the isolator 1.5 microbial tube for culture of synovial fluid from patients with septic arthritis. J Clin Microbiol 1997; 35:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/71\">",
"      Kiang KM, Ogunmodede F, Juni BA, et al. Outbreak of osteomyelitis/septic arthritis caused by Kingella kingae among child care center attendees. Pediatrics 2005; 116:e206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/72\">",
"      Verdier I, Gayet-Ageron A, Ploton C, et al. Contribution of a broad range polymerase chain reaction to the diagnosis of osteoarticular infections caused by Kingella kingae: description of twenty-four recent pediatric diagnoses. Pediatr Infect Dis J 2005; 24:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/73\">",
"      Chometon S, Benito Y, Chaker M, et al. Specific real-time polymerase chain reaction places Kingella kingae as the most common cause of osteoarticular infections in young children. Pediatr Infect Dis J 2007; 26:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/74\">",
"      Rosey AL, Abachin E, Quesnes G, et al. Development of a broad-range 16S rDNA real-time PCR for the diagnosis of septic arthritis in children. J Microbiol Methods 2007; 68:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/75\">",
"      Lyon RM, Evanich JD. Culture-negative septic arthritis in children. J Pediatr Orthop 1999; 19:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/76\">",
"      Greenwood BM, Whittle HC, Bryceson AD. Allergic complications of meningococcal disease. II. Immunological investigations. Br Med J 1973; 2:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/77\">",
"      Rush PJ, Shore A, Inman R, et al. Arthritis associated with Haemophilus influenzae meningitis: septic or reactive? J Pediatr 1986; 109:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/78\">",
"      Ahmed S, Ayoub EM. Poststreptococcal reactive arthritis. Pediatr Infect Dis J 2001; 20:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/79\">",
"      Viani RM, Bromberg K, Bradley JS. Obturator internus muscle abscess in children: report of seven cases and review. Clin Infect Dis 1999; 28:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/80\">",
"      Song J, Letts M, Monson R. Differentiation of psoas muscle abscess from septic arthritis of the hip in children. Clin Orthop Relat Res 2001; :258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/30/14826/abstract/81\">",
"      Harwell JI, Fisher D. Pediatric septic bursitis: case report of retrocalcaneal infection and review of the literature. Clin Infect Dis 2001; 32:E102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6030 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14826=[""].join("\n");
var outline_f14_30_14826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Site of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonates and infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hip arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Older children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Underlying arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5301190\">",
"      Hip radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cell count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Gram stain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5301219\">",
"      Culture for unusual pathogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INDICATIONS FOR CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other causes of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6030|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/53/22352\" title=\"diagnostic image 1\">",
"      Hip effusion plain film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/22/26981\" title=\"diagnostic image 2\">",
"      Hip effusion US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/31/10738\" title=\"diagnostic image 3\">",
"      Hip effusion MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6030|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/55/6015\" title=\"figure 1\">",
"      FABERE test (Patrick test, \"figure of four\" test)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6030|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/16/19712\" title=\"picture 1A\">",
"      Erythema migrans bulls eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/575\" title=\"picture 1B\">",
"      Erythema migrans uniform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/24/13711\" title=\"picture 2\">",
"      Systemic onset JIA rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/63/16369\" title=\"picture 3\">",
"      Splinter hemorrhages in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/54/31585\" title=\"picture 4\">",
"      Janeway lesion in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/10/28847\" title=\"picture 5\">",
"      Oslers nodes in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/50/15149\" title=\"table 1\">",
"      Clues to the etiology of septic arthritis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/60/9165\" title=\"table 2\">",
"      Infectious arthritis child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/0/37899\" title=\"table 3\">",
"      Noninfectious causes of  arthritis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=related_link\">",
"      Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=related_link\">",
"      Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=related_link\">",
"      Bacterial arthritis: Treatment and outcome in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21239?source=related_link\">",
"      Joint aspiration or injection in children: Indications, technique, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=related_link\">",
"      Pasteurella infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/63/17393?source=related_link\">",
"      Patient information: Septic arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33256?source=related_link\">",
"      Septic bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_30_14827="Etiology life or limb threatening limp in children";
var content_f14_30_14827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Life- or limb-threatening causes of limp in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Septic arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Osteomyelitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Leukemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Metastatic neuroblastoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Osteogenic sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ewing's tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Torsion of the testicle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Slipped capital femoral epiphysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fracture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Appendicitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Discitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Developmental dysplasia of the hip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meningitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epidural abscess of the spine",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14827=[""].join("\n");
var outline_f14_30_14827=null;
var title_f14_30_14828="ATS Dyspnea Treatment Guidelines";
var content_f14_30_14828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Thoracic Society Guidelines for the treatment of dyspnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mild dyspnea",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate dyspnea",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Treat underlying disease*",
"        </p>",
"        <p>",
"         Treat psychosocial factors",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Treat underlying disease",
"        </p>",
"        <p>",
"         Treat psychosocial factors",
"        </p>",
"        <p>",
"         Pulmonary rehabilitation",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Consider anxiolytic",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Treat underlying disease",
"        </p>",
"        <p>",
"         Treat psychosocial factors",
"        </p>",
"        <p>",
"         Pulmonary rehabilitation",
"        </p>",
"        <p>",
"         Facial cooling (by use of fan)",
"        </p>",
"        <p>",
"         Opioids",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         Anxiolytics",
"        </p>",
"        <p>",
"         Noninvasive ventilation",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Treat underlying disease includes anemia, pleural effusions, congestive heart failure, reversible airway obstruction, hypoxemia, main stem bronchial compression or obstruction.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Treat psychosocial factors: For anxiety, use relaxation techniques, distraction, activity modifications, behavior modifications, and breathing strategies. For depression, use cognitive therapy, antidepressants, or a combination of both.",
"      <br>",
"       &Delta; Pulmonary rehabilitation includes exercise training, psychosocial support, nutritional therapy, and self-management education, including breathing strategies, use of supplemental oxygen, pharmacologic therapy (to relieve airways obstruction), and panic control.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Evidence indicates that they do not cause premature death in end-of-life patients when titrated to relieve pain or dyspnea.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission of the American Thoracic Society. Copyright &copy; 2008 American Thoracic Society. Lanken PN, Terry PB, DeLisser HM, et al. An Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses. American Journal of Respiratory Critical Care Medicine 2008; 177:912. Official Journal of the American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14828=[""].join("\n");
var outline_f14_30_14828=null;
var title_f14_30_14829="Properties of statins";
var content_f14_30_14829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Properties of statins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Atorvastatin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fluvastatin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lovastatin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pitavastatin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pravastatin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rosuvastatin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Simvastatin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        LDL cholesterol reductions (dose range, mg)",
"       </td>",
"       <td>",
"        38 to 54 percent (10 to 80)",
"       </td>",
"       <td>",
"        17 to 33 percent (20 to 80)",
"       </td>",
"       <td>",
"        29 to 48 percent (20 to 80)",
"       </td>",
"       <td>",
"        31 to 41 percent (1 to 4)",
"       </td>",
"       <td>",
"        19 to 40 percent (10 to 40)",
"       </td>",
"       <td>",
"        52 to 63 percent (10 to 40)",
"       </td>",
"       <td>",
"        28 to 41 percent (10 to 40)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Elimination half-life, hours",
"       </td>",
"       <td>",
"        15 to 30",
"       </td>",
"       <td>",
"        0.5 to 2.3",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1.3 to 2.8",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Bioavailability, percent",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        19 to 29",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Protein binding, percent",
"       </td>",
"       <td>",
"        80 to 90",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        &gt;95",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        43 to 55",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        94 to 98",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Solubility",
"       </td>",
"       <td>",
"        Lipophilic",
"       </td>",
"       <td>",
"        Lipophilic",
"       </td>",
"       <td>",
"        Lipophilic",
"       </td>",
"       <td>",
"        Lipophilic",
"       </td>",
"       <td>",
"        Hydrophilic",
"       </td>",
"       <td>",
"        Hydrophilic",
"       </td>",
"       <td>",
"        Lipophilic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Cytochrome 450 metabolism and lsozyme",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"       <td>",
"        2C9",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"       <td>",
"        Limited 2C9, 2C8",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Limited 2C9",
"       </td>",
"       <td>",
"        3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Active metabolites",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Effect of food on absorption of drug",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Negligible",
"       </td>",
"       <td>",
"        Increased absorption",
"       </td>",
"       <td>",
"        Decreases",
"       </td>",
"       <td>",
"        Decreased absorption",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Optimal time of administration",
"       </td>",
"       <td>",
"        Anytime",
"       </td>",
"       <td>",
"        <p>",
"         IR: evening (or morning and evening if taken twice daily)",
"        </p>",
"        XR: anytime",
"       </td>",
"       <td>",
"        <p>",
"         IR: with evening meal (or with morning and evening meal if taken twice daily)",
"        </p>",
"        XR: anytime",
"       </td>",
"       <td>",
"        Anytime",
"       </td>",
"       <td>",
"        Anytime",
"       </td>",
"       <td>",
"        Anytime",
"       </td>",
"       <td>",
"        Evening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal excretion of absorbed dose, percent",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &lt;6",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IR: immediate release; XR: extended release.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14829=[""].join("\n");
var outline_f14_30_14829=null;
var title_f14_30_14830="End of life care in ICU";
var content_f14_30_14830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F80424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F80424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    End-of-life care in Intensive Care Units",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 372px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histogram showing the relative proportions of different types of end-of-life care of 5910 patients in 131 intensive care units. Less than one-half of all deaths were preceded by full resuscitative efforts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Prendergast, TJ, Claessens, MT, Luce, JM, Am J Respir Crit Care Med 1998;158:1163.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14830=[""].join("\n");
var outline_f14_30_14830=null;
var title_f14_30_14831="Thrombosed external hemorrhoid";
var content_f14_30_14831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thrombosed external hemorrhoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph shows a swollen external hemorrhoid (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of the American Society of Colon and Rectal Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_30_14831=[""].join("\n");
var outline_f14_30_14831=null;
